



UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549

FORM 10-K

ANNUAL REPORT  
PURSUANT TO SECTION 13 OR 15(d) OF  
THE SECURITIES EXCHANGE ACT OF 1934

- For the fiscal year ended December 31, 2008
- Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934  
For the Transition Period from \_\_\_\_\_ to \_\_\_\_\_

Commission File Number: 1-8351

**CHEMED CORPORATION**

(Exact name of registrant as specified in its charter)

**Delaware**

(State or other jurisdiction of  
incorporation or organization)

**31-0791746**

(I.R.S. Employer  
Identification Number)

2600 Chemed Center, 255 East Fifth Street, Cincinnati, Ohio  
(Address of principal executive offices)

45202-4726  
(Zip Code)

(513) 762-6900

(Registrant's Telephone number, including area code)

Securities registered pursuant to Section 12(b) of the Act:

Title of Each Class

Name of each exchange  
on which registered

Capital Stock — Par Value \$1 Per Share

New York Stock Exchange

Securities registered pursuant to Section 12(b) of the Act: None

Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes  No

Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. Yes  No

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes  No

Indicate by check mark if disclosure of delinquent filers pursuant to Item 405 of Regulation S-K is not contained herein, and will not be contained, to the best of registrant's knowledge, if definitive proxy or information statements incorporated by reference in Part III of this Form 10-K or any amendment to this Form 10-K. Yes  No

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of "large accelerated filer," "accelerated filer" and "smaller reporting company" in Rule 12b-2 of the Exchange Act. (Check one):

Large accelerated filer  Accelerated filer  Non-accelerated filer  Smaller reporting company   
(Do not check if a smaller reporting company)

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act). Yes  No

The aggregate market value of the voting stock held by non-affiliates of the registrant, based upon the average bid and asked price of said stock on the New York Stock Exchange — Composite Transaction Listing on June 30, 2008 (\$36.72 per share), was \$817,562,942.

At February 16, 2009, 22,530,217 shares of Chemed Capital Stock (par value \$1 per share) were outstanding.

**DOCUMENTS INCORPORATED BY REFERENCE**

<u>Document</u>	<u>Where Incorporated</u>
2008 Annual Report to Stockholders (specified portions)	Parts I, II, and IV
Proxy Statement for Annual Meeting to be held May 18, 2009	Part III



**CHEMED CORPORATION**  
**2008 FORM 10-K ANNUAL REPORT**

**Table of Contents**

**PART I**

<a href="#">Item 1. Business</a>	1
<a href="#">Item 1A. Risk Factors</a>	15
<a href="#">Item 1B. Unresolved Staff Comments</a>	26
<a href="#">Item 2. Properties</a>	26
<a href="#">Item 3. Legal Proceedings</a>	26
<a href="#">Item 4. Submission of Matters to a Vote of Security Holders</a>	27
<a href="#">Executive Officers of the Registrant</a>	27

**PART II**

<a href="#">Item 5. Market for the Registrant's Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities</a>	28
<a href="#">Item 6. Selected Financial Data</a>	32
<a href="#">Item 7. Management's Discussion and Analysis of Financial Condition and Results of Operations</a>	32
<a href="#">Item 7A. Quantitative and Qualitative Disclosures About Market Risk</a>	32
<a href="#">Item 8. Financial Statements and Supplementary Data</a>	32
<a href="#">Item 9. Changes in and Disagreements with Accountants on Accounting and Financial Disclosure</a>	32
<a href="#">Item 9A. Controls and Procedures</a>	32
<a href="#">Item 9B. Other Information</a>	33

**PART III**

<a href="#">Item 10. Directors, Executive Officers and Corporate Governance</a>	33
<a href="#">Item 11. Executive Compensation</a>	33
<a href="#">Item 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</a>	34
<a href="#">Item 13. Certain Relationships and Related Transactions and Director Independence</a>	34
<a href="#">Item 14. Principle Accountant Fees and Services</a>	34

**PART IV**

<a href="#">Item 15. Exhibits and Financial Statement Schedules</a>	35
<a href="#">EX-12</a>	
<a href="#">EX-13</a>	
<a href="#">EX-21</a>	
<a href="#">EX-23</a>	
<a href="#">EX-24</a>	
<a href="#">EX-31.1</a>	
<a href="#">EX-31.2</a>	
<a href="#">EX-31.3</a>	
<a href="#">EX-32.1</a>	
<a href="#">EX-32.2</a>	
<a href="#">EX-32.3</a>	

---

## Item 1. Business

### General

The Company was incorporated in Delaware in 1970 as a subsidiary of W. R. Grace & Co. and succeeded to the business of W. R. Grace & Co.'s Specialty Products Group as of April 30, 1971 and remained a subsidiary of W. R. Grace & Co. until March 10, 1982. As used herein, "Company" refers to Chemed Corporation, and its subsidiaries and "Grace" refers to W. R. Grace & Co. and its subsidiaries.

On March 10, 1982, the Company transferred to Dearborn Chemical Company, a wholly owned subsidiary of the Company, the business and assets of the Company's Dearborn Group, including the stock of certain subsidiaries within the Dearborn Group, plus \$185 million in cash, and Dearborn Chemical Company assumed the Dearborn Group's liabilities. Thereafter, on March 10, 1982 the Company transferred all of the stock of Dearborn Chemical Company to Grace in exchange for 33,481,604 shares of the capital stock of the Company owned by Grace with the result that Grace no longer has any ownership interest in the Company.

On December 31, 1986, the Company completed the sale of substantially all of the business and assets of Vestal Laboratories, Inc., a wholly owned subsidiary. The Company received cash payments aggregating approximately \$67.4 million over the four-year period following the closing, the substantial portion of which was received on December 31, 1986.

On April 2, 1991, the Company completed the sale of DuBois Chemicals, Inc. ("DuBois"), a wholly owned subsidiary, to the Diversey Corporation ("Diversey"), then a subsidiary of The Molson Companies Ltd. Under terms of the sale, Diversey agreed to pay the Company net cash payments aggregating \$223.4 million, including deferred payments aggregating \$32.4 million.

On December 21, 1992, the Company acquired The Veratex Corporation and related businesses ("Veratex Group") from Omnicare, Inc. The purchase price was \$62.1 million in cash paid at closing, plus a post-closing payment of \$1.5 million (paid in April 1993) based on the net assets of Veratex.

Effective January 1, 1994, the Company acquired all the capital stock of Patient Care, Inc. ("Patient Care"), for cash payments aggregating \$20.6 million, plus 35,000 shares of the Company's Capital Stock. An additional cash payment of \$1.0 million was made on March 31, 1996 and another payment of \$1.0 million was made on March 31, 1997.

In July 1995, the Company's Omnia Group (formerly Veratex Group) completed the sale of the business and assets of its Veratex Retail division to Henry Schein, Inc. ("HSI") for \$10 million in cash plus a \$4.1 million note for which payment was received in December 1995.

Effective September 17, 1996 the Company completed a merger of a subsidiary of the Company, Chemed Acquisition Corp., and Roto-Rooter, Inc. pursuant to a Tender Offer commenced on August 8, 1996 to acquire any and all of the outstanding shares of Common Stock of Roto-Rooter, Inc. for \$41.00 per share in cash.

On September 24, 1997 the Company completed the sale of its wholly owned business comprising the Omnia Group to Banta Corporation for \$50 million in cash and \$2.3 million in deferred payments.

Effective September 30, 1997, the Company completed a merger between its 81-percent-owned subsidiary, National Sanitary Supply Company, and a wholly owned subsidiary of Unisource Worldwide, Inc. for \$21.00 per share, with total payments of \$138.3 million.

Effective October 11, 2002, the Company sold its Patient Care subsidiary ("Patient Care") to an investor group that included Schroder Ventures Life Sciences Group, Oak Investment Partners, Prospect Partners and Salix

## Table of Contents

Ventures. The cash proceeds to the Company totaled \$57.5 million, of which \$5.0 million was placed in escrow pending settlement of Patient Care's receivables with third-party payers. Of this amount, \$2.5 million was distributed as of October 2003, \$1.7 million was distributed as of November 2004 and the remainder was distributed as of October 2006. In addition, the Company received a senior subordinated note receivable ("Note") for \$12.5 million and a common stock purchase warrant ("Warrant") for 2% of the outstanding stock of the purchasing company. The Note was due October 11, 2007, and bore interest at the annual rate of 7.5% through September 30, 2004, 8.5% from October 1, 2004, through September 30, 2005, and 9.5% thereafter. This sale was the subject of litigation which settled in October 2006. We agreed to forgive \$1.2 million of post-closing balance sheet valuation adjustments and convert the remainder into debt secured by a \$2.2 million promissory note with the same terms as the \$12.5 million Note. As part of the settlement, we also recorded a pretax impairment charge of \$1.4 million related to the Warrant. In December 2007 we amended the terms of both notes. We agreed to waive the prepayment penalties if Patient Care paid \$5 million of principal on or before December 31, 2007 and the remainder on or before March 31, 2008, which it paid.

Effective February 24, 2004, the Company completed a merger of its wholly owned indirect subsidiary, Marlin Merger Corp., and Vitas Healthcare Corporation. Under the terms of the merger agreement, Vitas stockholders received cash of \$30.00 per share. The transaction, including the refinancing of existing Vitas debt and other payments made in connection with the merger, totaled approximately \$415 million in cash. In order to complete the merger the Company sold four million shares of its Capital Stock in a private placement at a price of \$25.00 per share, issued \$110 million principal amount of floating rate senior secured notes due 2010 ("Floating Rate Notes"), issued \$150 million principal amount of 8.75% Senior Notes due 2011 ("Fixed Rate Notes"), and entered into new \$135 million senior secured credit facilities. These obligations were refinanced in 2005, 2006 and 2007.

On December 22, 2004, the Board of Directors authorized the discontinuance of the operations of the Company's Service America segment, through an asset sale to the employees of Service America. The acquiring corporation purchased a substantial majority of Service America's assets in exchange for assuming substantially all of Service America's liabilities in May 2005. Included in the assets acquired was a receivable from the Company for approximately \$4.7 million. The Company paid \$1 million of the receivable upon closing and the remainder was paid over the following year in 11 equal monthly installments.

During 2008 the Company conducted its business operations in two segments: Vitas Group ("Vitas") and the Roto-Rooter Group ("Roto-Rooter").

### **Forward Looking Statements**

This Annual Report contains or incorporates by reference certain forward looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The Company intends such statements to be subject to the safe harbors created by that legislation. Such statements involve risks and uncertainties that could cause actual results of operations to differ materially from these forward looking statements.

### **Financial Information about Industry Segments**

The required segment and geographic data for the Company's continuing operations (as described below) for three years ended December 31, 2006, 2007 and 2008 are shown in Note 4 of the Notes to Consolidated Financial Statements on pages 17-19 of the 2008 Annual Report to Stockholders and are incorporated herein by reference.

## [Table of Contents](#)

### **Description of Business by Segment**

The information called for by this item is included within Note 4 of the Notes to Consolidated Financial Statements appearing on pages 17-19 of the 2008 Annual Report to Stockholders is incorporated herein by reference.

### **Product and Market Development**

Each segment of the Company's business engages in a continuing program for the development and marketing of new services and products. While new products and services and new market development are important factors for the growth of each active segment of the Company's business, the Company does not expect that any new products and services or marketing effort, including those in the development stage, will require the investment of a material amount of the Company's assets.

### **Raw Materials**

The principal raw materials needed for the Company's manufacturing operations are purchased from United States sources. Product sales from goods manufactured by Roto-Rooter represent less than 3% of Chemed's total service revenues and sales. No segment of the Company experienced any material raw material shortages during 2008, although such shortages may occur in the future. Products manufactured and sold by the Company's Roto-Rooter segment generally may be reformulated to avoid the adverse impact of specific raw material shortage.

### **Patents, Service Marks and Licenses**

The Roto-Rooter® trademarks and service marks have been used and advertised since 1935 by Roto-Rooter Corporation, a wholly owned indirect subsidiary of the Company. The Roto-Rooter® marks are among the most highly recognized trademarks and service marks in the United States. The Company considers the Roto-Rooter® marks to be a valuable asset and a significant factor in the marketing of Roto-Rooter's franchises, products and services and the products and services provided by its franchises.

"Vitas" and "Innovative Hospice Care" are trademarks and servicemarks of Vitas Healthcare Corporation. The Company and its subsidiaries also own certain trade secrets including training manuals, cost information, customer information and software source codes.

### **Competition**

#### **Roto-Rooter**

All aspects of the sewer, drain, and pipe cleaning and plumbing repair businesses are highly competitive. Competition is, however, fragmented in most markets with local and regional firms providing the primary competition. The principal methods of competition are advertising, range of services provided, name recognition, speed and quality of customer service, service guarantees, and pricing.

No individual customer or market group is critical to the total sales of this segment.

#### **Vitas**

Hospice care in the United States is competitive. Because programs for hospice services are generally uniform, Vitas competes primarily on the basis of its ability to deliver quality, responsive services. Vitas is the nation's largest provider of hospice services in a market dominated by small, non-profit, community-based hospices. Approximately 50% of all hospices are not-for-profit. Because the hospice care market is highly fragmented, Vitas competes with a large number of organizations.

## Table of Contents

Vitas also competes with a number of national and regional hospice providers, including Odyssey Healthcare, Inc., hospitals, nursing homes, home health agencies and other health care providers. Many providers offer home care to patients who are terminally ill, and some actively market palliative care and hospice-like programs. In addition, various health care companies have diversified into the hospice market. Some of these health care companies have greater financial resources than Vitas.

Relatively few barriers to entry exist in the majority of markets served by Vitas. Accordingly, other companies that are not currently providing hospice care may enter these markets and expand the variety of services they offer to include hospice.

### **Research and Development**

The Company engages in a continuous program directed toward the development of new services, products and processes, the improvement of existing services, products and processes, and the development of new and different uses of existing products. The research and development expenditures from continuing operations have not been nor are they expected to be material.

### **Government Regulations**

#### **Roto-Rooter**

Roto-Rooter's franchising activities are subject to various federal and state franchising laws and regulations, including the rules and regulations of the Federal Trade Commission (the "FTC") regarding the offering or sale of franchises. The rules and regulations of the FTC require that Roto-Rooter provide all the prospective franchisees with specific information regarding the franchise program and Roto-Rooter in the form of a detailed franchise offering circular. In addition, a number of states require Roto-Rooter to register its franchise offering prior to offering or selling franchises in the state. Various state laws also provide for certain rights in favor of franchisees, including (i) limitations on the franchisor's ability to terminate a franchise except for good cause, (ii) restrictions on the franchisor's ability to deny renewal of a franchise, (iii) circumstances under which the franchisor may be required to purchase certain inventory of franchisees when a franchise is terminated or not renewed in violation of such laws, and (iv) provisions relating to arbitration. Roto-Rooter's ability to engage in the plumbing repair business is also subject to certain limitations and restrictions imposed by state and local licensing laws and regulations.

#### **Vitas**

*General.* The health care industry and Vitas' hospice programs are subject to extensive federal and state regulation. Vitas' hospices are licensed as required under state law as either hospices or home health agencies, or both, depending on the regulatory requirements of each particular state. In addition, Vitas' hospices are required to meet certain conditions of participation to be eligible to receive payments as hospices under Medicare and Medicaid programs. All of Vitas' hospices, other than those currently in development, are certified for participation as hospices in the Medicare program, and are also eligible to receive payments as hospices from the Medicaid program in each of the states in which Vitas operates. Vitas' hospices are subject to periodic survey by governmental authorities or private accrediting entities to assure compliance with state licensing, certification and accreditation requirements, as the case may be.

*Medicare Conditions of Participation.* Federal regulations require that a hospice program satisfy certain conditions of participation to be certified and receive Medicare payment for the services it provides. Failure to comply with the conditions of participation may result in sanctions, up to and including decertification from the Medicare program. See "Surveys and Audits" below.

## Table of Contents

The Medicare conditions of participation for hospice programs include the following:

*Governing Body.* Each hospice must have a governing body that assumes full responsibility for the policies and the overall operation of the hospice and for ensuring that all services are provided in a manner consistent with accepted standards of practice. The governing body must designate one individual who is responsible for the day-to-day management of the hospice.

*Medical Director.* Each hospice must have a medical director who is a physician and who assumes responsibility for overseeing the medical component of the hospice's patient care program.

*Direct Provision of Core Services.* Medicare limits those services for which the hospice may use individual independent contractors or contract agencies to provide care to patients. Specifically, substantially all nursing, social work, and counseling services must be provided directly by hospice employees meeting specific educational and professional standards. During periods of peak patient loads or under extraordinary circumstances, the hospice may be permitted to use contract workers, but the hospice must agree in writing to maintain professional, financial and administrative responsibility for the services provided by those individuals or entities.

*Professional Management of Non-Core Services.* A hospice may arrange to have non-core services such as therapy services, home health aide services, medical supplies or drugs provided by a non-employee or outside entity. If the hospice elects to use an independent contractor to provide non-core services, however, the hospice must retain professional management responsibility for the arranged services and ensure that the services are furnished in a safe and effective manner by qualified personnel, and in accordance with the patient's plan of care.

*Plan of Care.* The patient's attending physician, the medical director or the designated hospice physician, and interdisciplinary team must establish an individualized written plan of care prior to providing care to any hospice patient. The plan must assess the patient's needs and identify services to be provided to meet those needs and must be reviewed and updated at specified intervals.

*Continuation of Care.* A hospice may not discontinue or reduce care provided to a Medicare beneficiary if the individual becomes unable to pay for that care.

*Informed Consent.* The hospice must obtain the informed consent of the hospice patient, or the patient's legal representative, that specifies the type of care services that may be provided as hospice care.

*Training.* A hospice must provide ongoing training for its employees.

*Quality Assurance.* A hospice must conduct ongoing and comprehensive self-assessments of the quality and appropriateness of care it provides and that its contractors provide under arrangements to hospice patients.

*Interdisciplinary Team.* A hospice must designate an interdisciplinary team to provide or supervise hospice care services. The interdisciplinary team develops and updates plans of care, and establishes policies governing the day-to-day provision of hospice services. The team must include at least a physician, registered nurse, social worker and spiritual or other counselor. A registered nurse must be designated to coordinate the plan of care.

*Volunteers.* Hospice programs are required to recruit and train volunteers to provide patient care services or administrative services. Volunteer services must be provided in an amount equal to at least five percent of the total patient care hours provided by all paid hospice employees and contract staff.

## Table of Contents

*Licensure.* Each hospice and all hospice personnel must be licensed, certified or registered in accordance with applicable federal, state and local laws and regulations.

*Central Clinical Records.* Hospice programs must maintain clinical records for each hospice patient that are organized in such a way that they may be easily retrieved. The clinical records must be complete and accurate and protected against loss, destruction, and unauthorized use.

*Surveys and Audits.* Hospice programs are subject to periodic survey by federal and state regulatory authorities and private accrediting entities to ensure compliance with applicable licensing and certification requirements and accreditation standards. Regulators conduct periodic surveys of hospice programs and provide reports containing statements of deficiencies for alleged failure to comply with various regulatory requirements. Survey reports and statements of deficiencies are common in the healthcare industry. In most cases, the hospice program and regulatory authorities will agree upon any steps to be taken to bring the hospice into compliance with applicable regulatory requirements. In some cases, however, a state or federal regulatory authority may take a number of adverse actions against a hospice program, including the imposition of fines, temporary suspension of admission of new patients to the hospice's service or, in extreme circumstances, decertification from participation in the Medicare or Medicaid programs or revocation of the hospice's license.

From time to time Vitas receives survey reports containing statements of deficiencies. Vitas reviews such reports and takes appropriate corrective action. Vitas believes that its hospices are in material compliance with applicable licensure and certification requirements. If a Vitas hospice were found to be out of compliance and actions were taken against a Vitas hospice, they could materially adversely affect the hospice's ability to continue to operate, to provide certain services and to participate in the Medicare and Medicaid programs, which could materially adversely affect Vitas.

*Billing Audits/ Claims Reviews.* The Medicare program and its fiscal intermediaries and other payors periodically conduct pre-payment or post-payment reviews and other reviews and audits of health care claims, including hospice claims. There is pressure from state and federal governments and other payors to scrutinize health care claims to determine their validity and appropriateness. In order to conduct these reviews, the payor requests documentation from Vitas and then reviews that documentation to determine compliance with applicable rules and regulations, including the eligibility of patients to receive hospice benefits, the appropriateness of the care provided to those patients and the documentation of that care. During the past several years, Vitas' claims have been subject to review and audit.

*Certificate of Need Laws and Other Restrictions.* Some states, including Florida, have certificate of need or similar health planning laws that apply to hospice care providers. These states may require some form of state agency review or approval prior to opening a new hospice program, to adding or expanding hospice services, to undertaking significant capital expenditures or under other specified circumstances. Approval under these certificate of need laws is generally conditioned on the showing of a demonstrable need for services in the community. Vitas may seek to develop, acquire or expand hospice programs in states having certificate of need laws. To the extent that state agencies require Vitas to obtain a certificate of need or other similar approvals to expand services at existing hospice programs or to make acquisitions or develop hospice programs in new or existing geographic markets, Vitas' plans could be adversely affected by a failure to obtain such certificate or approval. In addition, competitors may seek administratively or judicially to challenge such an approval or proposed approval by the state agency. Such a challenge, whether or not ultimately successful, could adversely affect Vitas.

*Limitations on For-Profit Ownership.* A few states have laws that restrict the development and expansion of for-profit hospice programs. For example, in New York, a hospice generally cannot be owned by a corporation that has another corporation as a stockholder. These types of restrictions could affect Vitas' ability to expand into New York, or in other jurisdictions with similar restrictions.

## Table of Contents

*Limits on the Acquisition or Conversion of Non-Profit Health Care Organizations.* An increasing number of states have enacted laws that restrict the ability of for-profit entities to acquire or otherwise assume the operations of a non-profit health care provider. Some states may require government review, public hearings, and/or government approval of transactions in which a for-profit entity proposes to purchase certain non-profit healthcare organizations. Heightened scrutiny of these transactions may significantly increase the costs associated with future acquisitions of non-profit hospice programs in some states, otherwise increase the difficulty in completing those acquisitions or prevent them entirely. Vitas cannot assure that it will not encounter regulatory or governmental obstacles in connection with any proposed acquisition of non-profit hospice programs in the future.

*Professional Licensure and Participation Agreements.* Many hospice employees are subject to federal and state laws and regulations governing the ethics and practice of their profession, including physicians, physical, speech and occupational therapists, social workers, home health aides, pharmacists and nurses. In addition, those professionals who are eligible to participate in the Medicare, Medicaid or other federal health care programs as individuals must not have been excluded from participation in those programs at any time.

*State Licensure of Hospice.* Each of Vitas' hospices must be licensed in the state in which it operates. State licensure rules and regulations require that Vitas' hospices maintain certain standards and meet certain requirements, which may vary from state to state. Vitas believes that its hospices are in material compliance with applicable licensure requirements. If a Vitas hospice were found to be out of compliance and actions were taken against a Vitas hospice, they could materially adversely affect the hospice's ability to continue to operate, to provide certain services and to participate in the Medicare and Medicaid programs, which could materially adversely affect Vitas.

*Overview of Government Payments—General.* Over 90% of Vitas' revenue consisted of payments from the Medicare and Medicaid programs. Such payments are made primarily on a "per diem" basis. Under the per diem reimbursement methodology, Vitas is essentially at risk for the cost of eligible services provided to hospice patients. Profitability is therefore largely dependent upon Vitas' ability to manage the costs of providing hospice services to patients. Increases in operating costs, such as labor and supply costs that are subject to inflation and other increases, without a compensating increase in Medicare and Medicaid rates, could have a material adverse effect on Vitas' business in the future. The Medicare and Medicaid programs are increasing pressure to control health care costs and to decrease or limit increases in reimbursement rates for health care services. As with most government programs, the Medicare and Medicaid programs are subject to statutory and regulatory changes, possible retroactive and prospective rate and payment adjustments, administrative rulings, freezes and funding reductions, all of which may adversely affect the level of program payments and could have a material adverse effect on Vitas' business. Vitas' levels of revenues and profitability are subject to the effect of legislative and regulatory changes, including possible reductions in coverage or payment rates, or changes in methods of payment, by the Medicare and Medicaid programs.

### *Overview of Government Payments — Medicare*

*Medicare Eligibility Criteria.* To receive Medicare payment for hospice services, the hospice medical director and, if the patient has one, the patient's attending physician, must certify that the patient has a life expectancy of six months or less if the illness runs its normal course. This determination is made based on the physician's clinical judgement. Due to the uncertainty of such prognoses, however, it is likely and expected that some percentage of hospice patients will not die within six months of entering a hospice program. The Medicare program (among other third-party payers) recognizes that terminal illnesses often do not follow an entirely predictable course, and therefore the hospice benefit remains available to beneficiaries so long as the hospice physician or the patient's attending physician continues to certify that the patient's life expectancy remains six months or less. Specifically, the Medicare hospice benefit provides for two initial 90-day benefit periods followed by an unlimited number of 60-day periods. In order to qualify for hospice care, a Medicare beneficiary must elect hospice care and waive any right to other Medicare benefits related to his or her terminal illness. A Medicare beneficiary may revoke his or her election of the Medicare hospice benefit at any time and resume receiving regular

## Table of Contents

Medicare benefits. The patient may elect the hospice benefit again at a later date so long as he or she remains eligible. Increased regulatory scrutiny of compliance with the Medicare six-month eligibility rule has impacted the hospice industry. The Medicare program, however, has reaffirmed that Medicare hospice beneficiaries are not limited to six months of coverage and that there is no limit on how long a Medicare beneficiary can continue to receive hospice benefits and services, provided that the beneficiary continues to meet the eligibility criteria under the Medicare hospice program.

*Levels of Care.* Medicare pays for hospice services on a prospective payment system basis under which Vitas receives an established payment rate for each day that it provides hospice services to a Medicare beneficiary. These rates are subject to annual adjustments for inflation and vary based upon the geographic location where the services are provided. The rate Vitas receives depends on which of the following four levels of care is being provided to the beneficiary:

*Routine Home Care.* The routine home care rate is paid for each day that a patient is in a hospice program and is not receiving one of the other categories of hospice care. The routine home care rate does not vary based upon the volume or intensity of services provided by the hospice program.

*General Inpatient Care.* The general inpatient care rate is paid when a patient requires inpatient services for a short period for pain control or symptom management which cannot be managed in other settings. General inpatient care services must be provided in a Medicare or Medicaid certified hospital or long-term care facility or at a freestanding inpatient hospice facility with the required registered nurse staffing.

*Continuous Home Care.* Continuous home care, which Vitas refers to as “Intensive Comfort Care”, is provided to patients while at home, during periods of crisis when intensive monitoring and care, primarily nursing care, is required in order to achieve palliation or management of acute medical symptoms. Continuous home care requires a minimum of 8 hours of care within a 24-hour day, which begins and ends at midnight. The care must be predominantly nursing care provided by either a registered nurse or licensed practical nurse. While the published Medicare continuous home care rates are daily rates, Medicare actually pays for continuous home care services on an hourly basis. This hourly rate is calculated by dividing the daily rate by 24.

*Respite Care.* Respite care permits a hospice patient to receive services on an inpatient basis for a short period of time in order to provide relief for the patient’s family or other caregivers from the demands of caring for the patient. A hospice can receive payment for respite care for a given patient for up to five consecutive days at a time, after which respite care is reimbursed at the routine home care rate.

*Medicare Payment for Physician Services.* Payment for direct patient care physician services delivered by hospice physicians is billed separately by the hospice to the Medicare intermediary and paid at the lesser of the actual charge or the Medicare allowable charge for these services. This payment is in addition to the daily rates Vitas receives for hospice care. Payment for hospice physicians’ administrative and general supervisory activities is included in the daily rates discussed above. Payments for attending physician professional services (other than services furnished by hospice physicians) are not paid to the hospice, but rather are paid directly to the attending physician by the Medicare intermediary. For fiscal 2008, 1.8% of Vitas’ net revenue was attributable to physician services.

*Medicare Limits on Hospice Care Payments.* Medicare payments for hospice services are subject to two additional limits or “caps”. Each of Vitas’ hospice programs is separately subject to both of these “caps”. Both of these “caps” are determined on an annual basis for the period running from November 1 through October 31 of each year.

First, under a Medicare rule known as the “80-20” rule applicable to the Medicare inpatient services, if the number of inpatient care days furnished by a hospice to Medicare beneficiaries exceeds 20% of the total days of

## Table of Contents

hospice care furnished by such hospice to Medicare beneficiaries, Medicare payments to the hospice for inpatient care days exceeding the cap are reduced to the routine home care rate. Vitas has never exceeded the inpatient cap.

Second, Medicare payments to a hospice are also subject to a separate cap based on overall average payments per admission. Any payments exceeding this overall hospice cap must be refunded by the hospice. This cap was set at \$22,386.15 per admission for the twelve-month period ended on October 31, 2008, and is adjusted annually to account for inflation. Vitas' hospices may be subject to future payment reductions or recoupments as the result of this cap. As of December 31, 2008 we recorded no cap liability for 2008. We recorded a cap liability of \$235,000 for one program for the 2009 measurement period.

*Medicare Managed Care Programs.* The Medicare program has entered into contracts with managed care companies to provide managed care benefits to Medicare beneficiaries who elect to participate in managed care programs. These managed care programs are commonly referred to as Medicare HMOs, Medicare + Choice or Medicare risk products. Vitas provides hospice care to Medicare beneficiaries who participate in these managed care programs, and Vitas is paid for services provided to these beneficiaries in the same way and at the same rates as those of other Medicare beneficiaries who are not in a Medicare managed care program. Under current Medicare policy, Medicare pays the hospice directly for services provided to these managed care program participants and then reduces the standard per-member, per-month payment that the managed care program otherwise receives.

### *Overview of Government Payments — Medicaid*

*Medicaid Coverage and Reimbursements.* State Medicaid programs are another source of Vitas' net patient revenue. Medicaid is a state-administered program financed by state funds and matching federal funds to provide medical assistance to the indigent and certain other eligible persons. In 1986, hospice services became an optional state Medicaid benefit. For those states that elect to provide a hospice benefit, the Medicaid program is required to pay the hospice at rates at least equal to the rates provided under Medicare and calculated using the same methodology. States maintain flexibility to establish their own hospice election procedures and to limit the number and duration of benefit periods for which they will pay for hospice services. Reimbursement from state Medicaid programs in 2008 accounted for 5% of Vitas' revenues.

*Nursing Home Residents.* For Vitas' patients who receive nursing home care under a state Medicaid program and who elect hospice care under Medicare or Medicaid, Vitas contracts with nursing homes for the nursing homes' provision of room and board services. In addition to the applicable Medicare or Medicaid hospice daily or hourly rate, the state generally must pay Vitas an amount equal to at least 95% of the Medicaid daily nursing home rate for room and board services furnished to the patient by the nursing home. Under Vitas' standard nursing home contracts, Vitas pays the nursing home for these room and board services at the Medicaid daily nursing home rate.

*Adjustments to Medicare and Medicaid Payment Rates.* Payment rates under the Medicare and Medicaid programs are adjusted annually based upon the Hospital Market Basket Index; however, the adjustments have historically been less than actual inflation. On October 1, 2005 the base rates increased by 3.4%. On October 1, 2006 the base rates increased by 3.4%. On October 1, 2007, the base rates increased by 3.3%. On October 1, 2008 the base rates increased by 2.5%. These base rates are further modified by the Hospice Wage Index to reflect local differences in wages according to the revised wage index. It is possible that there will be further modifications to the rate structure under which the Medicare or Medicaid programs pay for hospice care services. Any future reductions in the rate of increase in Medicare and Medicaid payments may have an adverse impact on Vitas' net patient service revenue and profitability.

### **Other Healthcare Regulations**

*Federal and State Anti-Kickback Laws and Safe Harbor Provisions.* The federal Anti-Kickback Law makes it a felony to knowingly and willingly offer, pay, solicit or receive any form of remuneration in exchange for referring, recommending, arranging, purchasing, leasing or ordering items or services covered by a federal health care program including Medicare or Medicaid. The Anti-Kickback Law applies regardless of whether the remuneration is provided directly or indirectly, in cash or in kind. Although the Anti-Kickback statute does not prohibit all financial transactions or relationships that providers of healthcare items or services may have with each other, interpretations of the law have been very broad. Under current law, courts and federal regulatory authorities have stated that this law is violated if even one purpose (as opposed to the sole or primary purpose) of the arrangement is to induce referrals.

Violations of the Anti-Kickback Law carry potentially severe penalties including imprisonment of up to five years, criminal fines of up to \$25,000 per act, civil money penalties of up to \$50,000 per act, and additional damages of up to three times the amounts claimed or remuneration offered or paid. Federal law also authorizes exclusion from the Medicare and Medicaid programs for violations of the Anti-Kickback Law.

The Anti-Kickback Law contains several statutory exceptions to the broad prohibition. In addition, Congress authorized the Office of Inspector General (“OIG”) to publish numerous “safe harbors” that exempt some practices from enforcement action under the Anti-Kickback Law and related laws. These statutory exceptions and regulatory safe harbors protect various bona fide employment relationships, contracts for the rental of space or equipment, personal service arrangements, and management contracts, among other things, provided that certain conditions set forth in the statute or regulations are satisfied. The safe harbor regulations, however, do not comprehensively describe all lawful relationships between healthcare providers and referral sources, and the failure of an arrangement to satisfy all of the requirements of a particular safe harbor does not mean that the arrangement is unlawful. Failure to comply with the safe harbor provisions, however, may mean that the arrangement will be subject to scrutiny.

Many states, including states where Vitas does business, have adopted similar prohibitions against payments that are intended to induce referrals of patients, regardless of the source of payment. Some of these state laws lack explicit “safe harbors” that may be available under federal law. Sanctions under these state anti-kickback laws may include civil money penalties, license suspension or revocation, exclusion from the Medicare or Medicaid programs, and criminal fines or imprisonment. Little precedent exists regarding the interpretation or enforcement of these statutes.

Vitas is required under the Medicare conditions of participation and some state licensing laws to contract with numerous healthcare providers and practitioners, including physicians, hospitals and nursing homes, and to arrange for these individuals or entities to provide services to Vitas’ patients. In addition, Vitas has contracts with other suppliers, including pharmacies, ambulance services and medical equipment companies. Some of these individuals or entities may refer, or be in a position to refer, patients to Vitas, and Vitas may refer, or be in a position to refer, patients to these individuals or entities. These arrangements may not qualify for a safe harbor. Vitas from time to time seeks guidance from regulatory counsel as to the changing and evolving interpretations and the potential applicability of these anti-kickback laws to its programs, and in response thereto, takes such actions as it deems appropriate. The Company generally believes that Vitas’ contracts and arrangements with providers, practitioners and suppliers do not violate applicable anti-kickback laws. However, the Company cannot assure that such laws will ultimately be interpreted in a manner consistent with Vitas’ practices.

*HIPAA Anti-Fraud Provisions.* HIPAA includes several revisions to existing health care fraud laws by permitting the imposition of civil monetary penalties in cases involving violations of the anti-kickback statute or contracting with excluded providers. In addition, HIPAA created new statutes making it a federal felony to engage in fraud, theft, embezzlement, or the making of false statements with respect to healthcare benefit programs, which include private, as well as government programs. In addition, federal enforcement officials have the ability to

## Table of Contents

exclude from the Medicare and Medicaid programs any investors, officers and managing employees associated with business entities that have committed healthcare fraud, even if the investor, officer or employee had no actual knowledge of the fraud.

*OIG Fraud Alerts, Advisory Opinions and Other Program Guidance.* In 1976, Congress established the OIG to, among other things, identify and eliminate fraud, abuse and waste in HHS programs. To identify and resolve such problems, the OIG conducts audits, investigations and inspections across the country and issues public pronouncements identifying practices that may be subject to heightened scrutiny. In the last several years, there have been a number of hospice related audits and reviews conducted. These reviews and recommendations have included:

- Better ensuring that Medicare hospice eligibility determinations are made in accordance with the Medicare regulations; and
- Revising the annual cap on hospice benefits to better reflect the cost of care provided.

From time to time, various federal and state agencies, such as HHS and the OIG, issue a variety of pronouncements, including fraud alerts, the OIG's Annual Work Plan and other reports, identifying practices that may be subject to heightened governmental scrutiny. The Company cannot predict what, if any, changes may be implemented in coverage, reimbursement, or enforcement policies as a result of these OIG reviews and recommendations.

On April 7, 2005 the Company announced the Office of Inspector General ("OIG") for the Department of Health and Human Services served Vitas with civil subpoenas relating to Vitas' alleged failure to appropriately bill Medicare and Medicaid for hospice services. As part of this investigation, the OIG selected medical records for 320 past and current patients from Vitas' three largest programs for review. It also sought policies and procedures dating back to 1998 covering admissions, certifications, recertifications, and discharges. During the third quarter of 2005 and again in May 2006, the OIG requested additional information of the Company. The court dismissed a related qui tam complaint filed in U.S. District Court for the Southern District of Florida with prejudice in July 2007. The plaintiffs appealed this dismissal, which the Court of Appeals affirmed. The government continues to investigate the complaint's allegations.

*Federal False Claims Acts.* The federal law includes several criminal and civil false claims provisions, which provide that knowingly submitting claims for items or services that were not provided as represented may result in the imposition of multiple damages, administrative civil money penalties, criminal fines, imprisonment, and/or exclusion from participation in federally funded healthcare programs, including Medicare and Medicaid. In addition, the OIG may impose extensive and costly corporate integrity requirements upon a healthcare provider that is the subject of a false claims judgement or settlement. These requirements may include the creation of a formal compliance program, the appointment of a government monitor, and the imposition of annual reporting requirements and audits conducted by an independent review organization to monitor compliance with the terms of the agreement and relevant laws and regulations.

The Civil False Claims Act prohibits the known filing of a false claim or the known use of false statements to obtain payments. Penalties for violations include fines ranging from \$5,500 to \$11,000, plus treble damages, for each claim filed. Provisions in the Civil False Claims Act also permit individuals to bring actions against individuals or businesses in the name of the government as so called "qui tam" relators. If a qui tam relator's claim is successful, he or she is entitled to share the government's recovery.

Both direct enforcement activity by the government and qui tam actions have increased significantly in recent years and have increased the risk that a healthcare company may have to defend a false claims action, pay fines or be excluded from the Medicare and/or Medicaid programs as a result of an investigation arising out of this

## [Table of Contents](#)

type of an action. Because of the complexity of the government regulations applicable to the healthcare industry, the Company cannot assure that Vitas will not be the subject of other actions under the False Claims Act.

*State False Claims Laws.* At least 10 states and the District of Columbia, including states in which Vitas currently operates, have adopted state false claims laws that mirror to some degree the federal false claims laws. While these statutes vary in scope and effect, the penalties for violating these false claims laws include administrative, civil and/or criminal fines and penalties, imprisonment, and the imposition of multiple damages.

*The Stark Law and State Physician Self-Referral Laws.* Section 1877 of the Social Security Act, commonly known as the “Stark Law”, prohibits physicians from referring Medicare or Medicaid patients for “designated health services” to entities in which they hold an ownership or investment interest or with whom they have a compensation arrangement, subject to a number of statutory and regulatory exceptions. Penalties for violating the Stark Law are severe and include:

- Denial of payment;
- Civil monetary penalties of \$15,000 per referral or \$1,000,000 for “circumvention schemes;”
- Assessments equal to 200% of the dollar value of each such service provided; and
- Exclusion from the Medicare and Medicaid programs.

Hospice care itself is not specifically listed as a designated health service; however, certain services that Vitas provides, or in the future may provide, are among the services identified as designated health services for purposes of the self-referral laws. The Company cannot assure that future regulatory changes will not result in hospice services becoming subject to the Stark Law’s ownership, investment or compensation prohibitions in the future.

Many states where Vitas operates have laws similar to the Stark Law, but with broader effect because they apply regardless of the source of payment for care. Penalties similar to those listed above as well as the loss of state licensure may be imposed in the event of a violation of these state self-referral laws. Little precedent exists regarding the interpretation or enforcement of these statutes.

*Civil Monetary Penalties.* The Civil Monetary Penalties Statute provides that civil penalties ranging between \$10,000 and \$50,000 per claim or act may be imposed on any person or entity that knowingly submits improperly filed claims for federal health benefits or that offers or makes payment to induce a beneficiary or provider to reduce or limit the use of health care services or to use a particular provider or supplier. Civil monetary penalties may be imposed for violations of the anti-kickback statute and for the failure to return known overpayments, among other things.

*Prohibition on Employing or Contracting with Excluded Providers.* The Social Security Act and federal regulations state that individuals or entities that have been convicted of a criminal offense related to the delivery of an item or service under Medicare or Medicaid programs or that have been convicted, under state and federal law, of a criminal offense relating to neglect or abuse of residents in connection with the delivery of a healthcare item or service cannot participate in any federal health care programs, including Medicare and Medicaid. Additionally, individuals and entities convicted of fraud, that have had their licenses revoked or suspended, or that have failed to provide services of adequate quality also may be excluded from the Medicare and Medicaid programs. Federal regulations prohibit Medicare providers, including hospice programs, from submitting claims for items or services or their related costs if an excluded provider furnished those items or services. The OIG maintains a list of excluded persons and entities. Nonetheless, it is possible that Vitas might unknowingly bill for services provided by an excluded person or entity with whom it contracts. The penalty for contracting with an excluded provider may range

from civil monetary penalties of \$50,000 and damages of up to three times the amount of payment that was inappropriately received.

*Corporate Practice of Medicine and Fee Splitting.* Most states have laws that restrict or prohibit anyone other than a licensed physician, including business entities such as corporations, from employing physicians and/or prohibit payments or fee-splitting arrangements between physicians and corporations or unlicensed individuals. Penalties for violations of corporate practice of medicine and fee-splitting laws vary from state to state, but may include civil or criminal penalties, the restructuring or termination of the business arrangements between the physician and unlicensed individual or business entity, or even the loss of the physician's license to practice medicine. These laws vary widely from state to state both in scope and origin (e.g. statute, regulation, Attorney General opinion, court ruling, agency policy) and in most instances have been subject to only limited interpretation by the courts or regulatory bodies.

Vitas employs or contracts with physicians to provide medical direction and patient care services to its patients. Vitas has made efforts in those states where certain contracting or fee arrangements are restricted or prohibited to structure those arrangements in compliance with the applicable laws and regulations. Despite these efforts, however, the Company cannot assure that agency officials charged with enforcing these laws will not interpret Vitas' contracts with employed or independent contractor physicians as violating the relevant laws or regulations. Future determinations or interpretations by individual states with corporate practice of medicine or fee splitting restrictions may force Vitas to restructure its arrangements with physicians in those locations.

*Health Information Practices.* There currently are numerous legislative and regulatory initiatives at both the state and federal levels that address patient privacy concerns. In particular, federal regulations issued under the Health Insurance Portability and Accountability Act of 1996 ("HIPAA") require Vitas to protect the privacy and security of patients' individual health information. HIPAA does not automatically preempt applicable state laws and regulations concerning Vitas' use, disclosure and maintenance of patient health information, which means that Vitas is subject to a complex regulatory scheme that, in many instances, requires Vitas to comply with both federal and state laws and regulations.

In August 2000, HHS published final regulations establishing health care transaction standards, and code sets for the electronic transmission of health care information in connection with certain transactions, such as billing or health plan eligibility (the "Transactions Standard"). The official deadline for compliance with the Transactions Standards for covered entities such as Vitas was October 16, 2003. The Centers for Medicare and Medicaid Services ("CMS") is the division of HHS that is responsible for interpreting and enforcing the Transactions Standard. Failure to comply with the Transactions Standard may subject covered entities, including Vitas, to civil monetary penalties and possibly to criminal penalties. Vitas believes that it has made significant and appropriate good faith efforts to comply with the Transactions Standard and to develop an appropriate contingency plan as encouraged by CMS. It is unclear, however, how CMS will regulate providers in general or Vitas in particular with respect to compliance with the Transactions Standard. Consequently, it also is unclear whether Vitas would be found to be in material compliance with the Transactions Standard if CMS were to review Vitas' electronic claims submissions and assess Vitas' electronic transactions, or whether Vitas would be required to expend substantial sums on acquiring and implementing new information systems, or would otherwise be affected in a manner that would negatively impact its profitability.

*Additional Federal and State Regulation.* Federal and state governments also regulate various aspects of the hospice industry. In particular, Vitas' operations are subject to federal and state health regulatory laws covering professional services, the dispensing of drugs and certain types of hospice activities. Some of Vitas' employees are subject to state laws and regulations governing the ethics and professional practice of medicine, respiratory therapy, pharmacy and nursing.

*Compliance with Health Regulatory Laws.* Vitas maintains an internal regulatory compliance review program and from time to time retains regulatory counsel for guidance on compliance matters. The Company

## Table of Contents

cannot assure, however, that Vitas' practices, if reviewed, would be found to be in compliance with applicable health regulatory laws, as such laws ultimately may be interpreted, or that any non-compliance with such laws would not have a material adverse effect on Vitas.

### **Environmental Matters**

Roto-Rooter's operations are subject to various federal, state, and local laws and regulations regarding environmental matters and other aspects of the operation of a sewer and drain cleaning, HVAC and plumbing services business. For certain other activities, such as septic tank and grease trap pumping, Roto-Rooter is subject to state and local environmental health and sanitation regulations.

At December 31, 2008, the Company's accrual for its estimated liability for potential environmental cleanup and related costs arising from the sale of DuBois Chemicals Inc. ("DuBois") amounted to \$1.7 million. Of this balance, \$900,000 is included in other liabilities and \$800,000 is included in other current liabilities. The Company is contingently liable for additional DuBois-related environmental cleanup and related costs up to a maximum of \$14.9 million. On the basis of a continuing evaluation of the Company's potential liability, and in consultation with the Company's environmental attorney, management believes that it is not probable this additional liability will be paid. Accordingly, no provision for this contingent liability has been recorded. Although it is not presently possible to reliably project the timing of payments related to the Company's potential liability for environmental costs, management believes that any adjustments to its recorded liability will not materially adversely affect its financial position or results of operations.

The Company, to the best of its knowledge, is currently in compliance in all material respects with the environmental laws and regulations affecting its operations. Such environmental laws, regulations and enforcement proceedings have not required the Company to make material increases in or modifications to its capital expenditures and they have not had a material adverse effect on sales or net income. Capital expenditures for the purpose of complying with environmental laws and regulations during 2009 and 2010 with respect to continuing operations are not expected to be material in amount; there can be no assurance, however, that presently unforeseen legislative enforcement actions will not require additional expenditures.

### **Seasonality**

Advertising costs for Roto-Rooter inordinately impact the Company's fourth-quarter results. Roto-Rooter recognizes telephone directory costs immediately upon distribution of a directory by its publisher into the community. Since a large number of directories are distributed in the fourth quarter, this direct expense accounting policy results in fourth-quarter earnings including a disproportionately large share of Roto-Rooter's full-year telephone directory advertising expense. In the fourth quarter 2008, Roto-Rooter expensed \$7.4 million of total advertising costs that represented 31% of its aggregate advertising costs for the full-year 2008.

### **Employees**

On December 31, 2008, Chemed Corporation had a total of 11,884 employees.

### **Available Information**

The Company's Internet address is [www.chemed.com](http://www.chemed.com). The Company's Annual Report on Form 10-K, quarterly reports on Form 10-Q, and current reports on Form 8-K, and amendments to those reports filed or furnished pursuant to Section 13(a) or 15(d) of the Exchange Act are electronically available through the SEC (<http://www.sec.gov>) or the Company's website as soon as reasonably practicable after such reports are filed with, or furnished to, the SEC.

## [Table of Contents](#)

Annual reports, press releases, Board Committee charters, Code of Ethics, Corporate governance guidelines and other printed materials may be obtained from the website or from Chemed Investor Relations without charge by writing to 2600 Chemed Center, 255 East Fifth Street, Cincinnati, Ohio 45202 or by calling 800-2CHEMED or 513-762-6429.

### **Item 1A. Risk Factors**

You should carefully consider the risks described below. They are not the only ones facing the Company. Other risks and uncertainties not currently known to us or that we deem to be immaterial may also materially and adversely affect our business, financial condition, or results of operations.

#### **GENERAL**

##### **We have incurred debt to finance the operations of the Company. We reduced our outstanding debt by \$15 million in 2008.**

The Company has debt service obligations that may restrict our operating flexibility. We cannot assure you that our cash flow from operations will be sufficient to service our debt, which may require us to borrow additional funds, or restructure or otherwise refinance our debt. In addition, the Company has the ability to expand its debt and borrowing capacity subject to various restrictions and covenants defined by its creditors. The interest rate the Company pays will fluctuate from time to time based upon a number of factors including current LIBOR rates and Company operating performance. Significant changes in these factors could result in a material change in the Company's interest expense.

Our indebtedness could have important consequences for our business. Among other things, our indebtedness may:

- Limit our ability to obtain additional financing;
- Limit our flexibility in planning for, or reacting to, changes in the markets in which we compete;
- Place us at a competitive disadvantage relative to our competitors with less indebtedness;
- Increase our exposure to interest rate increases due to variable interest rates on certain borrowings;
- Limit our ability to complete future acquisitions;
- Limit our ability to make capital expenditures;
- Render us more vulnerable to general adverse economic and industry conditions; and
- Require us to dedicate a substantial portion of our cash flow to service and repay our debt.

Servicing our indebtedness will require a significant amount of cash, and our ability to generate cash depends on many factors beyond our control.

Our ability to repay or to refinance our indebtedness and to pay interest on our indebtedness will depend on our operating performance, which may be affected by factors beyond our control. These factors could include operating difficulties, increased operating costs, our competitors' actions and regulatory developments. Our ability to meet our debt service and other obligations may depend in significant part on the extent to which we successfully

## [Table of Contents](#)

implement our business strategy. We cannot assure you that we will be able to implement our strategy fully or that the anticipated results of our strategy will be realized. Current credit market conditions may make it difficult for us to obtain new financing or refinance our current debt on terms and conditions acceptable to us.

If our cash flows and capital resources are insufficient to fund our debt service obligations, we may be forced to reduce or delay capital expenditures, sell assets, seek additional equity capital or restructure our debt. We cannot assure you that our cash flows and capital resources will be sufficient to make scheduled payments of principal and interest on our indebtedness in the future or that alternative measures would successfully meet our debt service obligations.

As certain of our obligations under our credit facilities and certain other borrowings could bear interest at floating rates, an increase in interest rates could further increase our debt service costs and adversely affect our cash flows.

We have debt that is convertible into shares based on the Company's stock price. This could significantly dilute the ownership percentage of current stockholders.

### **The agreements and instruments governing our outstanding debt contain restrictions and limitations that could significantly impact our ability to operate our business and adversely affect the price of our Capital Stock.**

The operating and financial restrictions and covenants in our instruments of indebtedness restrict our ability to:

- Incur additional debt;
- Pay dividends, make redemptions and purchases of Capital Stock and make other restricted payments;
- Issue and sell capital stock of subsidiaries;
- Sell assets;
- Engage in transactions with affiliates;
- Restrict distributions from subsidiaries;
- Incur liens;
- Engage in business other than permitted businesses;
- Engage in sale/leaseback transactions;
- Engage in mergers or consolidations;
- Make capital expenditures;
- Make guarantees;
- Make investments and acquisitions;

## Table of Contents

- Enter into operating leases;
- Hedge interest rates; and
- Prepay other debt.

Moreover, if we are unable to meet the terms of the financial covenants or if we breach any of these covenants, a default could result under one or more of these agreements. A default, if not waived by our lenders, could accelerate repayment of our outstanding indebtedness. If acceleration occurs, we may not be able to repay our debt and it is unlikely that we would be able to borrow sufficient additional funds to refinance such debt on acceptable terms. In the event of any default under our credit facilities, the lenders thereunder could elect to declare all outstanding borrowings, together with accrued and unpaid interest and other fees, to be due and payable, and to require us to apply all of our available cash to repay these borrowings, any of which would be an event of default.

### **We depend on our management team and the loss of their service could have a material adverse effect on our business, financial condition and results of operations.**

Our success depends to a large extent upon the continued services of our executive management team. The loss of key personnel could have a material adverse effect on our business, financial condition, results of operations and cash flows. Additionally, we cannot assure you that we will be able to attract or retain other skilled personnel in the future.

### **Environmental compliance costs and liabilities could increase our expenses and adversely affect our financial condition.**

Our operations are subject to numerous environmental, health and safety laws and regulations that prohibit or restrict the discharge of pollutants into the environment and regulate employee exposure to hazardous substance in the workplace. Failure to comply with these laws could subject us to material costs and liabilities, including civil and criminal fines, costs to cleanup contamination we cause and, in some circumstances, costs to cleanup contamination we discover on our own property but did not cause.

Because we use and generate hazardous materials in some of our operations, we are potentially subject to material liabilities relating to the cleanup of contamination and personal injury claims. In addition, we have retained certain environmental liabilities in connection with the sale of former businesses. We are currently funding the cleanup of historical contamination at one of our former properties and contributing to the cleanup of third-party sites as a result of our sale of our former subsidiary DuBois Chemicals Inc. Although we have established a reserve for these liabilities, actual cleanup costs may exceed our current estimates due to factors beyond our control, such as the discovery of additional contamination or the enforcement of more stringent cleanup requirements. New laws and regulations or their stricter enforcement, the discovery of presently unknown conditions or the receipt of additional claims for indemnification could require us to incur costs or become the basis for new or increased liabilities that could have a material adverse effect on our business, financial condition and results of operations.

### **We are subject to certain anti-takeover statutes that might make it more difficult to effect a change in control of the Company.**

We are subject to the anti-takeover provisions of Section 203 of the Delaware General Corporation Law, which prohibits us from engaging in a “business combination” with an “interested stockholder” for a period of three years after the date of the transaction in which the person became an interested stockholder, unless the business combination is approved in a prescribed manner. The application of Section 203 could have the effect of delaying or preventing a change of control that could be advantageous to stockholders.

**An adverse ruling against us in certain litigation could have an adverse effect on our financial condition and results of operations.**

We are involved in litigation incidental to the conduct of our business currently and from time to time. The damages claimed against us in some of these cases are substantial.

See the “Legal Proceedings” sections of this 10-K for discussion of particular matters.

We cannot assure you that we will prevail in pending cases. Regardless of the outcome, such litigation is costly to manage, investigate and defend, and the related defense costs, diversion of management’s time and related publicity may adversely affect the conduct of our business and the results of our operations.

**ROTO-ROOTER**

**We face intense competition from numerous, fragmented competitors. If we do not compete effectively, our business may suffer.**

We face intense competition from numerous competitors, many of whom have less leverage than we do. The sewer, drain and pipe cleaning, and plumbing repair businesses are highly fragmented, with the bulk of the industries consisting of local and regional competitors. We compete primarily on the basis of advertising, range of services provided, name recognition, speed and quality of customer service, service guarantees and pricing. Our competitors may succeed in developing new or enhanced products and services more successful than ours and in marketing and selling existing and new products and services better than we do. In addition, new competitors may emerge. We cannot make any assurances that we will continue to be able to compete successfully with any of these companies.

**Our operations are subject to numerous laws and regulations, exposing us to potential claims and compliance costs that could adversely affect our business.**

We are subject to federal, state and local laws and regulations relating to franchising, insurance and other aspects of our business. These are discussed in greater detail under “Government Regulations” in the Description of Business section hereof. If we fail to comply with existing or future laws and regulations, we may be subject to governmental or judicial fines and sanctions. Our franchising activities are subject to various federal and state franchising laws and regulations, including the rules and regulations of the Federal Trade Commission (the “FTC”) regarding the offering or sale of franchises. The rules and regulations of the FTC require us to provide all of our prospective franchisees with specific information regarding us and our franchise program in the form of a detailed franchise offering circular. In addition, a number of states require us to register our franchise offering prior to offering or selling franchises in such states. Various state laws also provide for certain rights in favor of franchisees, including (i) limitations on the franchisor’s ability to terminate a franchise except for good cause, (ii) restrictions on the franchisor’s ability to deny renewal of a franchise, (iii) circumstances under which the franchisor may be required to purchase certain inventory of franchisees when a franchise is terminated or not renewed in violation of such laws and (iv) provisions relating to arbitration. The ability to engage in the plumbing repair business is also subject to certain limitations and restrictions imposed by the state and local licensing laws and regulations. We cannot predict what legislation or regulations affecting our business will be enacted in the future, how existing or future laws or regulations will be enforced, administered and interpreted, or the amount of future expenditures that may be required to comply with these laws or regulations. Compliance costs associated with governmental regulations could have a material adverse effect on our business, financial condition and results of operations.

## **VITAS**

**Vitas is highly dependent on payments from Medicare and Medicaid. If there are changes in the rate or methods governing these payments, Vitas' net patient service revenue and profits could materially decline.**

In excess of 90% of Vitas' net patient service revenue consists of payments from the Medicare and Medicaid programs. Such payments are made primarily on a "per diem" basis, subject to annual reimbursement caps. Because Vitas receives a per diem fee to provide eligible services to all patients, Vitas' profitability is largely dependent upon its ability to manage the costs of providing hospice services to patients. Increases in operating costs, such as labor and supply costs that are subject to inflation, without a compensating increase in Medicare and Medicaid rates, could have a material adverse effect on Vitas' business in the future. Medicare and Medicaid currently adjust the various hospice payment rates annually based on the increase or decrease of the hospital wage index basket, regionally adjusted. However, the increases may be less than actual inflation. Vitas' profitability could be negatively impacted if this adjustment were eliminated or reduced, or if Vitas' costs of providing hospice services increased more than the annual adjustment. In addition, cost pressures resulting from shorter patient lengths of stay and the use of more expensive forms of palliative care, including drugs and drug delivery systems, could negatively impact Vitas' profitability. Many payors are increasing pressure to control health care costs. In addition, both public and private payors are increasing pressure to decrease, or limit increases in, reimbursement rates for health care services. Vitas' levels of revenue and profitability will be subject to the effect of possible reductions in coverage or payment rates by third-party payors, including payment rates from Medicare and Medicaid.

Each state that maintains a Medicaid program has the option to provide reimbursement for hospice services at reimbursement rates generally required to be at least as much as Medicare rates. All states in which Vitas operates cover Medicaid hospice services; however, we cannot assure you that the states in which Vitas is presently operating or states into which Vitas could expand operations will continue to cover Medicaid hospice services. In addition, the Medicare and Medicaid programs are subject to statutory and regulatory changes, retroactive and prospective rate and payment adjustments, administrative rulings, freezes and funding reductions, all of which may adversely affect the level of program payments and could have a material adverse effect on Vitas' business. We cannot assure that Medicare and/or Medicaid payments to hospices will not decrease. Reductions in amounts paid by government programs for services or changes in methods or regulations governing payments could cause Vitas' net patient service revenue and profits to materially decline.

**Approximately one-third of Vitas' hospice patients reside in nursing homes. Changes in the laws and regulations regarding payments for hospice services and "room and board" provided to Vitas' hospice patients residing in nursing homes could reduce its net patient service revenue and profitability.**

For Vitas' hospice patients receiving nursing home care under certain state Medicaid programs who elect hospice care under Medicare and Medicaid, the state generally must pay Vitas, in addition to the applicable Medicare or Medicaid hospice per diem rate, an amount equal to at least 95% of the Medicaid per diem nursing home rate for "room and board" furnished to the patient by the nursing home. Vitas contracts with various nursing homes for the nursing homes' provision of certain "room and board" services that the nursing homes would otherwise provide Medicaid nursing home patients. Vitas bills and collects from the applicable state Medicaid program an amount equal to approximately 95% of the amount that would otherwise have been paid directly to the nursing home under the state's Medicaid plan. Under Vitas' standard nursing home contracts, it pays the nursing home for these "room and board" services at approximately 100% of the Medicaid per diem nursing home rate.

The reduction or elimination of Medicare and Medicaid payments for hospice patients residing in nursing homes would reduce Vitas' net patient service revenue and profitability. In addition, changes in the way nursing homes are reimbursed for "room and board" services provided to hospice patients residing in nursing homes could effect Vitas' ability to serve patients in nursing homes.

**If Vitas is unable to maintain relationships with existing patient referral sources or to establish new referral sources, Vitas' growth and profitability could be adversely affected.**

Vitas' success is heavily dependent on referrals from physicians, long-term care facilities, hospitals and other institutional health care providers, managed care companies, insurance companies and other patient referral sources in the communities that its hospice locations serve, as well as on its ability to maintain good relations with these referral sources. Vitas' referral sources may refer their patients to other hospice care providers or not to a hospice provider at all. Vitas' growth and profitability depend significantly on its ability to establish and maintain close working relationships with these patient referral sources and to increase awareness and acceptance of hospice care by its referral sources and their patients. We cannot assure you that Vitas will be able to maintain its existing relationships or that it will be able to develop and maintain new relationships in existing or new markets. Vitas' loss of existing relationships or its failure to develop new relationships could adversely affect its ability to expand or maintain its operations and operate profitably. Moreover, we cannot assure you that awareness or acceptance of hospice care will increase or remain at current levels.

**Vitas operates in an industry that is subject to extensive government regulation and claims reviews, and changes in law and regulatory interpretations could reduce its net patient service revenue and profitability and adversely affect its financial condition and results of operations.**

The healthcare industry is subject to extensive federal, state and local laws, rules and regulations relating to, among others:

- Payment for services;
- Conduct of operations, including fraud and abuse, anti-kickback prohibitions, self-referral prohibitions and false claims;
- Privacy and security of medical records;
- Employment practices; and
- Various state approval requirements, such as facility and professional licensure, certificate of need, compliance surveys and other certification or recertification requirements.

Changes in these laws, rules and regulations or in interpretations thereof could reduce Vitas' net patient service revenue and profitability. Vitas' ability to comply with such regulations is a key factor in determining the success of its business. See the "Government Regulations" section of this 10-K for a greater description of these matters.

*Fraud and Abuse Laws.* Vitas contracts with a significant number of health care providers and practitioners, including physicians, hospitals and nursing homes and arranges for these entities to provide services to Vitas' patients. Some of these health care providers and practitioners may refer, or be in a position to refer, patients to Vitas (or Vitas may refer patients to them). These arrangements may not qualify for a safe harbor. Vitas from time to time seeks guidance from regulatory counsel as to the changing and evolving interpretations and the potential applicability of the Anti-Kickback Law to its programs, and in response thereto, takes such actions as it deems appropriate. Vitas generally believes that its contracts and arrangements with providers, practitioners and suppliers should not be found to violate the Anti-Kickback Law. However, we cannot assure you that such laws will ultimately be interpreted in a manner consistent with Vitas' practices.

Several health care reform proposals have included an expansion of the Anti-Kickback Law to include referrals of any patients regardless of payor source, which is similar to the scope of certain laws that have been enacted at the state level. In addition, a number of states in which Vitas operates have laws, which vary from state

## [Table of Contents](#)

to state, prohibiting certain direct or indirect remuneration or fee-splitting arrangements between health care providers, regardless of payor source, for the referral of patients to a particular provider.

The federal Ethics in Patient Referral Act, Section 1877 of the Social Security Act (commonly known as the “Stark Law”) prohibits physicians from referring Medicare or Medicaid patients for “designated health services” to entities in which they hold an ownership or investment interest or with whom they have a compensation arrangement, subject to certain statutory or regulatory exceptions. We cannot assure you that future statutory or regulatory changes will not result in hospice services being subject to the Stark Law’s ownership, investment, compensation or referral prohibitions. Several states in which Vitas operates have similar laws which likewise are subject to change. Any such changes could adversely affect the business, financial condition and operating results of Vitas.

Further, under separate statutes, submission of claims for items or services that are “not provided as claimed” may lead to civil money penalties, criminal fines and imprisonment and/or exclusion from participation in Medicare, Medicaid and other federally funded state health care programs. These false claims statutes include the federal False Claims Act, which allows any person to bring suit on behalf of the federal government, known as a *qui tam* action, alleging false or fraudulent Medicare or Medicaid claims or other violations of the statute and to share in any amounts paid by the entity to the government in fines or settlement. See the discussion of the governmental investigation pending against Vitas under Other Healthcare Regulations, above.

*Certificate of Need Laws.* Many states, including Florida, have certificate of need laws or other similar health planning laws that apply to hospice care providers. These states may require some form of state agency review or approval prior to opening a new hospice program, to adding or expanding hospice services, to undertaking significant capital expenditures or under other specified circumstances. Approval under these certificate of need laws is generally conditioned on the showing of a demonstrable need for services in the community. Vitas may seek to develop, acquire or expand hospice programs in states having certificate of need laws. To the extent that state agencies require Vitas to obtain a certificate of need or other similar approvals to expand services at existing hospice programs or to make acquisitions or develop hospice programs in new or existing geographical markets, Vitas’ plans could be adversely affected by a failure to obtain a certificate or approval. In addition, competitors may seek administratively or judicially to challenge such an approval or proposed approval by the state agency. Such a challenge, whether or not ultimately successful, could adversely affect Vitas.

*Other Federal and State Regulations.* The federal government and all states regulate various aspects of the hospice industry and Vitas’ business. In particular, Vitas’ operations are subject to federal and state health regulatory laws, including those covering professional services, the dispensing of drugs and certain types of hospice activities. Certain of Vitas’ employees are subject to state laws and regulations governing professional practice. Vitas’ operations are subject to periodic survey by governmental authorities and private accrediting entities to assure compliance with applicable state licensing, and Medicare and Medicaid certification and accreditation standards, as the case may be. From time to time in the ordinary course of business, Vitas receives survey reports noting deficiencies for alleged failure to comply with applicable requirements. Vitas reviews such reports and takes appropriate corrective action. The failure to effect such action could result in one of Vitas’ hospice programs being terminated from the Medicare hospice program. Any termination of one or more of Vitas’ hospice locations from the Medicare hospice program could adversely affect Vitas’ net patient service revenue and profitability and adversely affect its financial condition and results of operations. The failure to obtain, renew or maintain any of the required regulatory approvals, certifications or licenses could materially adversely affect Vitas’ business and could prevent the programs involved from offering products and services to patients. In addition, laws and regulations often are adopted to regulate new products, services and industries. We cannot assure you that either the states or the federal government will not impose additional regulations on Vitas’ activities, which might materially adversely affect Vitas.

*Claims Review.* The Medicare and Medicaid programs and their fiscal intermediaries and other payors periodically conduct pre-payment or post-payment reviews and other reviews and audits of health care claims,

## Table of Contents

including hospice claims. As a result of such reviews or audits, Vitas could be required to return any amounts found to be overpaid, or amounts found to be overpaid could be recouped through reductions in future payments. There is pressure from state and federal governments and other payors to scrutinize health care claims to determine their validity and appropriateness. During the past several years, Vitas' claims have been subject to review and audit. We cannot assure you that reviews and/or similar audits of Vitas' claims will not result in material recoupments, denials or other actions that could have a material adverse effect on Vitas' business, financial condition and results of operations. See the discussion of OIG investigation pending against Vitas under Other Health Care Regulations, above.

*Regulation and Provision of Continuous Home Care.* Vitas provides continuous home care to patients requiring such care. Continuous home care is provided to patients while at home, during periods of crisis when intensive monitoring and care, primarily nursing care, is required in order to achieve palliation or management of acute medical symptoms. Continuous home care requires a minimum of 8 hours of care within a 24-hour day, which begins and ends at midnight. The care must be predominantly nursing care provided by either a registered nurse or licensed practical nurse.

Continuous home care can be challenging for a hospice to provide for a number of reasons, including the need to have available sufficient skilled and trained staff to furnish such care, the need to manage the staffing and provision of such care, and a shortage of nurses that can make it particularly difficult to attract and retain nurses that are required to furnish a majority of such care. Medicare reimbursement for continuous home care has been calculated by multiplying the applicable continuous home care hourly rate by the number of hours of care provided. If the care was provided for less than one hour, Medicare regulations allowed for rounding to the next hour increment. Effective January 1, 2007, Medicare requires reporting in 15-minute increments of care provided, with no rounding.

Medicare reimbursement for continuous home care is subject to a number of requirements posing further challenges for a hospice providing such care. For example, if a patient requires skilled interventions for palliation or symptom management that can be accomplished in less than 8 aggregate hours within the 24-hour period, if the majority of care can be accomplished by someone other than a registered nurse or a licensed practical nurse (e.g., if a majority of care is furnished by a home health aide or homemaker), or if for any reason less than 8 hours of direct care are provided (such as when a patient dies before 8 AM even if 7 or more hours of care has been provided), the care rendered cannot be reimbursed by Medicare at the continuous home care rate (although the care instead may be eligible for Medicare reimbursement at the reduced routine home care day rate). As a result of such requirements, Vitas may incur the costs of providing services intended to be continuous home care services yet be unable to bill or be reimbursed for such services at the continuous home care rate. We cannot assure you that challenges in providing continuous home care will not cause Vitas' net patient service revenue and profits to materially decline or that reviews and/or similar audits of Vitas' claims will not result in material recoupments, denials or other actions that could have a material adverse effect on Vitas' business, financial condition and results of operations.

*Compliance.* Vitas maintains an internal regulatory compliance review program and from time to time retains regulatory counsel for guidance on compliance matters. We cannot assure you, however, that Vitas' practices, if reviewed, would be found to be in compliance with applicable health regulatory laws, as such laws ultimately may be interpreted, or that any non-compliance with such laws would not have a material adverse effect on Vitas.

### **Federal and state legislative and regulatory initiatives relating to patient privacy could require Vitas to expend substantial sums on acquiring, implementing and supporting new information systems, which could negatively impact its profitability.**

There are currently numerous legislative and regulatory initiatives at both the state and federal levels that address patient privacy concerns. In particular, regulations issued under the Health Insurance Portability and Accountability Act of 1996 ("HIPAA") require Vitas to protect the privacy and security of patients' individual

## [Table of Contents](#)

health information. We cannot predict the total financial or other impact of the regulations on Vitas' operations. In addition, although Vitas' management believes it is in compliance with the requirement of patient privacy regulations, we cannot assure you that Vitas will not be found to have violated state and federal laws, rules or guidelines surrounding patient privacy. Compliance with current and future HIPAA requirements or any other federal or state privacy initiatives could require Vitas to make substantial investments, which could negatively impact its profitability and cash flows.

### **Vitas' growth strategies may not be successful, which could adversely affect its business.**

A significant element of Vitas' growth strategy is expected to include expansion of its business in new and existing markets. This aspect of Vitas' growth strategy may not be successful, which could adversely impact its growth and profitability. We cannot assure you that Vitas will be able to:

- Identify markets that meet its selection criteria for new hospice locations;
- Hire and retain qualified management teams to operate each of its new hospice locations;
- Manage a large and geographically diverse group of hospice locations;
- Become Medicare and Medicaid certified in new markets;
- Generate sufficient hospice admissions in new markets to operate profitably in these new markets;
- Compete effectively with existing hospices in new markets; or
- Obtain state licensure and/or a certificate of need from appropriate state agencies in new markets.

In addition to growing existing locations and developing new hospice locations, Vitas' growth is expected to include expansion through acquisition of other hospices. We cannot assure you that Vitas' acquisition strategy will be successful. The success of Vitas' acquisition strategy depends upon a number of factors, including:

- Its ability to identify suitable acquisition candidates;
- Its ability to negotiate favorable acquisition terms, including purchase price, which may be adversely affected due to increased competition with other buyers;
- The availability of financing on favorable terms, or at all;
- Its ability to integrate effectively the systems and operations of acquired hospices;
- Its ability to retain key personnel of acquired hospices; and
- Its ability to obtain required regulatory approvals.

Acquisitions involve a number of other risks, including diversion of management's attention from other business concerns and assuming known or unknown liabilities of acquired hospices, including liabilities for failure to comply with health care laws and regulations. Integrating acquired hospices may place significant strains on Vitas' current operating and financial systems and controls. Vitas may not successfully overcome these risks or any other problems encountered in connection with its acquisition strategy.

## [Table of Contents](#)

In addition, since 1990, Vitas has acquired hospice programs, some of which involved acquisitions of hospice programs from not-for-profit entities. Vitas believes that acquisitions of not-for-profit programs are generally more complex than acquisitions from for-profit entities and that a substantial number of acquisition opportunities are likely to involve acquisitions from not-for-profit entities. Such acquisitions are subject to provisions of the Internal Revenue Code and, in certain states, state attorney general powers, which have been interpreted to require that the consideration paid for the assets purchased be at fair market value and, where applicable, that any fees paid for services be reasonable. In many states there is no mechanism for state attorney general pre-clearance of transactions to assure that applicable standards have been met. Entities that acquired not-for-profit hospices could face potential liability if the acquisition transaction is not structured to comply with Internal Revenue Code and state law requirements, and in some cases the transaction could be enjoined or subject to rescission. The acquisition of not-for-profit businesses, including the fairness of the purchase price paid, has received increasing regulatory scrutiny by state attorneys general and other regulatory authorities. Although Vitas believes that reasonable actions have been taken to date to establish the fair market value of assets purchased in prior acquisitions of hospice operations from not-for-profit entities and the reasonableness of fees paid for services, we cannot assure you that such transactions or any future similar transactions will not be challenged or that, if challenged, the results of such challenge would not have a material adverse effect on Vitas' business.

### **Vitas' loss of key management personnel or its inability to hire and retain skilled employees could adversely affect its business, financial condition and results of operations.**

Vitas' future success significantly depends upon the continued service of its senior management personnel. The loss of one or more of Vitas' key senior management personnel or its inability to hire and retain new skilled employees could negatively impact Vitas' ability to maintain or increase patient referrals, a key aspect of its growth strategy, and could adversely affect its future operating results.

Competition for skilled employees is intense, and the process of locating and recruiting skilled employees with the combination of qualifications and attributes required to care effectively for terminally ill patients and their families can be difficult and lengthy. We cannot assure you that Vitas will be successful in attracting, retaining or training highly skilled nursing, management, community education, operations, admissions and other personnel. Vitas' business could be disrupted and its growth and profitability negatively impacted if it is unable to attract and retain skilled employees.

### **A nationwide shortage of qualified nurses could adversely affect Vitas' profitability, growth and ability to continue to provide quality, responsive hospice services to its patients as nursing wages and benefits increase.**

The substantial majority of Vitas' workforce is nurses. Vitas depends on qualified nurses to provide quality, responsive hospice services to its patients. The current nationwide shortage of qualified nurses impacts some of the markets in which Vitas provides hospice services. In response to this shortage, Vitas has adjusted its wages and benefits to recruit and retain nurses and to engage contract nurses. Vitas' inability to attract and retain qualified nurses could adversely affect its ability to provide quality, responsive hospice services to its patients and its ability to increase or maintain patient census in those markets. Increases in the wages and benefits required to attract and retain qualified nurses or an increase in reliance on contract nurses could negatively impact profitability.

### **Vitas may not be able to compete successfully against other hospice providers, and competitive pressures may limit its ability to maintain or increase its market position and adversely affect its profitability, financial condition and results of operations.**

Hospice care in the United States is highly competitive. In many areas in which Vitas' hospices are located, they compete with a large number of organizations, including:

- Community-based hospice providers;
- National and regional companies;

## Table of Contents

- Hospital-based hospice and palliative care programs;
- Physician groups;
- Nursing homes;
- Home health agencies;
- Infusion therapy companies; and
- Nursing agencies.

Various health care companies have diversified into the hospice market. Other companies, including hospitals and health care organizations that are not currently providing hospice care, may enter the markets Vitas serves and expand the variety of services offered to include hospice care. We cannot assure you that Vitas will not encounter increased competition in the future that could limit its ability to maintain or increase its market position, including competition from parties in a position to impact referrals to Vitas. Such increased competition could have a material adverse effect on Vitas' business, financial condition and results of operations.

### **Changes in rates or methods of payment for Vitas' services could adversely affect its revenues and profits.**

Managed care organizations have grown substantially in terms of the percentage of the population they cover and their control over an increasing portion of the health care economy. Managed care organizations have continued to consolidate to enhance their ability to influence the delivery of health care services and to exert pressure to control health care costs. Vitas has a number of contractual arrangements with managed care organizations and other similar parties.

Vitas provides hospice care to many Medicare beneficiaries who receive their non-hospice health care services from health maintenance organizations ("HMOs") under Medicare risk contracts. Under such contracts between HMOs and the federal Department of Health and Human Services, the Medicare payments for hospice services are excluded from the per-member, per-month payment from Medicare to HMOs and instead are paid directly by Medicare to the hospices. As a result, Vitas' payments for Medicare beneficiaries enrolled in Medicare risk HMOs are processed in the same way with the same rates as other Medicare beneficiaries. We cannot assure, however, that payment for hospice services will continue to be excluded from HMO payment under Medicare risk contracts and similar Medicare managed care plans or that if not excluded, managed care organization or other large third-party payors would not use their power to influence and exert pressure on health care providers to reduce costs in a manner that could have a material adverse effect on Vitas' business, financial condition and results of operations.

### **Liability claims may have an adverse effect on Vitas, and its insurance coverage may be inadequate.**

Participants in the hospice industry are subject to lawsuits alleging negligence, product liability or other similar legal theories, many of which involve large claims and significant defense costs. From time to time, Vitas is subject to such and other types of lawsuits. See the description below under Legal Proceedings. The ultimate liability for claims, if any, could have a material adverse effect on its financial condition or operating results. Although Vitas currently maintains liability insurance intended to cover the claims, we cannot assure you that the coverage limits of such insurance policies will be adequate or that all such claims will be covered by the insurance. In addition, Vitas' insurance policies must be renewed annually and may be subject to cancellation during the policy period. While Vitas has been able to obtain liability insurance in the past, such insurance varies in cost, is difficult to obtain and may not be available in the future on terms acceptable to Vitas, if at all.

## [Table of Contents](#)

A successful claim in excess of the insurance coverage could have a material adverse effect on Vitas. Claims, regardless of their merit or eventual outcome, also may have a material adverse effect on Vitas' business and reputation due to the costs of litigation, diversion of management's time and related publicity.

Vitas procures professional liability coverage on a claims-made basis. The insurance contracts specify that coverage is available only during the term of each insurance contract. Vitas' management intends to renew or replace the existing claims-made policy annually but such coverage is difficult to obtain, may be subject to cancellation and may be written by carriers that are unable, or unwilling to pay claims. During fiscal 2001, Vitas was notified that one of its prior carriers was ordered into rehabilitation, and in early fiscal 2002, into liquidation, creating the possibility that certain prior year claims could be underinsured or uninsured. Certain claims have been asserted where the coverage would be the responsibility of this prior carrier and/or other carriers that may not have the financial wherewithal to satisfy the claims. Additionally, some risks and liabilities, including claims for punitive damages, are not covered by insurance.

### **Item 1B. Unresolved Staff Comments**

None.

### **Item 2. Properties**

The Company's corporate offices and the headquarters for the Roto-Rooter Group are located in Cincinnati, Ohio. Roto-Rooter has manufacturing and distribution center facilities in West Des Moines, Iowa and has 75 office and service facilities in 27 states. Vitas, headquartered in Miami, operates 45 programs from 94 leased facilities in 15 states and the District of Columbia.

All "owned" property is held in fee and is subject to the security interests of the holders of our debt instruments. The leased properties have lease terms ranging from one year to nine years. Management does not foresee any difficulty in renewing or replacing the remainder of its current leases. The Company considers all of its major operating properties to be maintained in good operating condition and to be generally adequate for present and anticipated needs.

### **Item 3. Legal Proceedings**

Like other large California employers, Vitas faces allegations of purported class-wide wage and hour violations. Vitas Healthcare Corporation was party to a class action lawsuit filed in the Superior Court of California, Los Angeles County, in April of 2004 by Ann Marie Costa, Ana Jimenez, Mariea Ruteaya and Gracetta Wilson ("Costa"). It alleged failure to pay overtime wages for hours worked "off the clock" on administrative tasks, including voicemail retrieval, time entry, travel to and from work, and pager response. It also alleged Vitas failed to provide meal and break periods to a purported class of California nurses, home health aides and licensed clinical social workers. The case also sought payment of penalties, interest, and plaintiffs' attorney fees. The Company contested these allegations. Plaintiffs moved for class certification, and Vitas opposed this motion. We reached an agreement with the Plaintiff class in order to avoid the uncertainty of litigation and the diversion of resources and personnel resulting from it. On June 26, 2006, the court granted final approval of this settlement (\$19.9 million).

Vitas is party to a class action lawsuit filed in the Superior Court of California, Los Angeles County, in September 2006 by Bernadette Santos, Keith Knoche and Joyce White ("Santos"). This case, filed by the Costa case plaintiffs' counsel, makes similar allegations of failure to pay overtime and failure to provide meal and rest periods to a purported class of California admissions nurses, chaplains and sales representatives. The case likewise seeks payment of penalties, interest and plaintiffs' attorney fees. Vitas contests these allegations. The lawsuit is in its early stage and we are unable to estimate our potential liability, if any, with respect to these allegations.

## Table of Contents

Regardless of outcome, such litigation can adversely affect the Company through defense costs, diversion of management's time, and related publicity. In the normal course of business, we are a party to various claims and legal proceedings. We record a reserve for these matters when an adverse outcome is probable and the amount of the potential liability is reasonably estimable.

See also the OIG investigation pending against Vitas under Other Health Care Regulations, above.

### **Item 4. Submission of Matters to a Vote of Security Holders.**

None.

### **Executive Officers of the Company**

<u>Name</u>	<u>Age</u>	<u>Office</u>	<u>First Elected</u>
Kevin J. McNamara	55	President and Chief Executive Officer	August 2, 1994 (1)
Timothy S. O'Toole	53	Executive Vice President	May 18, 1992 (2)
Spencer S. Lee	53	Executive Vice President	May 15, 2000 (3)
David P. Williams	48	Executive Vice President and Chief Financial Officer	March 5, 2004 (4)
Arthur V. Tucker, Jr.	59	Vice President and Controller	February 1, 1989 (5)

- (1) Mr. K. J. McNamara is President and Chief Executive Officer of the Company and has held these positions since August 1994 and May 2001, respectively. Previously, he served as an Executive Vice President, Secretary and General Counsel of the Company, since November 1993, August 1986 and August 1986, respectively. He previously held the position of Vice President of the Company, from August 1986 to May 1992.
- (2) Mr. T.S. O'Toole is an Executive Vice President of the Company and has held this position since May 1992. He is also Chief Executive Officer of Vitas, a wholly owned subsidiary of the Company, and has held this position since February 24, 2004. Previously, from May 1992 to February 24, 2004, he also served the Company as Treasurer.
- (3) Mr. S. S. Lee is an Executive Vice President of the Company and has held this position since May 15, 2000. Mr. Lee is also Chairman and Chief Executive Officer of Roto-Rooter Services Company, a wholly owned subsidiary of the Company, and has held this position since January 1999. Previously, he served as a Senior Vice President of Roto-Rooter Services Company from May 1997 to January 1999.
- (4) Mr. D. P. Williams is an Executive Vice President and the Chief Financial Officer of the company and has held these positions since August 10, 2007 and March 5, 2004, respectively. Mr. Williams is also Senior Vice President and Chief Financial Officer of Roto-Rooter Group, Inc., and has held these positions since January 1999.
- (5) Mr. A. V. Tucker, Jr. is a Vice President and Controller of the Company and has held these positions since February 1989. From May 1983 to February 1989, he held the position of Assistant Controller of the Company.

Each executive officer holds office until the annual election at the next annual organizational meeting of the Board of Directors of the Company which is scheduled to be held on May 18, 2009.

**PART II****Item 5. Market for the Registrant's Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities**

The Company's Capital Stock (par value \$1 per share) is traded on the New York Stock Exchange under the symbol CHE. The range of the high and low sale prices on the New York Stock Exchange and dividends paid per share for each quarter of 2007 and 2008 are set forth below.

	Closing		Dividends Paid Per Share
	High	Low	
2007			
First Quarter	\$49.65	\$35.75	\$.06
Second Quarter	68.77	49.00	.06
Third Quarter	70.53	52.93	.06
Fourth Quarter	64.87	52.92	.06
2008			
First Quarter	\$55.88	\$41.65	\$.06
Second Quarter	44.00	32.75	.06
Third Quarter	47.00	36.51	.06
Fourth Quarter	45.09	32.04	.06

Future dividends are necessarily dependent upon the Company's earnings and financial condition, compliance with certain debt covenants and other factors not presently determinable.

As of February 16, 2009, there were approximately 2,744 stockholders of record of the Company's Capital Stock. This number only includes stockholders of record and does not include stockholders with shares beneficially held in nominee name or within clearinghouse positions of brokers, banks or other institutions.

During 2008, the number of shares of Capital Stock repurchased by the Company, the weighted average price paid for each share, the cumulative shares repurchased under each program and the dollar amounts remaining under each program were as follows:

### Company Purchase of Shares of Capital Stock

	<u>Total Number Of Shares Repurchased</u>	<u>Weighted Average Price Paid Per Share</u>	<u>Cumulative Shares Repurchased Under The Program</u>	<u>Dollar Amount Remaining Under The Program</u>
<b>April 2007 Program</b>				
January 1 through January 31, 2008	—	\$ —	1,293,250	\$ 65,004,906
February 1 through February 29, 2008	300,000	\$ 49.19	1,593,250	\$ 50,247,480
March 1 through March 31, 2008	—	\$ —	<u>1,593,250</u>	<u>\$ 50,247,480</u>
First Quarter Total — April 2007 Program	<u>300,000</u>	<u>\$ 49.19</u>		
April 1 through April 30, 2008	—	\$ —	1,593,250	\$ 50,247,480
May 1 through May 31, 2008	382,629	\$ 34.66	1,975,879	\$ 93,047,996
June 1 through June 30, 2008	447,068	\$ 36.15	<u>2,422,947</u>	<u>\$ 76,887,912</u>
Second Quarter Total — April 2007 Program	<u>829,697</u>	<u>\$ 35.46</u>		
July 1 through July 31, 2008	260,000	\$ 36.75	2,682,947	\$ 67,331,638
August 1 through August 30, 2008	300,000	\$ 44.64	2,982,947	\$ 53,940,328
September 1 through September 30, 2008	—	\$ —	<u>2,982,947</u>	\$ 53,940,328
Third Quarter Total — April 2007 Program	<u>560,000</u>	<u>\$ 40.98</u>		
October 1 through October 31, 2008	—	\$ —	2,982,947	\$ 53,940,328
November 1 through November 30, 2008	—	\$ —	2,982,947	\$ 53,940,328
December 1 through December 31, 2008	—	\$ —	<u>2,982,947</u>	<u>\$ 53,940,328</u>
Fourth Quarter Total — April 2007 Program	<u>—</u>	<u>\$ —</u>		

On April 26, 2007, our Board of Directors authorized a \$150 million share repurchase plan with no expiration date.

On May 20, 2008, our Board of Directors authorized an additional \$56 million under the April 2007 Program.

As of December 31, 2008, the number of stock options outstanding under the Company's equity compensation plans, the weighted average exercise price of outstanding options, and the number of securities remaining available for issuance were as follows:

**EQUITY COMPENSATION PLAN INFORMATION**

Plan Category	Number of securities to be issued upon exercise of outstanding warrants and rights (a)	Weighted-average exercise price of outstanding options, warrants and rights (b)	Number of securities remaining available for future issuance under equity compensation plans [excluding securities reflected in column (a)] (c)
Equity Compensation plans approved by stockholders	2,140,371	\$ 41.27	1,565,546
Equity Compensation plans not approved by stockholders (1)	34,788	23.82	—
<b>TOTAL</b>	<b>2,175,159</b>	<b>\$ 40.99</b>	<b>1,565,546</b>


- (1) In May 1999 the Board of Directors adopted the 1999 Long-Term Employee Incentive Plan without stockholder approval. This plan permits the Company to grant up to 500,000 shares of non-qualified options and stock awards to a broad base of salaried and hourly employees (excluding officers and directors) of the Company. Except for the exclusion of officers and directors, this plan has the same general terms and provisions as the 2006 Stock Incentive Plan. In addition, pursuant to this plan no individual may be granted more than 50,000 stock options in a calendar year, the aggregate number of the shares of Capital Stock which may be issued pursuant to stock incentives in the form of Stock Awards shall not be more than 270,000, and no stock incentives shall be granted under the plan after May 17, 2009.

**Comparative Stock Performance**

The graph below compares the yearly percentage change in the Company's cumulative total stockholder return on Capital Stock (as measured by dividing (i) the sum of (A) the cumulative amount of dividends for the period December 31, 2003, to December 31, 2008, assuming dividend reinvestment, and (B) the difference between the Company's share price at December 31, 2003 and December 31, 2008; by (ii) the share price at December 31, 2003) with the cumulative total return, assuming reinvestment of dividends, of the (1) S&P 500 Stock Index and (2) Dow Jones Industrial Diversified Index.

**Chemed Corporation  
Cumulative Total Stockholder Return for  
Five-Year Period Ending December 31, 2008**

Dollars



December 31...	2003	2004	2005	2006	2007	2008
Chemed Corporation	100.00	146.85	218.69	163.66	248.37	177.78
S&P 500	100.00	110.85	116.28	134.50	141.79	88.67
Dow Jones Industrial Diversified	100.00	119.18	116.07	127.13	135.70	69.14

**Item 6. Selected Financial Data**

The information called for by this Item for the five years ended December 31, 2008 is set forth on page 36 of the 2008 Annual Report to Stockholders and is incorporated herein by reference.

**Item 7. Management's Discussion and Analysis of Financial Condition and Results of Operations**

The information called for by this Item is set forth on pages 37 through 50 of the 2008 Annual Report to Stockholders and is incorporated herein by reference.

**Item 7A. Quantitative and Qualitative Disclosures About Market Risk**

The Company's primary market risk exposure relates to interest rate risk exposure through its variable interest term note and line of credit. At December 31, 2008 the Company had \$22.7 million of variable rate debt outstanding. For each \$10 million dollars borrowed under these credit facilities, an increase or decrease of 100 basis points (1% point), increases or decreases the Company's annual interest expense by \$100,000.

The Company continually evaluates this interest rate exposure and periodically weighs the cost versus the benefit of fixing the variable interest rates through a variety of hedging techniques.

The market value of the Company's long-term debt at December 31, 2008 is approximately \$147.2 million versus a carrying value of \$209.8 million.

**Item 8. Financial Statements and Supplementary Data**

The consolidated financial statements, together with the report thereon of PricewaterhouseCoopers LLP dated February 27, 2009, appearing on pages 1 through 33 of the 2008 Annual Report to Stockholders, along with the Supplementary Data (Unaudited Summary of Quarterly Results) appearing on pages 34-35, are incorporated herein by reference.

**Item 9. Changes in and Disagreements with Accountants on Accounting and Financial Disclosure**

None.

**Item 9A. Controls and Procedures**

**Evaluation of Disclosure Controls and Procedures**

The Company's management, under the supervision of and with the participation of the Company's President and Chief Executive Officer, Executive Vice President and Chief Financial Officer and Vice President and Controller, has evaluated the effectiveness of the Company's disclosure controls and procedures, as such term is defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), as of the end of the period covered by this report. Based on such evaluation, the Company's President and Chief Executive Officer, Executive Vice President and Chief Financial Officer and Vice President and Controller have concluded that, as of the end of such period, the Company's disclosure controls and procedures are effective and are reasonably designed to ensure that all material information relating to the Company required to be included in the Company's reports filed or submitted under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the rules and forms of the Securities and Exchange Commission and that such information is accumulated and communicated to management, including the President and Chief Executive Officer, Executive Vice President and Chief Financial Officer and Vice President and Controller, as appropriate, to allow timely decisions regarding required disclosure.

[Table of Contents](#)

**Management's Report on Internal Control Over Financial Reporting**

Refer to Management's Report on Internal Control over Financial Reporting and Report of Independent Registered Public Accounting Firm on pages 1 and 2 of the Company's 2008 Annual Report to Stockholders, which are incorporated herein by reference.

**Changes in Internal Control Over Financial Reporting**

There have not been any changes in the Company's internal control over financial reporting, as such term is defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act during the Company's fiscal quarter ended December 31, 2008 that have materially affected, or are reasonably likely to materially affect, the Company's internal control over financial reporting.

**Item 9B. Other Information**

Not applicable.

**PART III**

**Item 10. Directors, Executive Officers and Corporate Governance**

The directors of the Company are:

Edward L. Hutton  
Kevin J. McNamara  
Joel F. Gemunder  
Patrick P. Grace  
Thomas C. Hutton  
Walter L. Krebs  
Sandra E. Laney  
Andrea R. Lindell  
Timothy S. O'Toole  
Donald E. Saunders  
George J. Walsh III  
Frank E. Wood

The additional information required under this Item is set forth in the Company's 2009 Proxy Statement and in Part I hereof under the caption "Executive Officers of the Registrant" and is incorporated herein by reference.

The Company has adopted a Code of Ethics that applies to the Company's principal executive officer, principal financial officer, principal accounting officer, directors and employees. A copy of this Code of Ethics is incorporated with this report as Exhibit 14 and it is also posted on the Company's Web site, [www.chemed.com](http://www.chemed.com).

**Item 11. Executive Compensation**

Information required under this Item is set forth in the Company's 2009 Proxy Statement, which is incorporated herein by reference.

**Item 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters**

Information required under this Item is set forth in the Company's 2009 Proxy Statement, which is incorporated herein by reference.

**Item 13. Certain Relationships and Related Transactions and Director Independence.**

Information required under this Item is set forth in the Company's 2009 Proxy Statement, which is incorporated herein by reference.

A description of related party transactions is shown in Note 20 of the Notes to Consolidated Financial Statements on page 28 of the 2008 Annual Report to Stockholders and is incorporated herein by reference.

**Item 14. Principal Accountant Fees and Services**

**Audit Fees**

PricewaterhouseCoopers LLP billed the Company \$1,500,000 for 2007 and \$1,560,000 for 2008. These fees were for professional services rendered for the integrated audit of the Company's annual financial statements and of its internal control over financial reporting, review of the financial statements included in the Company's Forms 10-Q and review of documents filed with the SEC.

**Audit-Related Fees**

PricewaterhouseCoopers LLP billed the Company \$341,000 and \$90,000 for 2007 and 2008, respectively, for audit-related services. In 2007, \$38,000 was related to the adoption of FIN 48, \$218,000 was related to a proposed offering of debt, and \$85,000 was related to the audit of one of Vitas' Florida subsidiaries. In 2008, \$90,000 was related to the audit of one of Vitas' Florida subsidiaries.

**Tax Fees**

No such services were rendered in 2007 or 2008.

**All Other Fees**

No other services were rendered in 2007 or 2008.

The Audit Committee has adopted a policy which requires the Committee's pre-approval of audit and non-audit services performed by the independent auditor to assure that the provision of such services does not impair the auditor's independence. The Audit Committee pre-approved all of the audit and non-audit services rendered by PricewaterhouseCoopers LLP as listed above.

**PART IV**

**Item 15 Exhibits and Financial Statement Schedule**

Exhibits

- 3.1 Certificate of Incorporation of Chemed Corporation.\*
- 3.2 Certificate of Amendment to Certificate of Incorporation.\*
- 3.3 By-Laws of Chemed Corporation.\*
- 10.1 Agreement and Plan of Merger among Diversey U.S. Holdings, Inc., D.C. Acquisition Inc., Chemed Corporation and DuBois Chemicals, Inc., dated as of February 25, 1991.\*
- 10.2 Agreement and Plan of Merger among National Sanitary Supply Company, Unisource Worldwide, Inc. and TFBD, Inc. dated as of August 11, 1997.\*
- 10.3 Stock Purchase Agreement dated as of May 8, 2002 by and between PCI Holding Corp. and Chemed Corporation.\*
- 10.4 Amendment No. 1 to Stock Purchase Agreement dated as of October 11, 2002 by and among PCI Holding Corp., PCI-A Holding Corp. and Chemed Corporation.\*
- 10.5 Common Stock Purchase Warrant dated as of October 11, 2002 by and between PCI Holding Corp. and Chemed Corporation.\*
- 10.6 1999 Stock Incentive Plan.\*,\*\*
- 10.7 1999 Long-Term Employee Incentive Plan as amended through May 20, 2002.\*,\*\*
- 10.8 2002 Stock Incentive Plan.\*,\*\*
- 10.9 2002 Executive Long-Term Incentive Plan, as amended May 18, 2004.\*,\*\*
- 10.10 2004 Stock Incentive Plan.\*,\*\*
- 10.11 2006 Stock Incentive Plan, as amended August 11, 2006.\*,\*\*
- 10.12 Repurchase Agreement dated May 8, 2007 by and among Chemed Corporation, J.P. Morgan Securities Inc. and Citigroup Global Markets, Inc.\*
- 10.13 Convertible Senior Note Indenture dated May 14, 2007 for 1.875% Convertible Senior Notes due 2014 by and among Chemed Corporation, the Subsidiary Guarantors and LaSalle Bank NA, as Trustee.\*
- 10.14 Employment Agreement with David P. Williams dated December 1, 2006.\*,\*\*

## Table of Contents

### Exhibits

- 10.15 Employment Agreement with Timothy S. O'Toole dated May 6, 2007.\*,\*\*
- 10.16 Employment Agreement with Kevin J. McNamara dated May 3, 2008.\*,\*\*
- 10.17 Registration Rights Agreement, dated May 14, 2007 by and among Chemed Corporation, J.P. Morgan Securities, Inc. and Citigroup Global Markets Inc.\*
- 10.18 Confirmation of Convertible Note Hedge, dated May 8, 2007 between Chemed Corporation and J.P. Morgan Chase Bank, NA.\*
- 10.19 Confirmation of Convertible Note Hedge, dated May 8, 2007 between Chemed Corporation and Citibank, NA.\*
- 10.20 Form of Convertible Note Warrant Transaction, dated May 8, 2007 between Chemed Corporation and Citibank NA.\*
- 10.21 Form of Convertible Note Warrant Transaction, dated May 8, 2007 between Chemed Corporation and J.P. Morgan Chase Bank, NA.\*
- 10.22 Excess Benefits Plan, as restated and amended, effective June 1, 2001.\*,\*\*
- 10.23 Amendment No. 1 to Excess Benefits Plan, effective July 1, 2001.\*,\*\*
- 10.24 Amendment No. 2 to Excess Benefits Plan, effective November 7, 2003.\*,\*\*
- 10.25 Non-Employee Directors' Deferred Compensation Plan.\*,\*\*
- 10.26 Chemed/Roto-Rooter Savings & Retirement Plan, effective January 1, 1999.\*,\*\*
- 10.27 First Amendment to Chemed/Roto-Rooter Savings & Retirement Plan, effective September 6, 2000.\*,\*\*
- 10.28 Second Amendment to Chemed/Roto-Rooter Savings & Retirement Plan, effective January 1, 2001.\*,\*\*
- 10.29 Third Amendment to Chemed/Roto-Rooter Savings & Retirement Plan, effective December 12, 2001.\*,\*\*
- 10.30 Directors Emeriti Plan.\*,\*\*
- 10.31 Split Dollar Agreement with Edward L. Hutton.\*,\*\*
- 10.32 Change in Control Severance Plan.\*,\*\*
- 10.33 Senior Executive Severance Policy.\*,\*\*
- 10.34 Roto-Rooter Deferred Compensation Plan No. 1, as amended January 1, 1998.\*,\*\*

## Table of Contents

### Exhibits

- 10.35 Roto-Rooter Deferred Compensation Plan No. 2. \*,\*\*
- 10.36 Agreement and Plan of Merger, dated as of December 18, 2003, among Roto-Rooter, Inc., Marlin Merger Corp. and Vitas Healthcare Corporation.\*
- 10.37 Credit Agreement, dated as of May 2, 2007, among Chemed Corporation, the lenders from time to time parties thereto and J.P. Morgan Chase Bank, NA, as Administrative Agent.\*
- 10.38 Amended and Restated Credit Agreement, dated as of February 24, 2005, among Chemed Corporation, the lenders from time to time parties thereto and J.P. Morgan Chase Bank, NA, as Administrative Agent.\*
- 10.39 Amendment No. 1 to Amended and Restated Credit Agreement, dated March 31, 2006 among Chemed Corporation, the lenders from time to time parties thereto, and J.P. Morgan Chase Bank NA, as Administrative Agent.\*
- 10.40 Form of Restricted Stock Award. \*,\*\*
- 10.41 Form of Stock Option Grant. \*,\*\*
- 10.42 Assets Purchase Agreement of April 1, 2005 between Service America Network, Inc. and Service America Enterprise, Inc.\*
- 12 Computation of Ratio to Earnings to Fixed Charges.
- 13 2008 Annual Report to Stockholders.
- 14 Policies on Business Ethics of Chemed Corporation.\*
- 21 Subsidiaries of Chemed Corporation.
- 23 Consent of Independent Registered Public Accounting Firm.
- 24 Powers of Attorney.
- 31.1 Certification by Kevin J. McNamara pursuant to Rule 13a-14(a)/15d-14(a) of the Exchange Act of 1934.
- 31.2 Certification by David P. Williams pursuant to Rule 13a-14(a)/15d-14(a) of the Exchange Act of 1934.
- 31.3 Certification by Arthur V. Tucker, Jr. pursuant to Rule 13a-14(a)/15d-14(a) of the Exchange Act of 1934.
- 32.1 Certification by Kevin J. McNamara pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
- 32.2 Certification by David P. Williams pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
- 32.3 Certification by Arthur V. Tucker, Jr. pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

## [Table of Contents](#)

---

- \* This exhibit is being filed by means of incorporation by reference (see Index to Exhibits on page E-1). Each other exhibit is being filed with this Annual Report on Form 10-K.
- \*\* Management contract or compensatory plan or arrangement.

### **Financial Statement Schedule**

See Index to Financial Statements and Financial Statement Schedule on page S-1.



**CHEMED CORPORATION AND SUBSIDIARY COMPANIES**  
**INDEX TO FINANCIAL STATEMENTS AND FINANCIAL STATEMENT SCHEDULE**  
**2006, 2007 AND 2008**

	<u>Page(s)</u>
<b>Chemed Corporation Consolidated Financial Statements and Financial Statement Schedule</b>	
Report of Independent Registered Public Accounting Firm	2*
Consolidated Statement of Income	3*
Consolidated Balance Sheet	4*
Consolidated Statement of Cash Flows	5*
Consolidated Statement of Changes in Stockholders' Equity	6-7*
Notes to Consolidated Financial Statements	8-33*
Report of Independent Registered Public Accounting Firm on Financial Statement Schedule	S-2
Schedule II – Valuation and Qualifying Accounts	S-3

\* Indicates page numbers in Chemed Corporation 2008 Annual Report to Stockholders

The consolidated financial statements of Chemed Corporation listed above, appearing in the 2008 Annual Report to Stockholders, are incorporated herein by reference. The Financial Statement Schedule should be read in conjunction with the consolidated financial statements listed above. Schedules not included have been omitted because they are not applicable or the required information is shown in the financial statements or notes thereto as listed above.

Report of Independent Registered Public Accounting  
Firm on Financial Statement Schedule

To the Board of Directors of Chemed Corporation

Our audits of the consolidated financial statements and of the effectiveness of internal control over financial reporting referred to in our report dated February 27, 2009 appearing in the 2008 Annual Report to Stockholders of Chemed Corporation (which report and consolidated financial statements are incorporated by reference in this Annual Report on Form 10-K) also included an audit of the financial statement schedule listed in Item 15(a)(2) of this Form 10-K. In our opinion, this financial statement schedule presents fairly, in all material respects, the information set forth therein when read in conjunction with the related consolidated financial statements.

/s/ PricewaterhouseCoopers LLP

PricewaterhouseCoopers LLP

Cincinnati, Ohio

February 27, 2009

**CHEMED CORPORATION AND SUBSIDIARY COMPANIES**  
**VALUATION AND QUALIFYING ACCOUNTS**  
**(IN THOUSANDS)**  
**DR/(CR)**

DESCRIPTION	BALANCE AT BEGINNING OF PERIOD	ADDITIONS		APPLICABLE TO COMPANIES ACQUIRED IN PERIOD	DEDUCTIONS (a)	BALANCE AT END OF PERIOD
		(CHARGED) CREDITED TO COSTS AND EXPENSES	(CHARGED) CREDITED TO OTHER ACCOUNTS			
Allowances for doubtful accounts (b)						
For the year 2008	\$ (9,746)	\$ (9,870)	\$ 13	\$ —	\$ 9,283	\$ (10,320)
For the year 2007	\$ (10,180)	\$ (8,375)	\$ 490	\$ —	\$ 8,319	\$ (9,746)
For the year 2006	\$ (8,311)	\$ (8,169)	\$ 170	\$ —	\$ 6,130	\$ (10,180)
Allowances for doubtful accounts — notes receivable (c)						
For the year 2008	\$ (529)	\$ 51	\$ (13)	\$ —	\$ 9	\$ (482)
For the year 2007	\$ (170)	\$ 2	\$ (366)	\$ —	\$ 5	\$ (529)
For the year 2006	\$ —	\$ —	\$ (170)	\$ —	\$ —	\$ (170)

- (a) With respect to allowances for doubtful accounts, deductions include accounts considered uncollectible or written off, payments, companies divested, etc.
- (b) Classified in consolidated balance sheet as a reduction of accounts receivable.
- (c) Classified in consolidated balance sheet as a reduction of other assets.

## INDEX TO EXHIBITS

Exhibit Number		Page Number or Incorporation by Reference	
		File No. and Filing Date	Previous Exhibit No.
3.1	Certificate of Incorporation of Chemed Corporation	Form S-3 Reg. No. 33-44177 11/26/91	4.1
3.2	Certificate of Amendment to Certificate of Incorporation	Form 8-K 5/16/06	3.1
3.3	By-Laws of Chemed Corporation as amended November 5, 2004	Form 8-K 11/5/04	1
10.1	Agreement and Plan of Merger among Diversey U.S. Holdings, Inc., D.C. Acquisition Inc., Chemed Corporation and DuBois Chemicals, Inc., dated as of February 25, 1991	Form 8-K 3/11/91	1
10.2	Agreement and Plan of Merger among National Sanitary Supply Company, Unisource Worldwide, Inc. and TFBD, Inc.	Form 8-K 10/13/97	1
10.3	Stock Purchase Agreement dated as of May 8, 2002 by and between PCI Holding Corp. and Chemed Corporation	Form 8-K 10/11/02	2.1
10.4	Amendment No. 1 to Stock Purchase Agreement dated as of October 11, 2002 by and among PCI Holding Corp., PCI-A Holding Corp. and Chemed Corporation	Form 8-K 10/11/02	2.2
10.5	Common Stock Purchase Warrant dated as of October 11, 2002 by and between PCI Holding Corp. and Chemed Corporation	Form 8-K 10/11/02	2.4
10.6	1999 Stock Incentive Plan	Form 10-K 3/29/00, **	10.11

## Table of Contents

<u>Exhibit Number</u>		Page Number OF Incorporation by Reference	
		<u>File No. and Filing Date</u>	<u>Previous Exhibit No.</u>
10.7	1999 Long Term Employee Incentive Plan as amended through May 20, 2002	Form 10-K 3/28/03, **	10.16
10.8	2002 Stock Incentive Plan	Form 10-K 3/28/03, **	10.17
10.9	2002 Executive Long-Term Incentive Plan, as amended May 18, 2004	Form 10-Q 8/19/04, **	10.16
10.10	2004 Stock Incentive Plan	Proxy Statement 3/25/04, **	A
10.11	2006 Stock Incentive Plan, as amended August 11, 2006	Form 10-Q 8/14/06, **	10.1
10.12	Repurchase Agreement dated May 8, 2007 by and among Chemed Corporation, J.P. Morgan Securities Inc. and Citigroup Global Markets, Inc.	Form 8-K 5/17/07	1.1
10.13	Convertible Senior Note Indenture dated May 14, 2007 for 1.875% Convertible Senior Notes due 2014 by and among Chemed Corporation, the Subsidiary Guarantors and LaSalle Bank NA, as Trustee.	Form 8-KA 5/22/07	4.1
10.14	Employment Agreement with David P. Williams dated December 1, 2006.	Form 8-K 12/1/06, **	10.01
10.15	Employment Agreement with Timothy S. O'Toole dated May 6, 2007.	Form 8-K 5/7/07, **	10.02
10.16	Employment Agreement with Kevin J. McNamara dated May 3, 2008.	Form 8-K 5/6/08, **	10.01
10.17	Registration Rights Agreement, dated May 14, 2007 by and among Chemed Corporation, J.P. Morgan Securities, Inc. and Citigroup Global Markets Inc.	Form 8-K 5/17/07	10.5

## Table of Contents

<u>Exhibit Number</u>		Page Number OF Incorporation by Reference	
		<u>File No. and Filing Date</u>	<u>Previous Exhibit No.</u>
10.18	Confirmation of Convertible Note Hedge, dated May 8, 2007 between Chemed Corporation and J.P. Morgan Chase Bank, NA.	Form 8-K 5/17/07	10.1
10.19	Confirmation of Convertible Note Hedge, dated May 8, 2007 between Chemed Corporation and Citibank, NA.	Form 8-K 5/17/07	10.2
10.20	Form of Convertible Note Warrant Transaction, dated May 8, 2007 between Chemed Corporation and Citibank, NA.	Form 8-K 5/17/07	10.4
10.21	Form of Convertible Note Warrant Transaction, dated May 8, 2007 between Chemed Corporation and J.P. Morgan Chase Bank, NA.	Form 8-K 5/17/07	10.5
10.22	Excess Benefits Plan, as restated and amended, effective June 1, 2001	Form 10-K 3/12/04, **	10.24
10.23	Amendment No. 1 to Excess Benefits Plan, effective July 1, 2002	Form 10-K 3/12/04, **	10.25
10.24	Amendment No. 2 to Excess Benefits Plan, effective November 7, 2003	Form 10-K 3/12/04, **	10.26
10.25	Non-Employee Directors' Deferred Compensation Plan	Form 10-K 3/24/88, **	10.10
10.26	Chemed/Roto-Rooter Savings & Retirement Plan, effective January 1, 1999	Form 10-K 3/25/99, **	10.25
10.27	First Amendment to Chemed/Roto-Rooter Savings & Retirement Plan effective September 6, 2000	Form 10-K 3/28/02, **	10.22
10.28	Second Amendment to Chemed/Roto-Rooter Savings & Retirement Plan effective January 1, 2001	Form 10-K 3/28/02, **	10.23
10.29	Third Amendment to Chemed/Roto-Rooter Savings & Retirement Plan effective December 12, 2001	Form 10-K 3/28/02, **	10.24

## Table of Contents

<u>Exhibit Number</u>		Page Number OF Incorporation by Reference	
		<u>File No. and Filing Date</u>	<u>Previous Exhibit No.</u>
10.30	Directors Emeriti Plan	Form 10-Q 5/12/88, **	10.11
10.31	Split Dollar Agreement with Edward L. Hutton	Form 10-K 3/28/96, **	10.16
10.32	Change in Control Severance Plan	Form 8-K 12/1/06, **	10.02
10.33	Senior Executive Severance Policy	Form 8-K 12/1/06, **	10.03
10.34	Roto-Rooter Deferred Compensation Plan No. 1, as amended January 1, 1998	Form 10-K 3/28/01, **	10.37
10.35	Roto-Rooter Deferred Compensation Plan No. 2	Form 10-K 3/28/01, **	10.38
10.36	Agreement and Plan of Merger, dated as of December 18, 2003, among Roto-Rooter, Inc., Marlin Merger Corp. and Vitas Healthcare Corporation	Form 8-K 12/19/03	99.2
10.37	Credit Agreement, dated as of May 2, 2007, among Chemed Corporation, the lenders from time to time parties thereto and J. P. Morgan Chase Bank, NA, as Administrative Agent.	Form 8-K 5/07/07	10.01
10.38	Amended and Restated Credit Agreement dated as of February 24, 2005 among Chemed Corporation, the lenders from time to time, parties thereto and JP Morgan Chase Bank NA, as Administrative Agent.	Form 10-K 3/28/05	10.46
10.39	Amendment No. 1 to Amended and Restated Credit Agreement, dated March 31, 2006 among Chemed Corporation, the lenders from Time to time parties thereto, and JP Morgan Chase Bank NA, as Administrative Agent.	Form 10-Q 4/4/06	10.1
10.40	Form of Restricted Stock Award	Form 10-K 3/28/05, **	10.50
10.41	Form of Stock Option Grant	Form 10-K 3/28/05, **	10.51

## Table of Contents

<u>Exhibit Number</u>		<u>Page Number or Incorporation by Reference</u>	
		<u>File No. and Filing Date</u>	<u>Previous Exhibit No.</u>
10.42	Assets Purchase Agreement of April 1, 2005 between Service America Network, Inc. and Service America Enterprise, Inc.	Form 8-K 4/7/05	10.1
12	Computation of Ratio of Earnings to Fixed Charges	*	
13	2008 Annual Report to Stockholders	*	
14	Policies on Business Ethics of Chemed Corporation	Form 10-K 3/12/04	14
21	Subsidiaries of Chemed Corporation	*	
23	Consent of Independent Registered Public Accounting Firm	*	
24	Powers of Attorney	*	
31.1	Certification by Kevin J. McNamara pursuant to Rule 13a-14(a)/15d-14(a) of the Exchange Act of 1934.	*	
31.2	Certification by David P. Williams pursuant to Rule 13a-14(a)/15d-14(a) of the Exchange Act of 1934.	*	
31.3	Certification by Arthur V. Tucker, Jr. pursuant to Rule 13a-14(a)/15d-14(a) of the Exchange Act of 1934.	*	
32.1	Certification by Kevin J. McNamara pursuant to Section 906 of the Sarbanes-Oxley Act of 2002	*	
32.2	Certification by David P. Williams pursuant to Section 906 of the Sarbanes-Oxley Act of 2002	*	
32.3	Certification by Arthur V. Tucker, Jr. pursuant to Section 906 of the Sarbanes-Oxley Act of 2002	*	

\* Filed herewith.

\*\* Management contract or compensatory plan or arrangement.

**CHEMED CORPORATION**  
**COMPUTATION OF RATIO OF EARNINGS TO FIXED CHARGES**  
(in thousands, except ratios)

	<u>2004</u>	<u>2005</u>	<u>2006</u>	<u>2007</u>	<u>2008</u>
Pretax income/ (loss) from continuing operations before equity in earnings/ (loss) of affiliate	\$ 36,936	\$ 54,656	\$ 90,284	\$ 101,838	\$ 122,345
Additions:					
Fixed charges	28,597	30,738	24,055	31,675	8,637
Amortization of capitalized interest	1	2	2	4	5
Deductions:					
Capitalized interest	<u>(72)</u>	<u>(380)</u>	<u>(751)</u>	<u>(951)</u>	<u>(659)</u>
Adjusted income/ (loss)	<u>\$ 65,462</u>	<u>\$ 85,016</u>	<u>\$ 113,590</u>	<u>\$ 132,566</u>	<u>\$ 130,328</u>
Fixed Charges:					
Interest expense	\$ 21,167	\$ 21,264	\$ 17,468	\$ 11,244	\$ 5,985
Capitalized interest	72	380	751	951	659
Interest component of rental expense	4,028	5,123	5,406	5,682	6,201
Loss/(Gain) on extinguishment of debt (a), (b), (c), (d), (e)	<u>3,330</u>	<u>3,971</u>	<u>430</u>	<u>13,798</u>	<u>(4,208)</u>
Fixed charges	<u>\$ 28,597</u>	<u>\$ 30,738</u>	<u>\$ 24,055</u>	<u>\$ 31,675</u>	<u>\$ 8,637</u>
Ratio of earnings to fixed charges (f)	<u>2.3x</u>	<u>2.8x</u>	<u>4.7x</u>	<u>4.2x</u>	<u>15.1x</u>

- (a) The year ended December 31, 2004 includes interest penalties related to the retirement of the Company's 7.31% senior notes due 2005 through 2009.
- (b) The year ended December 31, 2005 includes interest penalties related to the retirement of the Company's floating rate notes due 2010.
- (c) The year ended December 31, 2006 includes interest penalties related to the retirement of the Company's \$84.4 million term loan due 2009 .
- (d) The year ended December 31, 2007 includes interest penalties related to the retirement of the Company's \$150 million fixed rate notes due 2011. Refer to Note 2 in the Notes to Consolidated Financial Statements for further discussion.
- (e) The year ended December 31, 2008 includes a gain related to the repurchase of \$13 million of the Company's \$200 million convertible debt. Refer to Note 2 in the Notes to Consolidated Financial Statements for further discussion.
- (f) For purposes of computing the ratio of earnings to fixed charges, pretax income/ (loss) from continuing operations before equity in earnings/ (loss) of affiliate has been added to fixed charges and adjusted for capitalized interest to derive adjusted income/ (loss). Fixed charges consist of interest expense on debt (including the amortization of deferred financing costs), capitalized interest, prepayment penalties on the early extinguishment of debt and one-third (the proportion deemed representative of the interest component) of rental expense. Fixed charge amounts include interest from both continuing and discontinued operations.

Chemed Corporation and Subsidiary Companies

**Financial Review**

**Contents**

<b>Report of Independent Registered Public Accounting Firm</b>	<b>2</b>
<b>Consolidated Statement of Income</b>	<b>3</b>
<b>Consolidated Balance Sheet</b>	<b>4</b>
<b>Consolidated Statement of Cash Flows</b>	<b>5</b>
<b>Consolidated Statement of Changes in Stockholders' Equity</b>	<b>6</b>
<b>Notes to Consolidated Financial Statements</b>	<b>8</b>
<b>Unaudited Summary of Quarterly Results</b>	<b>34</b>
<b>Selected Financial Data</b>	<b>36</b>
<b>Management's Discussion and Analysis of Financial Conditions and Results of Operations</b>	<b>37</b>
<b>Officers' and Directors' Listing and Corporate Information</b>	<b>IBC</b>

**MANAGEMENT'S REPORT ON INTERNAL CONTROL OVER FINANCIAL REPORTING**

The Company's management is responsible for establishing and maintaining adequate internal control over financial reporting, as that term is defined in Exchange Act Rules 13a-15(f) and 15d-15(f). A company's internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company's internal control over financial reporting includes those policies and procedures that (i) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and disposition of the assets of the company; (ii) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorization of management and directors of the company; and (iii) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the Company's assets that could have a material effect on the financial statements.

Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

The Company's management, including the President and Chief Executive Officer, Executive Vice President and Chief Financial Officer and Vice President and Controller, has conducted an evaluation of the effectiveness of its internal control over financial reporting as of December 31, 2008, based on the framework established in *Internal Control—Integrated Framework* issued by the Committee of Sponsoring Organizations of the Treadway Commission ("COSO"). Based on this evaluation, management concluded that internal control over financial reporting was effective as of December 31, 2008, based on criteria in *Internal Control—Integrated Framework* issued by COSO.

PricewaterhouseCoopers LLP, our independent registered public accounting firm, has audited the effectiveness of the Company's internal control over financial reporting as of December 31, 2008, as stated in their report which appears on page 2.

*Report of Independent Registered Public Accounting Firm*

To the Stockholders and Board of Directors of Chemed Corporation

In our opinion, the accompanying consolidated balance sheet and the related consolidated statement of income, cash flows and changes in stockholders' equity present fairly, in all material respects, the financial position of Chemed Corporation and its subsidiaries at December 31, 2008 and 2007, and the results of their operations and their cash flows for each of the three years in the period ended December 31, 2008 in conformity with accounting principles generally accepted in the United States of America. Also in our opinion, the Company maintained, in all material respects, effective internal control over financial reporting as of December 31, 2008, based on criteria established in *Internal Control — Integrated Framework* issued by the Committee of Sponsoring Organizations of the Treadway Commission (COSO). The Company's management is responsible for these financial statements, for maintaining effective internal control over financial reporting and for its assessment of the effectiveness of internal control over financial reporting, included in the accompanying Management's Report on Internal Control over Financial Reporting. Our responsibility is to express opinions on these financial statements and on the Company's internal control over financial reporting based on our integrated audits. We conducted our audits in accordance with the standards of the Public Company Accounting Oversight Board (United States). Those standards require that we plan and perform the audits to obtain reasonable assurance about whether the financial statements are free of material misstatement and whether effective internal control over financial reporting was maintained in all material respects. Our audits of the financial statements included examining, on a test basis, evidence supporting the amounts and disclosures in the financial statements, assessing the accounting principles used and significant estimates made by management, and evaluating the overall financial statement presentation. Our audit of internal control over financial reporting included obtaining an understanding of internal control over financial reporting, assessing the risk that a material weakness exists, and testing and evaluating the design and operating effectiveness of internal control based on the assessed risk. Our audits also included performing such other procedures as we considered necessary in the circumstances. We believe that our audits provide a reasonable basis for our opinions.

A company's internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company's internal control over financial reporting includes those policies and procedures that (i) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (ii) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and (iii) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company's assets that could have a material effect on the financial statements.

Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

/s/ PricewaterhouseCoopers LLP

\_\_\_\_\_  
PricewaterhouseCoopers LLP

Cincinnati, Ohio

February 27, 2009

**CONSOLIDATED STATEMENT OF INCOME**Chemed Corporation and Subsidiary Companies  
(in thousands, except per share data)

For the Years Ended December 31,	2008	2007	2006
<b>Continuing Operations</b>			
Service revenues and sales	\$ 1,148,941	\$ 1,100,058	\$ 1,018,587
Cost of services provided and goods sold (excluding depreciation)	810,547	767,066	730,123
Selling, general and administrative expenses	175,333	184,060	161,183
Depreciation	21,581	20,118	16,775
Amortization	5,924	5,270	5,255
Other operating expenses—net (Note 6)	2,699	789	272
Total costs and expenses	1,016,084	977,303	913,608
Income from operations	132,857	122,755	104,979
Interest expense	(5,985)	(11,244)	(17,468)
Gain/(loss) on extinguishment of debt (Note 2)	4,208	(13,798)	(430)
Loss from impairment of investment (Note 8)	—	—	(1,445)
Other income/(expense)—net (Note 10)	(8,735)	4,125	4,648
Income before income taxes	122,345	101,838	90,284
Income taxes (Note 11)	(50,240)	(39,063)	(32,562)
Income from continuing operations	72,105	62,775	57,722
<b>Discontinued Operations, Net of Income Taxes (Note 8)</b>	<b>(1,088)</b>	<b>1,201</b>	<b>(7,071)</b>
<b>Net Income</b>	<b>\$ 71,017</b>	<b>\$ 63,976</b>	<b>\$ 50,651</b>
<b>Earnings Per Share (Note 15)</b>			
Income from continuing operations	\$ 3.13	\$ 2.56	\$ 2.21
Net Income	\$ 3.08	\$ 2.61	\$ 1.94
<b>Diluted Earnings Per Share (Note 15)</b>			
Income from continuing operations	\$ 3.08	\$ 2.50	\$ 2.16
Net Income	\$ 3.04	\$ 2.55	\$ 1.90
<b>Average Number of Shares Outstanding (Note 15)</b>			
Earnings per share	23,058	24,520	26,118
Diluted earnings per share	23,374	25,077	26,669

The Notes to Consolidated Financial Statements are integral parts of this statement.

**CONSOLIDATED BALANCE SHEET**Chemed Corporation and Subsidiary Companies  
(in thousands, except shares and per share data)

December 31,	2008	2007
<b>Assets</b>		
Current assets		
Cash and cash equivalents (Note 9)	\$ 3,628	\$ 4,988
Accounts receivable less allowances of \$10,320 (2007 - \$9,746)	98,076	101,170
Inventories	7,569	6,596
Current deferred income taxes (Note 11)	15,392	14,212
Prepaid expenses and other current assets	11,596	10,496
Total current assets	<u>136,261</u>	<u>137,462</u>
Investments of deferred compensation plans held in trust (Notes 14 and 16)	22,628	29,417
Note receivable (Notes 8 and 16)	—	9,701
Properties and equipment, at cost, less accumulated depreciation (Note 12)	76,962	74,513
Identifiable intangible assets less accumulated amortization of \$21,271 (2007 - \$17,245) (Note 5)	61,303	65,177
Goodwill (Note 5)	448,721	438,689
Other assets	15,049	15,411
Total Assets	<u>\$ 760,924</u>	<u>\$ 770,370</u>
<b>Liabilities</b>		
Current liabilities		
Accounts payable	\$ 52,810	\$ 46,168
Current portion of long-term debt (Note 2)	10,169	10,162
Income taxes (Note 11)	2,156	4,221
Accrued insurance	35,994	36,337
Accrued compensation	40,741	40,072
Other current liabilities	12,180	13,929
Total current liabilities	<u>154,050</u>	<u>150,889</u>
Deferred income taxes (Note 11)	7,597	5,802
Long-term debt (Note 2)	199,656	214,669
Deferred compensation liabilities (Note 14)	22,417	29,149
Other liabilities	5,612	5,512
Commitments and contingencies (Notes 13, 18 and 19)		
Total Liabilities	<u>389,332</u>	<u>406,021</u>
<b>Stockholders' Equity</b>		
Capital stock — authorized 80,000,000 shares \$1 par; issued 29,514,877 shares (2007 - 29,260,791 shares)	29,515	29,261
Paid-in capital	282,206	267,312
Retained earnings	343,810	278,336
Treasury stock — 7,100,475 shares (2007 - 5,299,056 shares), at cost	(285,977)	(213,041)
Deferred compensation payable in Company stock (Note 14)	2,038	2,481
Total Stockholders' Equity	<u>371,592</u>	<u>364,349</u>
Total Liabilities and Stockholders' Equity	<u>\$ 760,924</u>	<u>\$ 770,370</u>

The Notes to Consolidated Financial Statements are integral parts of this statement.

**CONSOLIDATED STATEMENT OF CASH FLOWS**Chemed Corporation and Subsidiary Companies  
(in thousands)

For the Years Ended December 31,	2008	2007	2006
<b>Cash Flows from Operating Activities</b>			
Net income	\$ 71,017	\$ 63,976	\$ 50,651
Adjustments to reconcile net income/(loss) to net cash provided by operations:			
Depreciation and amortization	27,505	25,388	22,030
Provision for uncollectible accounts receivable	9,820	8,373	8,169
Stock option expense	7,303	4,665	1,211
Noncash loss/(gain) on early extinguishment of debt	(4,208)	7,235	430
Loss on impairment of equipment	2,699	—	—
Discontinued operations (Note 8)	1,088	(1,201)	7,071
Amortization of debt issuance costs	1,039	1,186	1,774
Provision for deferred income taxes (Note 11)	426	8,113	7,408
Noncash portion of long-term incentive compensation	—	6,154	—
Loss on impairment of investment	—	—	1,445
Changes in operating assets and liabilities, excluding amounts acquired in business combinations:			
Increase in accounts receivable	(6,659)	(18,299)	(12,527)
Increase in inventories	(898)	(18)	(78)
Decrease/(increase) in prepaid expenses and other current assets	305	(549)	(2,188)
Increase/(decrease) in accounts payable and other current liabilities	5,585	(8,416)	(13,017)
Increase/(decrease) in income taxes	(770)	6,321	18,726
Decrease/(increase) in other assets	5,481	(3,655)	(722)
Increase/(decrease) in other liabilities	(6,423)	4,426	3,788
Excess tax benefit on share-based compensation	(2,422)	(3,091)	(5,600)
Other sources/(uses)	1,195	(1,024)	898
Net cash provided by continuing operations	112,083	99,584	89,469
Net cash provided by discontinued operations (Note 8)	—	—	9,120
Net cash provided by operating activities	112,083	99,584	98,589
<b>Cash Flows from Investing Activities</b>			
Capital expenditures	(26,094)	(26,640)	(21,987)
Business combinations, net of cash acquired (Note 7)	(11,200)	(1,079)	(4,145)
Net proceeds/(uses) of discontinued operations (Note 8)	8,824	(5,402)	(922)
Proceeds from sales of property and equipment	387	3,104	347
Other uses	(544)	(1,701)	(1,025)
Net cash used by investing activities	(28,627)	(31,718)	(27,732)
<b>Cash Flows from Financing Activities</b>			
Purchases of treasury stock (Note 22)	(69,788)	(131,704)	(19,885)
Repayment of long-term debt (Note 2)	(18,713)	(225,709)	(84,563)
Net increase in revolving line of credit	8,200	—	—
Dividends paid	(5,543)	(5,888)	(6,322)
Excess tax benefit on share-based compensation	2,422	3,091	5,600
Increase/(decrease) in cash overdraft payable	(856)	(919)	2,571
Proceeds from exercise of stock options (Note 3)	291	2,467	3,861
Proceeds from issuance of long-term debt (Note 2)	—	300,000	—
Purchase of note hedges (Note 2)	—	(55,100)	—
Proceeds from issuance of warrants (Note 2)	—	27,614	—
Debt issuance costs	—	(6,949)	(154)
Other sources/(uses)	(829)	945	176
Net cash provided/(used) by financing activities	(84,816)	(92,152)	(98,716)
<b>Decrease in cash and cash equivalents</b>	<b>(1,360)</b>	<b>(24,286)</b>	<b>(27,859)</b>
Cash and cash equivalents at beginning of year	4,988	29,274	57,133
Cash and cash equivalents at end of year	\$ 3,628	\$ 4,988	\$ 29,274

The Notes to Consolidated Financial Statements are integral parts of this statement.

**CONSOLIDATED STATEMENT OF CHANGES IN STOCKHOLDERS' EQUITY**

Chemed Corporation and Subsidiary Companies

(in thousands, except per share data)

	Capital Stock	Paid-in Capital	Retained Earnings	Treasury Stock- at Cost	Deferred Compensation Payable in Company Stock	Notes Receivable for Shares Sold	Total
Balance at December 31, 2005	\$ 28,374	\$ 234,910	\$ 171,188	\$ (52,127)	\$ 2,379	\$ (549)	\$ 384,175
Net income	—	—	50,651	—	—	—	50,651
Dividends paid (\$.24 per share)	—	—	(6,322)	—	—	—	(6,322)
Stock awards and exercise of stock options (Note 3)	476	17,663	—	(9,840)	—	—	8,299
Purchases of treasury stock	—	—	—	(15,612)	—	—	(15,612)
Decrease in notes receivable	—	—	—	(485)	—	549	64
Other	—	66	—	—	40	—	106
Balance at December 31, 2006	28,850	252,639	215,517	(78,064)	2,419	—	421,361
Cumulative effect of change in accounting principle as of January 1, 2007 (Notes 1 and 11)	—	—	4,731	—	—	—	4,731
Net income	—	—	63,976	—	—	—	63,976
Dividends paid (\$.24 per share)	—	—	(5,888)	—	—	—	(5,888)
Stock awards and exercise of stock options (Note 3)	411	21,141	—	(7,032)	—	—	14,520
Purchases of treasury stock (Note 22)	—	—	—	(127,881)	—	—	(127,881)
Purchase of note hedges (Note 2)	—	(54,894)	—	—	—	—	(54,894)
Deferred tax benefit of purchased note hedges (Note 2)	—	20,036	—	—	—	—	20,036
Proceeds from issuance of warrants (Note 2)	—	27,614	—	—	—	—	27,614
Other	—	776	—	(64)	62	—	774
Balance at December 31, 2007	29,261	267,312	278,336	(213,041)	2,481	—	364,349
Net income	—	—	71,017	—	—	—	71,017
Dividends paid (\$.24 per share)	—	—	(5,543)	—	—	—	(5,543)
Stock awards and exercise of stock options (Note 3)	254	15,752	—	(6,253)	—	—	9,753
Purchases of treasury stock (Note 22)	—	—	—	(67,125)	—	—	(67,125)
Other	—	(858)	—	442	(443)	—	(859)
Balance at December 31, 2008	\$ 29,515	\$ 282,206	\$ 343,810	\$ (285,977)	\$ 2,038	\$ —	\$ 371,592

The Notes to Consolidated Financial Statements are integral parts of this statement.

[page intentionally left blank]

## 1. Summary of Significant Accounting Policies

### *NATURE OF OPERATIONS*

We operate through our two wholly owned subsidiaries: VITAS Healthcare Corporation (“VITAS”) and Roto-Rooter Group, Inc. (“Roto-Rooter”). VITAS focuses on hospice care that helps make terminally ill patients’ final days as comfortable as possible. Through its team of doctors, nurses, home health aides, social workers, clergy and volunteers, VITAS provides direct medical services to patients, as well as spiritual and emotional counseling to both patients and their families. Roto-Rooter is focused on providing plumbing and drain cleaning services to both residential and commercial customers. Through its network of company-owned branches, independent contractors and franchisees, Roto-Rooter offers plumbing and drain cleaning service to over 90% of the U.S. population.

### *PRINCIPLES OF CONSOLIDATION*

The consolidated financial statements include the accounts of Chemed Corporation and its wholly owned subsidiaries. All significant intercompany transactions have been eliminated.

We have analyzed the provisions of Financial Accounting Standards Board (“FASB”) Interpretation No. 46R “Consolidation of Variable Interest Entities—an interpretation of Accounting Research Bulletin No. 51 (revised)” (“FIN 46R”) relative to contractual relationships with our Roto-Rooter independent contractors and franchisees. FIN 46R requires the primary beneficiary of a Variable Interest Entity (“VIE”) to consolidate the accounts of the VIE. Based upon guidance provided in FIN 46R, we have concluded that certain of the independent contractors may be VIEs. We believe consolidation, if required, of the accounts of any independent contractor for which we might be the primary beneficiary would not materially impact our financial position, results of operations or cash flow. The franchisees are not VIEs.

### *CASH EQUIVALENTS*

Cash equivalents comprise short-term, highly liquid investments that have been purchased within three months of their dates of maturity.

### *ACCOUNTS AND LOANS RECEIVABLE AND CONCENTRATION OF RISK*

Accounts and loans receivable are recorded at the principal balance outstanding less estimated allowances for uncollectible accounts. For the Roto-Rooter segment, allowances for trade accounts receivable are generally provided for accounts more than 90 days past due, although collection efforts continue beyond that time. Due to the small number of loans receivable outstanding, allowances for loan losses are determined on a case-by-case basis. For the VITAS segment, allowances for accounts receivable are provided on accounts based on expected collection rates by payer types. The appropriate collection rate is based on both historical averages and known current trends. Final write-off of overdue accounts or loans receivable is made when all reasonable collection efforts have been made and payment is not forthcoming. We closely monitor our receivables and periodically review procedures for granting credit to attempt to hold losses to a minimum.

As of December 31, 2008 and 2007, approximately 68% and 63%, respectively, of VITAS’ total accounts receivable balance were due from Medicare and 23% and 28%, respectively, of VITAS’ total accounts receivable balance were due from various state Medicaid programs. Combined accounts receivable from Medicare and Medicaid represent 83% of the net accounts receivable in the accompanying consolidated balance sheet as of December 31, 2008.

As of December 31, 2008, VITAS has approximately \$13.9 million in unbilled revenue included in accounts receivable (December 31, 2007 — \$9.5 million). The unbilled revenue at VITAS relates to hospice programs currently undergoing focused medical reviews (“FMR”). During FMR, surveyors working on behalf of the U.S. Federal government review certain patient files for compliance with Medicare regulations. During the time the patient file is under review, we are unable to bill for care provided to those patients. During the past year, the pace of FMR activity has increased industry-wide, resulting in our significant unbilled revenue balances. We make appropriate provisions to reduce our accounts receivable balance for potential denials of patient service revenue due to FMR activity.

### *INVENTORIES*

Substantially all of the inventories are either general merchandise or finished goods. Inventories are stated at the lower of cost or market. For determining the value of inventories, cost methods that reasonably approximate the first-in, first-out (“FIFO”) method are used.

*DEPRECIATION AND PROPERTIES AND EQUIPMENT*

Depreciation of properties and equipment is computed using the straight-line method over the estimated useful lives of the assets. Leasehold improvements are amortized over the lesser of the remaining lease terms (excluding option terms) or their useful lives. Expenditures for maintenance, repairs, renewals and betterments that do not materially prolong the useful lives of the assets are expensed as incurred. The cost of property retired or sold and the related accumulated depreciation are removed from the accounts, and the resulting gain or loss is reflected currently in income.

Expenditures for major software purchases and software developed for internal use are capitalized and depreciated using the straight-line method over the estimated useful lives of the assets. For software developed for internal use, external direct costs for materials and services and certain internal payroll and related fringe benefit costs are capitalized in accordance with Statement of Position 98-1, "Accounting for the Costs of Computer Software Developed or Obtained for Internal Use."

The weighted average lives of our property and equipment at December 31, 2008, were:

Buildings	12.3 yrs.
Transportation equipment	7.7
Machinery and equipment	5.8
Computer software	4.3
Furniture and fixtures	4.8

*GOODWILL AND INTANGIBLE ASSETS*

Identifiable, definite-lived intangible assets arise from purchase business combinations and are amortized using either an accelerated method or the straight-line method over the estimated useful lives of the assets. The selection of an amortization method is based on which method best reflects the economic pattern of usage of the asset. The VITAS trade name is considered to have an indefinite life. Goodwill and the VITAS trade name are tested at least annually for impairment.

The weighted average lives of our identifiable, definite-lived intangible assets at December 31, 2008, were:

Covenants not to compete	6.4 yrs.
Referral networks	10.0
Customer lists	13.3

*LONG-LIVED ASSETS*

If we believe a triggering event may have occurred that indicates a possible impairment of our long-lived assets, we perform an estimate and valuation of the future benefits of our long-lived assets (other than goodwill and the VITAS trade name) based on key financial indicators. If the projected undiscounted cash flows of a major business unit indicate that property and equipment or identifiable, definite-lived intangible assets have been impaired, a write-down to fair value is made.

*OTHER ASSETS*

Debt issuance costs are included in other assets and are amortized using the effective interest method over the life of the debt.

We capitalize the direct costs of obtaining licenses to operate hospice programs subject to a minimum capitalization threshold. These costs are amortized over the life of the license using the straight-line method. Certain licenses are granted without an expiration and thus, we believe them to be indefinite-lived assets subject to impairment testing on at least an annual basis.

*REVENUE RECOGNITION*

Both the VITAS segment and Roto-Rooter segment recognize service revenues and sales when the earnings process has been completed. Generally, this occurs when services are provided or products are delivered. Sales of Roto-Rooter products, including drain cleaning machines and drain cleaning solution, comprise less than 3% of our total service revenues and sales for each of the three years in the period ended December 31, 2008.

VITAS recognizes revenue at the estimated realizable amount due from third-party payers, which are primarily Medicare and Medicaid. Payers may deny payment for services in whole or in part on the basis that such services are not eligible for coverage and do not qualify for reimbursement. We estimate denials each period and make adequate

provision in the financial statements. The estimate of denials is based on historical trends and known circumstances and does not vary materially from period to period on an aggregate basis. Medicare billings are subject to certain limitations, as described below.

VITAS is subject to certain limitations on Medicare payments for services. Specifically, if the number of inpatient care days any hospice program provides to Medicare beneficiaries exceeds 20% of the total days of hospice care such program provided to all Medicare patients for an annual period beginning September 28, the days in excess of the 20% figure may be reimbursed only at the routine homecare rate. None of VITAS' hospice programs exceeded the payment limits on inpatient services in 2008, 2007 or 2006.

VITAS is also subject to a Medicare annual per-beneficiary cap ("Medicare cap"). Compliance with the Medicare cap is measured by comparing the total Medicare payments received under a Medicare provider number with respect to services provided to all Medicare hospice care beneficiaries in the program or programs covered by that Medicare provider number between November 1 of each year and October 31 of the following year with the product of the per-beneficiary cap amount and the number of Medicare beneficiaries electing hospice care for the first time from that hospice program or programs from September 28 through September 27 of the following year.

We actively monitor each of our hospice programs, by provider number, as to their specific admission, discharge rate and median length of stay data in an attempt to determine whether revenues are likely to exceed the annual per-beneficiary Medicare cap. Should we determine that revenues for a program are likely to exceed the Medicare cap based on projected trends, we attempt to institute corrective actions, which include changes to the patient mix and increased patient admissions. However, should we project our corrective action will not prevent that program from exceeding its Medicare cap, we estimate the amount of revenue recognized during the period that will require repayment to the Federal government under the Medicare cap and record the amount as a reduction to service revenue.

Our estimate of the Medicare cap liability is particularly sensitive to allocations made by our fiscal intermediary relative to patient transfers between hospices. We are allocated a percentage of the Medicare cap based on the days a patient spent in our care as compared to the total days a patient spent in all hospice care. The allocation for patient transfers cannot be determined until a patient dies. As the number of days a patient spends in hospice is based on a future event, this allocation process may take several years. Therefore, we use only first-time Medicare admissions in our estimate of the Medicare cap billing limitation. This method assumes that credit received for patients who transfer into our program will be offset by credit lost from patients who transfer out of our program. The amount we record is our best estimate of the liability as of the date of the financial statements but could change as more patient information becomes available.

During the years ended December 31, 2008, 2007 and 2006, we recorded pretax charges in continuing operations of \$235,000, \$242,000 and \$3.9 million, respectively, for the estimated Medicare cap liability. The amount recorded in 2008 relates to one program's projected liability through year end for the 2009 measurement period. We are currently pursuing the corrective actions mentioned above to attempt to mitigate the liability before the end of the measurement period. The amount recorded in 2007 relates primarily to retroactive billings for prior-measurement periods due to patients who transferred between multiple hospice providers.

#### *SALES TAX*

The Roto-Rooter segment collects sales tax from customers when required by state and federal laws. We record the amount of sales tax collected net in the accompanying consolidated statement of income.

#### *GUARANTEES*

In the normal course of business, Roto-Rooter enters into various guarantees and indemnifications in our relationships with customers and others. These arrangements include guarantees of services for periods ranging from one day to one year and product satisfaction guarantees. Mainly due to our technicians being commission-based, guarantees and indemnifications do not materially impact our financial condition, results of operations or cash flows. Therefore, no liability for guarantees has been recorded as of December 31, 2008 or 2007.

#### *OPERATING EXPENSES*

Cost of services provided and goods sold (excluding depreciation) includes salaries, wages and benefits of service providers and field personnel, material costs, medical supplies and equipment, pharmaceuticals, insurance costs, service vehicle costs and other expenses directly related to providing service revenues or generating sales. Selling, general and administrative expenses include salaries, wages, stock option expense and benefits of selling, marketing and

administrative employees, advertising expenses, communications and branch telephone expenses, office rent and operating costs, legal, banking and professional fees and other administrative costs.

#### *ADVERTISING*

We expense the production costs of advertising the first time the advertising takes place. The costs of yellow page listings are expensed when the directories are placed in circulation. These directories are generally in circulation for approximately one year, at which point they are replaced by the publisher with a new directory. We generally pay for directory placement assuming it is in circulation for one year. If the directory is in circulation for less than or greater than one year, we receive a credit or additional billing, as necessary. We do not control the timing of when a new directory is placed in circulation. Advertising expense in continuing operations for the year ended December 31, 2008, was \$26.8 million (2007 — \$26.0 million; 2006 — \$23.3 million).

#### *COMPUTATION OF EARNINGS PER SHARE*

Earnings per share are computed using the weighted average number of shares of capital stock outstanding. Diluted earnings per share reflect the dilutive impact of our outstanding stock options and nonvested stock awards. Stock options whose exercise price is greater than the average market price of our stock are excluded from the computation of diluted earnings per share.

#### *STOCK-BASED COMPENSATION PLANS*

Effective January 1, 2006, we adopted the provisions of Statement of Financial Accounting Standards No. 123, revised (“SFAS 123(R)”) which establishes accounting for stock-based compensation for employees. Under SFAS 123(R), stock-based compensation cost is measured at the grant date, based on the fair value of the award and recognized as expense over the employee’s requisite service period on a straight-line basis.

#### *INSURANCE ACCRUALS*

For our Roto-Rooter segment and Corporate Office, we self-insure for all casualty insurance claims (workers’ compensation, auto liability and general liability). As a result, we closely monitor and frequently evaluate our historical claims experience to estimate the appropriate level of accrual for self-insured claims. Our third-party administrator (“TPA”) processes and reviews claims on a monthly basis. Currently, our exposure on any single claim is capped at \$500,000. In developing our estimates, we accumulate historical claims data for the previous 10 years to calculate loss development factors (“LDF”) by insurance coverage type. LDFs are applied to known claims to estimate the ultimate potential liability for known and unknown claims for each open policy year. LDFs are updated annually. Because this methodology relies heavily on historical claims data, the key risk is whether the historical claims are an accurate predictor of future claims exposure. The risk also exists that certain claims have been incurred and not reported on a timely basis. To mitigate these risks, in conjunction with our TPA, we closely monitor claims to ensure timely accumulation of data and compare claims trends with the industry experience of our TPA.

For the VITAS segment, we self-insure for workers’ compensation claims. Currently, VITAS’ exposure on any single claim is capped at \$500,000. For VITAS’ self-insurance accruals for workers’ compensation, the valuation methods used are similar to those used internally for our other business units.

Our casualty insurance liabilities are recorded gross before any estimated recovery for amounts exceeding our stop loss limits. Estimated recoveries from insurance carriers are recorded as accounts receivable.

#### *TAXES ON INCOME*

Deferred taxes are provided on an asset and liability method whereby deferred tax assets are recognized for deductible temporary differences and operating loss carry-forwards and deferred tax liabilities are recognized for taxable temporary differences. Temporary differences are the differences between the reported amount of assets and liabilities and their tax basis. Deferred tax assets are reduced by a valuation allowance when, in our opinion, it is more likely than not that some portion or all of the deferred tax assets will not be realized. Deferred tax assets and liabilities are adjusted for the effects of changes in laws and rates on the date of enactment.

We are subject to income taxes in Canada, U.S. Federal and most state jurisdictions. Significant judgment is required to determine our provision for income taxes. On January 1, 2007, we adopted FASB Interpretation No. 48 (“FIN 48”), “Accounting for Uncertainty in Income Taxes — an Interpretation of FASB Statement 109,” which prescribes a comprehensive model to recognize, measure, present and disclose in financial statements uncertain tax positions taken or expected to be taken on a tax return. Upon adoption of FIN 48, our financial statements reflect expected future tax consequences of such uncertain positions assuming the taxing authorities’ full knowledge of the position and all relevant facts. FIN 48 also revises disclosure requirements and introduces an annual, tabular roll-forward of the unrecognized tax

benefits. The cumulative effect upon adoption of FIN 48 was to reduce our accrual for uncertain tax positions by approximately \$4.7 million, which has been recorded in retained earnings as of January 1, 2007, in the accompanying consolidated balance sheet.

#### *ESTIMATES*

The preparation of consolidated financial statements in conformity with accounting principles generally accepted in the United States requires us to make estimates and assumptions that affect amounts reported in the consolidated financial statements and accompanying notes. Actual results could differ from those estimates. Disclosures of aftertax expenses and adjustments are based on estimates of the effective income tax rates for the applicable segments.

#### *RECENT ACCOUNTING STATEMENTS*

In June 2008, the FASB issued Staff Position No. EITF 03-6-1, "Determining Whether Instruments Granted in Share-Based Payment Transactions are Participating Securities." The new guidance requires that unvested share-based payment awards containing non-forfeitable rights to dividends or dividend equivalents are participating securities and shall be included in the computation of earnings per share pursuant to the two-class method. The new standard is effective for all fiscal years beginning after December 15, 2008 and must be applied retrospectively for all periods presented. Adoption of the new guidance in fiscal 2009 will not have a material impact on our earnings per share.

In June 2008, the EITF reached a consensus on EITF Issue No. 07-5, "Determining Whether an Instrument (or an Embedded Feature) Is Indexed to an Entity's Own Stock". The consensus provides additional guidance when determining whether an option or warrant on an entity's own shares are eligible for the equity classification provided for in EITF 00-19. The consensus is effective for fiscal years beginning after December 15, 2008. As such, we adopted the new standard on January 1, 2009. The adoption of EITF Issue No. 07-5 did not impact the accounting for our 2007 convertible debt transaction.

In May 2008, the FASB issued Staff Position No. APB 14-1, "Accounting for Convertible Debt Instruments that may be Settled in Cash Upon Conversion (Including Partial Cash Settlement)." This new guidance requires all convertible debentures classified as Instruments B or C under EITF 90-19 to separately account for the debt and equity pieces of the instrument. At inception of the convertible instrument, cash flows related to the convertible instrument are to be discounted using a market rate of interest. This will create a discount at inception to be recorded in equity. The debt portion is to be accreted to its face value, through interest expense, over the life of the instrument using the effective interest method. This will result in higher interest expense over the life of the instrument and an increase in equity at the inception of the instrument. Debt issuance costs are also to be allocated between the debt and equity components using a rationale method. Finally, the FSP requires that the Company value any embedded features of the instrument, other than the conversion option, as a part of the liability. The new standard is effective for all fiscal years (and interim periods) beginning after December 15, 2008. As such, we adopted the new standard on January 1, 2009. The FSP is to be applied retrospectively. Upon adoption, our \$200 million, 1.875% Convertible Debentures issued in May 2007 had a discount of approximately \$55 million. Additionally, the gain on extinguishment of debt discussed in more detail in Note 2 decreased by approximately \$830,000 upon retrospective adoption due to a portion of the extinguishment being attributed to the equity component of our convertible debenture.

In May 2008, the FASB issued Statement of Financial Accounting Standard No. 162 "The Hierarchy of Generally Accepted Accounting Principles" ("SFAS 162"). The purpose of this standard is to provide a consistent framework for determining what accounting principles should be used when preparing U.S. GAAP financial statements. SFAS 162 categorizes accounting pronouncements in a descending order of authority. In the instance of potentially conflicting accounting principles, the standard in the highest category must be used. This statement will be effective 60 days after the SEC approves the Public Company Accounting and Oversight Board's related amendments. We believe that SFAS 162 will have no impact on our existing accounting methods.

In December 2007, the FASB issued Statement of Financial Accounting Standard No. 141(R) "Business Combinations (revised 2007)" ("SFAS 141(R)"), which changes certain aspects of the accounting for business combinations. This Statement retains the fundamental requirements in Statement No. 141 that the purchase method of accounting be used for all business combinations and for an acquirer to be identified for each business combination. SFAS 141(R) modifies existing accounting guidance in the areas of deal and restructuring costs, acquired contingencies, contingent consideration, in-process research and development, accounting for subsequent tax adjustments and assessing the valuation date. This Statement applies prospectively to business combinations for which the acquisition date is on or after the beginning of the first annual reporting period beginning on or after December 15, 2008. An entity may not apply it before that date. There was no impact on our financial statements as a result of the adoption of SFAS 141(R); however our accounting for all business combinations after adoption will comply with the new standard.

In December 2007, the FASB issued Statement of Financial Accounting Standard No. 160 “Non-controlling Interests in Consolidated Financial Statements — an amendment of ARB No. 51” (“SFAS 160”), which requires ownership interests in subsidiaries held by others to be clearly identified, labeled and presented in the consolidated balance sheet within equity but separate from the parent company’s equity. SFAS 160 also affects the accounting requirements when the parent company either purchases a higher ownership interest or deconsolidates the equity investment. This Statement applies prospectively to business combinations for which the acquisition date is on or after the beginning of the first annual reporting period beginning on or after December 15, 2008. An entity may not apply it before that date. There was no impact on our financial statements as a result of the adoption of SFAS No. 160. We currently do not have non-controlling interests in our consolidated financial statements.

## 2. Long-Term Debt and Lines of Credit

A summary of our long-term debt follows (in thousands):

	December 31,	
	2008	2007
Convertible Notes due 2014	<b>\$ 186,956</b>	\$ 200,000
Term loan due 2007-2012	<b>14,500</b>	24,500
Revolving line of credit	<b>8,200</b>	—
Other	<b>169</b>	331
Subtotal	<b>209,825</b>	224,831
Less current portion	<b>(10,169)</b>	(10,162)
Long-term debt, less current portion	<b><u>\$ 199,656</u></b>	<b><u>\$ 214,669</u></b>

The average interest rate for our long-term debt was 2.1% and 4.4% for the years ended December 31, 2008 and 2007, respectively.

In the fourth quarter of 2008, we purchased approximately \$13.0 million face value of our Convertible Notes due 2014 for approximately \$8.5 million. This resulted in a pre-tax net gain of \$4.2 million comprised of \$4.5 million related to the purchase of the Convertible Notes partially offset by \$300,000 in the write-off of unamortized debt issuance costs. The net gain was recorded as a gain on extinguishment of debt in the accompanying statement of income in 2008.

### 2007 REFINANCING

On May 2, 2007, we entered into a new senior secured credit facility with JPMorgan Chase Bank (the “2007 Facility”) to replace our existing credit facility. The 2007 Facility includes a \$100 million term loan, a \$175 million revolving credit facility and a \$100 million expansion feature. The facility has a 5-year maturity with principal payments on the term loan due quarterly and on the revolving credit facility due at maturity. Interest is payable quarterly at a floating rate equal to our choice of various indices plus a specified margin based on our leverage ratio. The interest rate at the inception of the agreement was LIBOR plus 0.875%. In connection with replacing our existing credit facility, we wrote-off approximately \$2.3 million in deferred debt costs. This write-off was recorded as loss on extinguishment of debt in the accompanying statement of income in 2007.

On May 4, 2007, we used the proceeds from the 2007 Facility to fund the redemption of our \$150 million 8.75% Senior Notes due 2011. The redemption was made pursuant to the terms of the indenture at a price of 104.375% plus accrued but unpaid interest. In connection with the redemption, we wrote-off approximately \$4.8 million in deferred debt costs. The premium payment of \$6.6 million and the write-off of deferred debt costs was recorded as loss on extinguishment of debt in the accompanying statement of income in 2007.

On May 8, 2007, we entered into a Purchase Agreement with J.P. Morgan Securities Inc. and Citigroup Global Markets Inc. (the “Initial Purchasers”) for issuance and sale of \$180 million in aggregate principal amount of our 1.875% Senior Convertible Notes due 2014 (the “Notes”). On May 9, 2007, the Initial Purchasers exercised an over-allotment option to purchase an additional \$20 million in aggregate principal amount of Notes. On May 14, 2007, a total of \$200 million in aggregate principal amount of the Notes were sold to the Initial Purchasers at a price of \$1,000 per Note, less an underwriting fee of \$27.50 per Note. The Notes are to be resold by the Initial Purchasers pursuant to Rule 144A of the Securities Act of 1933, as amended (the “Securities Act”).

We received approximately \$194 million in net proceeds from the sale of the Notes after paying underwriting fees, legal and other expenses. Proceeds from the offering were used to purchase treasury shares of our stock, as discussed in Note 22 and to pay down a portion of the 2007 Facility. We pay interest on the Notes on May 15 and November 15 of each year, beginning on November 15, 2007. The Notes mature on May 15, 2014. The Notes are guaranteed on an unsecured senior basis by each of our subsidiaries that are a borrower or a guarantor under any senior credit facility, as defined in the Indenture. The Notes are convertible, under certain circumstances, into our Capital Stock at a conversion rate of 12.3874 shares per \$1,000 principal amount of Notes. This conversion rate is equivalent to an initial conversion price of approximately \$80.73 per share. Prior to March 1, 2014, holders may convert their Notes under certain circumstances. On and after March 1, 2014, the Notes will be convertible at any time prior to the close of business three days prior to the stated maturity date of the Notes. Upon conversion of a Note, if the conversion value is \$1,000 or less, holders will receive cash equal to the lesser of \$1,000 or the conversion value of the number of shares of our Capital Stock. If the conversion value exceeds \$1,000, in addition to this, holders will receive shares of our Capital Stock for the excess amount. The Indenture contains customary terms and covenants that upon certain events of default, including without limitation, failure to pay when due any principal amount, a fundamental change or certain cross defaults in other agreements or instruments, occurring and continuing; either the trustee or the holders of 25% in aggregate principal amount of the Notes may declare the principal of the Notes and any accrued and unpaid interest through the date of such declaration immediately due and payable. In the case of certain events of bankruptcy or insolvency relating to any significant subsidiary or to us, the principal amount of the Notes and accrued interest automatically becomes due and payable.

Pursuant to the guidance in EITF 90-19, EITF 00-19 "Accounting for Derivative Instruments Indexed to, and Potentially Settled in a Company's Own Stock", EITF 01-6 "The Meaning of Indexed to a Company's Own Stock," and EITF 07-5, the Notes are accounted for as convertible debt in the accompanying consolidated balance sheet and the embedded options within the Notes have not been accounted for as separate derivatives.

We, our subsidiary guarantors and the Initial Purchasers also entered into a Registration Rights Agreement (the "RRA") dated May 14, 2007. Pursuant to the RRA, we agreed to, no later than the 120th day after May 14, 2007, file a shelf registration statement covering resale of the Notes and the Capital Stock issuable upon conversion pursuant to Rule 415 under the Securities Act. On August 17, 2007, we filed a shelf registration statement, that became immediately effective, to register the Notes and Capital Stock issuable upon conversion.

On May 8, 2007, we entered into a purchased call transaction and a warrant transaction (written call) with JPMorgan Chase, National Association and Citibank, N.A. (the "Counterparties"). The purchased call options cover approximately 2,477,000 shares of our Capital Stock, which under most circumstances represents the maximum number of shares of Capital Stock that underlie the Notes. Concurrently with entering into the purchased call options, we entered into warrant transactions with each of the Counterparties. Pursuant to the warrant transactions, we sold to the Counterparties warrants to purchase in the aggregate approximately 2,477,000 shares of our Capital Stock. In most cases, the sold warrants may not be exercised prior to the maturity of the Notes.

The purchased call options and sold warrants are separate contracts with the Counterparties, are not part of the terms of the Notes and do not affect the rights of holders under the Notes. A holder of the Notes will not have any rights with respect to the purchased call options or the sold warrants. The purchased call options are expected to reduce the potential dilution upon conversion of the Notes if the market value per share of the Capital Stock at the time of exercise is greater than approximately \$80.73, which corresponds to the initial conversion price of the Notes. The sold warrants have an exercise price of \$105.44 and are expected to result in some dilution should the price of our Capital Stock exceed this exercise price.

Our net cost for these transactions was approximately \$27.3 million. Pursuant to EITF 07-5, EITF 00-19 and EITF 01-6, the purchased call option and the sold warrants are accounted for as equity transactions. Therefore, our net cost was recorded as a decrease in stockholders' equity in the accompanying consolidated balance sheet.

#### *OTHER*

Other long-term debt has arisen from loans in connection with acquisitions of various businesses and properties. Interest rates range from 5% to 8%, and the obligations are due on various dates through December 2009.

## Chemed Corporation Subsidiary Companies

Since May 2007, we have repaid \$85.5 million of the \$100 million term note under the 2007 Facility using cash on hand. Of the amount paid, \$68.0 million represents a prepayment. The following is a schedule by year of required long-term debt payments as of December 31, 2008 (in thousands):

<b>2009</b>	<b>\$ 10,169</b>
<b>2010</b>	4,500
<b>2011</b>	—
<b>2012</b>	8,200
<b>2013</b>	—
<b>Thereafter</b>	186,956
<b>Total long-term debt</b>	<b><u>\$ 209,825</u></b>

During 2008, 2007 and 2006, interest totaling \$659,000, \$951,000 and \$751,000, respectively, was capitalized. Summarized below are the total amounts of interest paid during the years ended December 31 (in thousands):

<b>2008</b>	<b>\$ 5,628</b>
2007	15,466
2006	16,462

### DEBT COVENANTS

Collectively, the 2007 Facility and the Notes require us to meet certain restrictive financial covenants, in addition to non-financial covenants, including maximum leverage ratios, minimum fixed charge coverage and consolidated net worth ratios, limits on operating leases and minimum asset value limits. We are in compliance with all debt covenants, financial and non-financial, as of December 31, 2008. We have issued \$26.9 million in standby letters of credit as of December 31, 2008, mainly for insurance purposes. Issued letters of credit reduce our available credit under the revolving credit agreement. As of December 31, 2008, we have approximately \$139.9 million of unused lines of credit available and eligible to be drawn down under our revolving credit facility, excluding the expansion feature.

### 3. Stock-Based Compensation Plans

We provide employees the opportunity to acquire our stock through a number of plans, as follows:

- We have five stock incentive plans under which 6,700,000 shares can be issued to key employees through a grant of stock awards and/or options to purchase shares. The Compensation/Incentive Committee (“CIC”) of the Board of Directors administers these plans. All options granted under these plans provide for a purchase price equal to the market value of the stock at the date of grant. The latest plan, covering a total of 3,000,000 shares, was adopted in May 2006 and amended in August 2006. The plans are not qualified, restricted or incentive plans under the U.S. Internal Revenue Code. The terms of each plan differ slightly, however, stock options issued under the plans generally have a maximum term of 10 years. Under one plan, adopted in 1999, up to 500,000 shares may be issued to employees who are not our officers or directors.
- In May 2002, our shareholders approved the adoption of the Executive Long-Term Incentive Plan (“LTIP”) covering our officers and key employees. The CIC periodically approves a pool of shares to be awarded based on stock price hurdles, EBITDA targets and a discretionary component for the LTIP.

The current stock price hurdles were established in 2006, as follows:

Stock Price Hurdle	Shares to be Issued
\$62.00	20,000
\$68.00	30,000
\$75.00	30,000
Total	<u>80,000</u>

The stock price hurdles must be achieved during 30 trading days out of any 60 trading day period during the three years ending May 15, 2009. There were no share-based awards made from the LTIP in fiscal 2008.

Chemed Corporation Subsidiary Companies

In February 2007, we met the cumulative EBITDA target established in 2004 and on March 9, 2007 the CIC approved a stock grant of 100,000 shares and the related allocation to participants. The pretax cost of the stock grant was \$5.4 million and is included in selling, general and administrative expenses in the accompanying consolidated statement of income.

In May 2007, the CIC approved a pool of shares to be awarded based on new EBITDA targets. The participants of the LTIP may be awarded 80,000 shares of our capital stock if we attain adjusted EBITDA of either \$465 million for the three-year period beginning January 1, 2007, or \$604 million for the four-year period beginning January 1, 2007.

In June 2007, we met the \$62.00 per share stock price hurdle and on June 27, 2007, the CIC approved a stock grant of 22,200 shares and the related allocation to participants. The pretax cost of the stock grant was \$1.6 million and is included in selling, general and administrative expenses in the accompanying statement of income.

There were no awards made under the LTIP during fiscal 2006. As of December 31, 2008, there are 22,800 shares issuable from the approved discretionary pool.

- We maintain an Employee Stock Purchase Plan (“ESPP”). The ESPP allows eligible participants to purchase our shares through payroll deductions at current market value. We pay administrative and broker fees associated with the ESPP. Shares purchased for the ESPP are purchased on the open market and credited directly to participants’ accounts. In accordance with the provisions of SFAS 123(R), the ESPP is non-compensatory.

For the years ended December 31, 2008, 2007 and 2006, we recorded \$1.9 million, \$1.2 million and \$1.3 million, respectively, in amortization expense in the accompanying statement of income for stock-based compensation related to the amortization of restricted stock awards granted. For the years ended December 31, 2008, 2007 and 2006, we recorded \$7.3 million, \$4.7 million and \$1.2 million, respectively, in selling, general and administrative expenses for stock-based compensation related to stock options granted. There were no capitalized stock-based compensation costs for any period presented.

As of December 31, 2008, approximately \$3.9 million of total unrecognized compensation costs related to non-vested stock awards are expected to be recognized over a weighted average period of 2.1 years. As of December 31, 2008, approximately \$10.5 million of total unrecognized compensation costs related to non-vested stock options are expected to be recognized over a weighted average period of 1.7 years.

The following table summarizes stock option and award activity:

	Stock Options		Stock Awards	
	Number of Shares	Weighted Average Exercise Price	Number of Shares	Weighted Average Grant-Date Price
Stock-based compensation shares:				
Outstanding at January 1, 2008	1,887,549	\$ 40.60	155,392	\$ 37.26
Granted	508,600	33.75	52,915	47.00
Exercised/Vested	(202,400)	19.49	(69,862)	26.18
Forfeited	(18,590)	37.68	(1,229)	21.78
Outstanding at December 31, 2008	<u>2,175,159</u>	<u>\$ 40.99</u>	<u>137,216</u>	<u>\$ 46.80</u>
Vested at December 31, 2008	<u>1,237,433</u>	<u>\$ 36.10</u>		

The weighted average contractual life of outstanding and exercisable options was 6.0 years at December 31, 2008.

Options outstanding at December 31, 2008, were in the following exercise price ranges:

Exercise Price Range	Number of Options	Weighted Average Exercise Price	Aggregate Intrinsic Value
\$16.10 to \$27.18	575,142	\$20.21	\$11,250,000
\$27.19 to \$40.78	771,100	\$35.11	\$3,593,000
\$40.79 to \$70.00	828,917	\$60.88	\$—

The total intrinsic value of stock options exercised during the years ended December 31, 2008, 2007 and 2006 was \$5.2 million, \$7.8 million and \$14.7 million, respectively. The total intrinsic value of stock options that were vested as of December 31, 2008, 2007 and 2006 was \$11.3 million, \$33.5 million and \$16.8 million, respectively. The total intrinsic value of stock awards vested during the years ended December 31, 2008, 2007 and 2006 was \$2.7 million, \$8.5 million and \$1.7 million, respectively. The total cash received from employees as a result of employee stock option exercises for the years ended December 31, 2008, 2007 and 2006 was \$291,000, \$2.5 million and \$3.9 million, respectively. In connection with these exercises, the excess tax benefits realized for the years ended December 31, 2008, 2007 and 2006, were \$2.4 million, \$3.1 million and \$5.6 million, respectively. We settle employee stock options with newly issued shares.

We estimate the fair value of stock options using the Black-Scholes valuation model, consistent with the provisions of SFAS 123(R) and the Securities and Exchange Commission ("SEC") Staff Accounting Bulletin No. 110. We determine expected term, volatility, dividend yield and forfeiture rate based on our historical experience. We believe that historical experience is the best indicator of these factors. We granted 508,600 stock options on May 19, 2008 and 470,600 stock options on May 21, 2007, pursuant to the 2006 Stock Incentive Plan. For purposes of determining the key assumptions and the related fair value of the options granted, we analyzed the participants of the LTIP separately from the other stock option recipients. The assumptions we used to value the 2008 and 2007 grants are as follows:

	2008		2007	
	LTIP Participants	All Others	LTIP Participants	All Others
Stock price at issuance	\$ 33.75	\$ 33.75	\$ 67.96	\$ 67.96
Grant date fair value	\$ 11.18	\$ 10.18	\$ 25.18	\$ 21.87
Number of options granted	325,000	183,600	320,000	150,600
Expected term (years)	5.7	4.3	5.8	4.3
Risk free rate of return	3.08%	2.92%	4.74%	4.76%
Volatility	31.8%	34.0%	30.4%	31.3%
Dividend yield	0.7%	0.7%	0.4%	0.4%
Forfeiture rate	—%	5.2%	—%	5.2%

#### 4. Segments and Nature of the Business

Our segments include the VITAS segment and the Roto-Rooter segment. Relative contributions of each segment to service revenues and sales were 69% and 31%, respectively, in both 2008 and 2007. The vast majority of our service revenues and sales from continuing operations are generated from business within the United States.

The reportable segments have been defined along service lines, which is consistent with the way the businesses are managed. In determining reportable segments, the Roto-Rooter Services and Roto-Rooter Franchising and Products operating units of the Roto-Rooter segment have been aggregated on the basis of possessing similar operating and economic characteristics. The characteristics of these operating segments and the basis for aggregation are reviewed annually. Accordingly, the reportable segments are defined as follows:

- The VITAS segment provides hospice services for patients with severe, life-limiting illnesses. This type of care is aimed at making the terminally ill patient's end of life as comfortable and pain-free as possible. Hospice care is typically available to patients who have been initially certified or re-certified as terminally ill (i.e., a prognosis of six months or less) by their attending physician, if any, and the hospice physician. VITAS offers all levels of hospice care in a given market, including routine home care, inpatient care and continuous care. Over 90% of VITAS' revenues are derived through Medicare and Medicaid reimbursement programs.

Chemed Corporation and Subsidiary Companies

- The Roto-Rooter segment provides repair and maintenance services to residential and commercial accounts using the Roto-Rooter registered service mark. Such services include plumbing and sewer, drain and pipe cleaning. They are delivered through company-owned and operated territories, independent contractor-operated territories and franchised locations. This segment also manufactures and sells products and equipment used to provide such services.
- We report corporate administrative expenses and unallocated investing and financing income and expense not directly related to either segment as “Corporate”. Corporate administrative expense includes the stewardship, accounting and reporting, legal, tax and other costs of operating a publicly held corporation. Corporate investing and financing income and expenses include the costs and income associated with corporate debt and investment arrangements. Beginning on January 1, 2008, the income statement impact of our deferred compensation plans covering Roto-Rooter employees has been classified as a Corporate activity. Historically, the income statement impact has been recorded as a Roto-Rooter activity. Due to the volatility in the capital markets, Roto-Rooter’s operational results were being distorted in our management reporting as a result of the activity of the deferred compensation plans. Our Chief Operating Decision Maker (“CODM”), determined that the income statement impact of Roto-Rooter’s deferred compensation plans is more appropriately classified as a Corporate activity. Our internal management reporting documents have been changed to reflect this determination. In connection with our adoption of SFAS 123(R) in 2006, we reassessed the classification within our business segments of stock-based compensation expense and determined that our CODM analyzes stock-based compensation as a corporate expense. The table below has been reclassified to conform all periods presented.

Segment data for our continuing operations are set forth below (in thousands):

	For the Years Ended December 31,		
	2008	2007	2006
<b>Revenues by Type of Service</b>			
<b>VITAS</b>			
Routine homecare	\$ 585,891	\$ 546,872	\$ 492,012
Continuous care	124,894	115,801	121,096
General inpatient	97,895	92,995	89,882
Medicare cap	(235)	(242)	(3,898)
Total segment	<u>808,445</u>	<u>755,426</u>	<u>699,092</u>
<b>Roto-Rooter</b>			
Sewer and drain cleaning	146,150	151,111	144,758
Plumbing repair and maintenance	145,831	143,021	129,048
Independent contractors	21,968	22,070	19,169
HVAC repair and maintenance	4,059	3,929	2,821
Other products and services	22,488	24,501	23,699
Total segment	<u>340,496</u>	<u>344,632</u>	<u>319,495</u>
Service revenues and sales	<u>\$ 1,148,941</u>	<u>\$ 1,100,058</u>	<u>\$ 1,018,587</u>
<b>Aftertax Segment Earnings/(Loss)</b>			
VITAS	\$ 64,719	\$ 59,833	\$ 48,418
Roto-Rooter	33,592	38,971	32,598
Subtotal	<u>98,311</u>	<u>98,804</u>	<u>81,016</u>
Corporate	(26,206)	(36,029)	(23,294)
Discontinued operations	(1,088)	1,201	(7,071)
Net income	<u>\$ 71,017</u>	<u>\$ 63,976</u>	<u>\$ 50,651</u>
<b>Interest Income</b>			
VITAS	\$ 5,336	\$ 7,405	\$ 5,443
Roto-Rooter	3,824	5,370	4,082
Subtotal	<u>9,160</u>	<u>12,775</u>	<u>9,525</u>
Corporate	490	2,776	2,492
Intercompany eliminations	(8,907)	(12,247)	(9,326)
Interest income	<u>\$ 743</u>	<u>\$ 3,304</u>	<u>\$ 2,691</u>

	For the Years Ended December 31,		
	2008	2007	2006
<b>Interest Expense</b>			
VITAS	\$ 155	\$ 146	\$ 191
Roto-Rooter	246	495	368
Subtotal	401	641	559
Corporate	5,584	10,603	16,909
Interest expense	<u>\$ 5,985</u>	<u>\$ 11,244</u>	<u>\$ 17,468</u>
<b>Income Tax Provision</b>			
VITAS	\$ 38,710	\$ 35,722	\$ 28,705
Roto-Rooter	20,742	24,145	18,877
Subtotal	59,452	59,867	47,582
Corporate	(9,212)	(20,804)	(15,020)
Income tax provision	<u>\$ 50,240</u>	<u>\$ 39,063</u>	<u>\$ 32,562</u>
<b>Identifiable Assets</b>			
VITAS	\$ 523,178	\$ 527,809	\$ 515,286
Roto-Rooter	188,003	185,982	185,580
Subtotal	711,181	713,791	700,866
Corporate	49,743	56,579	84,890
Discontinued Operations	—	—	5,705
Identifiable assets	<u>\$ 760,924</u>	<u>\$ 770,370</u>	<u>\$ 791,461</u>
<b>Additions to Long-Lived Assets</b>			
VITAS	\$ 8,797	\$ 20,435	\$ 14,419
Roto-Rooter	18,906	9,341	10,268
Subtotal	27,703	29,776	24,687
Corporate	9,492	193	137
Additions to long-lived assets	<u>\$ 37,195</u>	<u>\$ 29,969</u>	<u>\$ 24,824</u>
<b>Depreciation and Amortization</b>			
VITAS	\$ 16,984	\$ 15,430	\$ 12,669
Roto-Rooter	8,344	8,419	7,737
Subtotal	25,328	23,849	20,406
Corporate	2,177	1,539	1,624
Depreciation and amortization	<u>\$ 27,505</u>	<u>\$ 25,388</u>	<u>\$ 22,030</u>

**5. Goodwill and Intangible Assets**

Amortization of definite-lived intangible assets from continuing operations was \$4.0 million for each of the years ended December 31, 2008, 2007 and 2006, respectively. The following is a schedule by year of projected amortization expense for definite-lived intangible assets (in thousands):

2009	\$4,018
2010	2,012
2011	1,213
2012	1,210
2013	1,210
Thereafter	340

The balance in identifiable intangible assets comprises the following (in thousands):

	Gross Asset	Accumulated Amortization	Net Book Value
<b>December 31, 2008</b>			
Referral networks	\$ 21,140	\$ (13,445)	\$ 7,695
Covenants not to compete	8,911	(6,813)	2,098
Customer lists	1,223	(1,013)	210
<b>Subtotal — definite-lived intangibles</b>	<b>31,274</b>	<b>(21,271)</b>	<b>10,003</b>
VITAS trade name	51,300	—	51,300
<b>Total</b>	<b>\$ 82,574</b>	<b>\$ (21,271)</b>	<b>\$ 61,303</b>
<b>December 31, 2007</b>			
Referral networks	\$ 21,140	\$ (10,650)	\$ 10,490
Covenants not to compete	8,753	(5,624)	3,129
Customer lists	1,229	(971)	258
Subtotal — definite-lived intangibles	31,122	(17,245)	13,877
VITAS trade name	51,300	—	51,300
<b>Total</b>	<b>\$ 82,422</b>	<b>\$ (17,245)</b>	<b>\$ 65,177</b>

The date of our annual goodwill and indefinite-lived intangible asset impairment analysis is October 1. For all reporting units included in continuing operations, the impairment tests indicated that our goodwill and VITAS trade name are not impaired. For the purpose of impairment testing, we consider the reporting units to be VITAS, Roto-Rooter Services (plumbing and drain cleaning services) and Roto-Rooter Franchising and Products (franchising and manufacturing and sale of plumbing and drain cleaning products).

## 6. Other Operating Expenses — Net

Other expenses from continuing operations include the following pretax charges (in thousands):

	For the Year Ended December 31,		
	2008	2007	2006
Impairment of long-lived assets	\$ 2,699	\$ —	\$ —
Costs related to class action litigation	—	1,927	272
Gain on sale of property	—	(1,138)	—
<b>Total other expenses</b>	<b>\$ 2,699</b>	<b>\$ 789</b>	<b>\$ 272</b>

In December 2008, the Executive Committee of the Board of Directors authorized us to place old transportation equipment for sale. We determined that these assets meet the definition of held for sale under Statement of Financial Accounting Standard No. 144, "Accounting for the Impairment or Disposal of Long-Lived Assets." As a result, we discontinued depreciation on these assets and wrote-down the assets to their fair value less selling costs resulting in a pre-tax charge to other operating expenses — net of approximately \$2.7 million.

## 7. Business Combinations

During 2008, we completed four business combinations within the Roto-Rooter segment for \$11.2 million in cash to increase our market penetration in Colorado Springs, Colorado; Dayton, Ohio; Eugene, Oregon; and Topeka, Kansas. We made no acquisitions within the VITAS segment during 2008. The purchase price of these acquisitions was allocated as follows (in thousands):

Working capital	\$ 99
Identifiable intangible assets	160
Goodwill	10,487
Other assets and liabilities — net	454
	<b>\$ 11,200</b>

Chemed Corporation and Subsidiary Companies

During 2007, we completed one business combination within the Roto-Rooter segment for \$1.1 million in cash to increase our market penetration in Burlington, Vermont. We made no acquisitions within the VITAS segment during 2007.

During 2006, we completed three business combinations within the Roto-Rooter segment for an aggregate purchase price of \$4.1 million in cash. We made no acquisitions within the VITAS segment during 2006. The Roto-Rooter acquisitions were completed mainly to increase our market penetration in Erie, Pennsylvania; Tyler, Texas; and Lexington, Kentucky.

The unaudited pro forma results of operations, assuming purchase business combinations completed in 2008 and 2007 were completed on January 1, 2007, do not materially impact the accompanying consolidated financial statements. The results of operations of each of the above business combinations are included in our results of operations from the date of the respective acquisition. The allocations of purchase price are immaterial to the accompanying consolidated financial statements.

## 8. Discontinued Operations

Discontinued operations comprise (in thousands, except per share amounts):

	For the Years Ended December 31,		
	2008	2007	2006
<b>Phoenix (2006):</b>			
Income/(loss) before income taxes	\$ —	\$ 1,938	\$ (9,117)
Income taxes	—	(737)	3,645
Income/(loss) from operations, net of income taxes	—	1,201	(5,472)
Gain on disposal, net of income tax expense of \$391	—	—	600
	<u>—</u>	<u>1,201</u>	<u>(4,872)</u>
<b>Service America (2004):</b>			
Income/(loss) before income taxes	—	—	(141)
Income taxes	—	—	109
	<u>—</u>	<u>—</u>	<u>(32)</u>
<b>Adjustment to accruals of operations discontinued in prior years:</b>			
Casualty insurance costs (2004, 2002, 1997)	(1,719)	—	—
Settlement costs and other accruals (2002)	—	—	(2,246)
Environmental accruals (1991)	—	—	(1,194)
All other	—	—	28
Loss before income taxes	(1,719)	—	(3,412)
All other income taxes	631	—	1,245
Total adjustments	(1,088)	—	(2,167)
Total discontinued operations	<u>\$ (1,088)</u>	<u>\$ 1,201</u>	<u>\$ (7,071)</u>
Earnings/(loss) per share	<u>\$ (0.05)</u>	<u>\$ 0.05</u>	<u>\$ (0.27)</u>
Diluted earnings/(loss) per share	<u>\$ (0.04)</u>	<u>\$ 0.05</u>	<u>\$ (0.26)</u>

In December 2008, we recorded a \$1.7 million pre-tax charge for residual casualty insurance claims related to our discontinued operations.

In September 2006, our Board of Directors approved and we announced our intention to exit the hospice market in Phoenix, Arizona. Although we were successful in growing admissions of terminally ill patients, our growth was primarily patients who reside in assisted living settings. Patients residing in these types of facilities tend to exit curative care and enter into hospice care relatively early in their terminal diagnosis. The Medicare Cap limits payment for hospice care when a significant portion of the patient census enters into hospice early in their terminal diagnosis. Although we have, on average, relatively short average and median lengths of stay in the majority of our programs, all programs are measured separately and cannot be considered in the aggregate of programs under common control. Due to these billing limitations, we experienced significant operating losses at this program. As a result of our announcement, we performed impairment tests of our long-lived assets of the Phoenix operation as of September 30, 2006, in accordance with Statement of Financial Accounting Standards No. 144. An impairment charge of \$2.4 million was recorded for the referral network intangible asset and fixed assets during the third quarter of 2006. The sale was completed in November 2006. The acquiring corporation purchased the substantial majority of assets of the Phoenix

program for \$2.5 million. In October 2007, we received notification from the Federal government’s fiscal intermediary regarding our Medicare cap liabilities related to the 2006 measurement period. The notification revealed that we were over accrued at our discontinued Phoenix operation by \$1.9 million. We recorded the reversal of this over accrual and its related tax effects in discontinued operations during the year ended December 31, 2007. As of December 31, 2008, we have \$500,000 accrued for potential retroactive billings related to the Medicare Cap for Phoenix.

On September 28, 2006, we announced a preliminary settlement in regard to litigation related to the 2002 divestiture of our Patient Care business segment. Prior to the settlement, we had a long-term receivable from Patient Care of \$12.5 million. We also had current accounts receivable from Patient Care for the post-closing balance sheet valuation and for expenses paid by us after closing on Patient Care’s behalf of \$3.4 million. We were in litigation with Patient Care over the collection of these current amounts and their allegations that our acquisition of VITAS violated a non-compete covenant in the sales agreement. We agreed to forgive \$1.2 million of the current receivable related to the post-closing balance sheet valuation and convert the remaining amount into debt secured by a promissory note with the same terms as the \$12.5 million long-term receivable. We incurred additional costs related to the settlement of \$1.1 million for additional insurance and legal costs related to workers’ compensation claims incurred prior to the sale. The aftertax charge related to these amounts of \$1.5 million has been recorded as discontinued operations in 2006.

In December 2007, the parties amended the terms of the long-term notes receivable from Patient Care. We agreed to waive the prepayment penalty provisions in the notes provided that Patient Care paid \$5 million of principal on or before December 31, 2007, and the remaining outstanding principal on or before March 31, 2008. On December 31, 2007, we received a principal payment of \$5 million from Patient Care. In the first quarter of 2008, we received principal payments for the remaining amount due from Patient Care.

We also have a warrant to purchase 2% of Patient Care’s common stock that we recorded as a \$1.4 million investment. As a result of financial information received in 2006, we determined that the value of the warrants was permanently impaired and recorded a pretax impairment charge of \$1.4 million. This charge is included in income from continuing operations on the consolidated statement of income in 2006.

During 2006, we increased our accrual for environmental liabilities related to the disposal of DuBois Chemical, Inc., by \$1.2 million. The adjustment made by us is based on an assessment by our environmental attorney, a preliminary settlement agreement with respect to one site and ongoing discussions with the U.S. Environmental Protection Agency. At December 31, 2008 and 2007, the accrual for our estimated liability for potential environmental cleanup and related costs arising from the sale of DuBois amounted to \$1.7 million. Of the 2008 balance, \$826,000 is included in other current liabilities and \$931,000 is included in other liabilities (long-term). We are contingently liable for additional DuBois-related environmental cleanup and related costs up to a maximum of \$14.9 million. On the basis of a continuing evaluation of the potential liability, we believe it is not probable this additional liability will be paid. Accordingly, no provision for this contingent liability has been recorded. The potential liability is not insured, and the recorded liability does not assume the recovery of insurance proceeds. Also, the environmental liability has not been discounted because it is not possible to reliably project the timing of payments. We believe that any adjustments to our recorded liability will not materially adversely affect our financial position, results of operations or cash flows.

Revenues generated by discontinued operations were \$1.9 million for the year ended December 31, 2007. Revenues generated by discontinued operations were not material for the years ended December 31, 2008 and 2006.

At December 31, 2008, other current liabilities include accruals of \$1.3 million and other liabilities (long-term) include accruals of \$1.2 million for costs related to discontinued operations. The estimated timing of payments of these liabilities follows (in thousands):

2009	\$ 1,337
2010	1,162
Thereafter	—
	<u>\$ 2,499</u>

## 9. Cash Overdrafts and Cash Equivalents

Included in accounts payable are cash overdrafts of \$8.8 million and \$9.7 million as of December 31, 2008 and 2007, respectively.

From time to time throughout the year, we invest excess cash in repurchase agreements directly with major commercial banks. We do not physically hold the collateral, but the term of such repurchase agreements is less than 10

Chemed Corporation and Subsidiary Companies

days. Investments of significant amounts are spread among a number of banks and the amounts invested in each bank are varied constantly. We closely monitor the creditworthiness of the institutions with which we invest our overnight funds and the quality of the collateral underlying those investments. Included in cash and cash equivalents at December 31, 2007, are cash equivalents in the amount of \$3.4 million. We had no cash equivalents as of December 31, 2008. The weighted average rate of return for our cash equivalents was 2.3% in 2008 and 2.8% in 2007.

**10. Other Income/(Expense) —Net**

Other income/(expense)—net from continuing operations comprises the following (in thousands):

	For the Years Ended December 31,		
	2008	2007	2006
Interest income	\$ 743	\$ 3,304	\$ 2,691
(Loss)/gain on trading investments of employee benefit trust	(9,139)	963	2,030
Loss on disposal of property and equipment	(415)	(286)	(161)
Other — net	76	144	88
<b>Total other income/(expense) — net</b>	<b>\$ (8,735)</b>	<b>\$ 4,125</b>	<b>\$ 4,648</b>

**11. Income Taxes**

The provision for income taxes comprises the following (in thousands):

	For the Years Ended December 31,		
	2008	2007	2006
<b>Continuing Operations:</b>			
Current			
U.S. federal	\$ 42,919	\$ 26,458	\$ 21,955
U.S. state and local	6,226	3,995	2,808
Foreign	669	497	391
Deferred			
U.S. federal, state and local	488	8,057	7,474
Foreign	(62)	56	(66)
<b>Total</b>	<b>\$ 50,240</b>	<b>\$ 39,063</b>	<b>\$ 32,562</b>
<b>Discontinued Operations:</b>			
Current U.S. federal	\$ (735)	\$ 647	\$ (4,175)
Current U.S. state and local	(55)	90	(440)
Deferred U.S. federal, state and local	159	—	7
<b>Total</b>	<b>\$ (631)</b>	<b>\$ 737</b>	<b>\$ (4,608)</b>

A summary of the temporary differences that give rise to deferred tax assets/(liabilities) follows (in thousands):

	2008	2007
Accrued liabilities	\$ 25,094	\$ 26,557
Amortization of original issue discount	15,237	18,602
Stock compensation expense	4,825	2,126
Allowance for uncollectible accounts receivable	1,839	1,226
State net operating loss carryforwards	1,567	1,514
Other	2,888	2,789
Deferred income tax assets	51,450	52,814
Amortization of intangible assets	(35,791)	(33,928)
Accelerated tax depreciation	(6,325)	(8,268)
Currents assets	(1,103)	(1,651)
Other	(172)	(310)
Deferred income tax liabilities	(43,391)	(44,157)
<b>Net deferred income tax assets</b>	<b>\$ 8,059</b>	<b>\$ 8,657</b>

Chemed Corporation and Subsidiary Companies

Included in other assets at December 31, 2008, are deferred income tax assets of \$264,000 (2007 — \$247,000). At December 31, 2008 and 2007, state net operating loss carryforwards were \$29.3 million and \$37.4 million, respectively. These net operating losses will expire, in varying amounts, between 2009 and 2028. Based on our history of operating earnings, we have determined that our operating income will, more likely than not, be sufficient to ensure realization of our deferred income tax assets.

The cumulative effect upon adoption of FIN 48 was to reduce our accrual for uncertain tax positions by approximately \$4.7 million, which has been recorded in retained earnings as of January 1, 2007, in the accompanying consolidated balance sheet. After adoption, we had approximately \$1.3 million in unrecognized tax benefits. The majority of this amount would affect our effective tax rate, if recognized in a future period. The years ended December 31, 2005, and forward remain open for review for Federal income tax purposes. The earliest open year relating to any of our material state jurisdictions is the fiscal year ended December 31, 2003. During the next twelve months, we do not anticipate a material net change in unrecognized tax benefits.

As permitted by FIN 48, we classify interest related to our accrual for uncertain tax positions in separate interest accounts. As of December 31, 2008 and 2007, we have approximately \$152,000 and \$142,000, respectively, accrued in interest payable related to uncertain tax positions. These accruals are included in other current liabilities in the accompanying consolidated balance sheet. Net interest expense related to uncertain tax positions included in interest expense in the accompanying consolidated statement of income is not material.

A roll forward of the significant changes to our unrecognized tax benefits is as follows (in thousands):

	2008	2007
Balance at January 1,	\$ 1,169	\$ 1,281
Unrecognized tax benefits due to positions taken in current year	413	178
Gross change due to positions taken in prior years	53	—
Decrease due to settlement with taxing authorities	(174)	(40)
Decrease due to expiration of statute of limitations	(259)	(250)
Balance at December 31,	<u>\$ 1,202</u>	<u>\$ 1,169</u>

The difference between the actual income tax provision for continuing operations and the income tax provision calculated at the statutory U.S. federal tax rate is explained as follows (in thousands):

	2008	2007	2006
Income tax provision calculated using the statutory rate of 35%	\$ 42,821	\$ 35,643	\$ 31,599
State and local income taxes, less federal income tax effect	3,802	3,998	3,112
Impact of deferred compensation plans	3,084	(186)	(473)
Tax accrual adjustments	268	(765)	(1,758)
Other —net	265	373	82
Income tax provision	<u>\$ 50,240</u>	<u>\$ 39,063</u>	<u>\$ 32,562</u>
Effective tax rate	<u>41.1%</u>	<u>38.4%</u>	<u>36.1%</u>

Summarized below are the total amounts of income taxes paid/(refunded) during the years ended December 31 (in thousands):

<b>2008</b>	\$50,535
2007	24,345
2006	3,823

Provision has not been made for additional taxes on \$35.1 million of undistributed earnings of our domestic subsidiaries. Should we elect to sell our interest in all of these businesses rather than to effect a tax-free liquidation, additional taxes amounting to approximately \$12.9 million would be incurred based on current income tax rates.

**12. Properties and Equipment**

A summary of properties and equipment follows (in thousands):

	December 31,	
	2008	2007
Land	\$ 1,355	\$ 1,355
Buildings	28,150	27,159
Transportation equipment	19,329	12,237
Machinery and equipment	48,378	46,927
Computer software	25,154	22,839
Furniture and fixtures	41,711	38,770
Projects under development	14,574	13,865
Total properties and equipment	178,651	163,152
Less accumulated depreciation	(101,689)	(88,639)
Net properties and equipment	<u>\$ 76,962</u>	<u>\$ 74,513</u>

The net book value of computer software at December 31, 2008 and 2007, was \$5.6 million and \$7.6 million, respectively. Depreciation expense for computer software was \$4.3 million, \$4.4 million and \$4.0 million for the years ended December 31, 2008, 2007 and 2006, respectively.

**13. Lease Arrangements**

We have operating leases that cover our corporate office headquarters, various warehouse and office facilities, office equipment and transportation equipment. The remaining terms of these leases range from one year to nine years, and in most cases we expect that these leases will be renewed or replaced by other leases in the normal course of business. We have no significant capital leases as of December 31, 2008 or 2007.

The following is a summary of future minimum rental payments and sublease rentals to be received under operating leases that have initial or remaining noncancelable terms in excess of one year at December 31, 2008 (in thousands):

2009	\$ 16,247
2010	12,016
2011	9,415
2012	6,346
2013	4,047
After 2013	4,037
Total minimum rental payments	52,108
Less: minimum sublease rentals	(262)
Net minimum rental payments	<u>\$ 51,846</u>

Total rental expense incurred under operating leases for continuing operations follows (in thousands):

	For the Years Ended December 31,		
	2008	2007	2006
Total rental payments	\$ 18,867	\$ 17,307	\$ 16,859
Less sublease rentals	(265)	(260)	(687)
Net rental expense	<u>\$ 18,602</u>	<u>\$ 17,047</u>	<u>\$ 16,172</u>

**14. Pension and Retirement Plans**

Retirement obligations under various plans cover substantially all full-time employees who meet age and/or service eligibility requirements. The major plans providing retirement benefits to our employees are defined contribution plans. Expenses charged to continuing operations for our retirement and profit-sharing plans, excess benefit plans and other similar plans were \$2.7 million, \$12.8 million and \$11.1 million for the years ended December 31, 2008, 2007 and 2006, respectively.

We have excess benefit plans for key employees whose participation in the qualified plans is limited by U.S. Employee Retirement Income Security Act requirements. Benefits are determined based on theoretical participation in

the qualified plans. Benefits are only invested in mutual funds, and participants are not permitted to diversify accumulated benefits in shares of our stock. Trust assets invested in shares of our stock are included in treasury stock, and the corresponding liability is included in a separate component of stockholders' equity. At December 31, 2008, these trusts held 108,416 shares or \$2.0 million of our stock (2007 — 134,104 shares or \$2.5 million). The diversified assets of our excess benefit and deferred compensation plans, all of which are invested in either company-owned life insurance or various mutual funds, totaled \$22.6 million at December 31, 2008 (2007 — \$29.4 million).

## 15. Earnings Per Share

The computation of earnings per share follows (in thousands, except per share data):

For the Years Ended December 31,	Income from Continuing Operations			Net Income		
	Income	Shares	Earnings per Share	Income	Share s	Earnings per Share
<b>2008</b>						
Earnings	\$ 72,105	23,058	\$ 3.13	\$ 71,017	23,058	\$ 3.08
Dilutive stock options	—	287		—	287	
Nonvested stock awards	—	29		—	29	
<b>Diluted earnings</b>	<b>\$ 72,105</b>	<b>23,374</b>	<b>\$ 3.08</b>	<b>\$ 71,017</b>	<b>23,374</b>	<b>\$ 3.04</b>
<b>2007</b>						
Earnings	\$ 62,775	24,520	\$ 2.56	\$ 63,976	24,520	\$ 2.61
Dilutive stock options	—	456		—	456	
Nonvested stock awards	—	101		—	101	
<b>Diluted earnings</b>	<b>\$ 62,775</b>	<b>25,077</b>	<b>\$ 2.50</b>	<b>\$ 63,976</b>	<b>25,077</b>	<b>\$ 2.55</b>
<b>2006</b>						
Earnings	\$ 57,722	26,118	\$ 2.21	\$ 50,651	26,118	\$ 1.94
Dilutive stock options	—	496		—	496	
Nonvested stock awards	—	55		—	55	
<b>Diluted earnings</b>	<b>\$ 57,722</b>	<b>26,669</b>	<b>\$ 2.16</b>	<b>\$ 50,651</b>	<b>26,669</b>	<b>\$ 1.90</b>

During 2008, 827,917 stock options were excluded from the computation of diluted earnings per share as their exercise prices were greater than the average market price during most of the year. During 2007, 290,096 stock options were so excluded. During 2006, 369,850 stock options were so excluded.

Diluted earnings per share may be impacted in future periods as the result of the issuance of our \$200 million Notes and related purchased call options and sold warrants. Under Emerging Issues Task Force ("EITF") 04-8, "The Effect of Contingently Convertible Instruments on Diluted Earnings per Share" and EITF 90-19, "Convertible Bonds with Issuer Option to Settle for Cash Upon Conversion" we will not include any shares related to the Notes in our calculation of diluted earnings per share until our average stock price for a quarter exceeds the conversion price of \$80.73. We would then include in our diluted earnings per share calculation those shares issuable using the treasury stock method. The amount of shares issuable is based upon the amount by which the average stock price for the quarter exceeds the conversion price. The purchased call option does not impact the calculation of diluted earnings per share, as it is always anti-dilutive. The sold warrants become dilutive when our average stock price for a quarter exceeds the strike price of the warrant.

Chemed Corporation and Subsidiary Companies

The following table provides examples of how changes in our stock price impact the number of shares that would be included in our diluted earnings per share calculation. It also shows the impact on the number of shares issuable upon conversion of the Notes and settlement of the purchased call options and sold warrants:

Share Price	Shares Underlying 1.875% Convertible Notes	Warrant Shares	Total Treasury Method Incremental Shares (a)	Shares Due to the Company under Notes Hedges	Incremental Shares Issued/(Received) by the Company upon Conversion (b)
\$ 80.73	—	—	—	—	—
\$ 90.73	255,243	—	255,243	(273,061)	(17,818)
\$100.73	459,807	—	459,807	(491,905)	(32,098)
\$110.73	627,423	118,359	745,782	(671,222)	74,560
\$120.73	767,272	313,764	1,081,036	(820,833)	260,203
\$130.73	885,726	479,274	1,365,000	(947,556)	417,444

- (a) Represents the number of incremental shares that must be included in the calculation of fully diluted shares under U.S. GAAP.  
(b) Represents the number of incremental shares to be issued/(received) by the Company upon conversion of the 1.875% Convertible Notes, assuming concurrent settlement of the note hedges and warrants.

**16. Financial Instruments**

On January 1, 2008, we partially adopted the provisions of Statement of Financial Accounting Standards No. 157, “Fair Value Measurements” (“SFAS 157”). This statement defines a hierarchy which prioritizes the inputs in fair value measurements. Level 1 measurements are measurements using quoted prices in active markets for identical assets or liabilities. Level 2 measurements use significant other observable inputs. Level 3 measurements are measurements using significant unobservable inputs which require a company to develop its own assumptions. In recording the fair value of assets and liabilities, companies must use the most reliable measurement available. There was no impact on our financial position, results of operations or cash flows upon adoption of SFAS 157. We have elected to partially defer adoption of SFAS 157 related to our goodwill and indefinite lived intangible assets in accordance with FASB Staff Position No. 157-2.

The following shows the carrying value, fair value and SFAS 157 hierarchy for our financial instruments as of December 31, 2008 (in thousands):

	Carrying Value	Fair Value Measure		
		Quoted Prices in Active Markets for Identical Assets (Level 1)	Significant Other Observable Inputs (Level 2)	Significant Unobservable Inputs (Level 3)
Mutual fund investments of deferred compensation plans held in trust	\$ 5,744	\$ 5,744	\$—	\$—
Long-term debt	209,825	147,200	—	—

For cash and cash equivalents, accounts receivable and accounts payable, the carrying amount is a reasonable estimate of fair value because of the liquidity and short-term nature of these instruments. The remaining amount of investments of deferred compensation plans held in trust at December 31, 2008 relate to the cash surrender value of life insurance policies which are not subject to the guidance in SFAS 157. The December 31, 2007 carrying value of \$9.7 million related to our note receivable due from Patient Care is considered to be the best available indicator of fair value. The note receivable was collected during the first quarter of 2008.

**17. Loans Receivable from Independent Contractors**

At December 31, 2008, we had contractual arrangements with 63 independent contractors to provide plumbing repair and drain cleaning services under sublicensing agreements using the Roto-Rooter name in lesser-populated areas of the United States and Canada. The arrangements give the independent contractors the right to conduct a plumbing and drain cleaning business using the Roto-Rooter name in a specified territory in exchange for a royalty based on a

percentage of labor sales, generally approximately 40%. We also pay for yellow pages advertising in these areas, provide certain capital equipment and provide operating manuals to serve as resources for operating a plumbing and drain cleaning business. The contracts are generally cancelable upon 90 days' written notice (without cause) or upon a few days' notice (with cause). The independent contractors are responsible for running the businesses as they believe best.

Our maximum exposure to loss from arrangements with our independent contractors at December 31, 2008 and 2007 is approximately \$1.6 million. The exposure to loss is mainly the result of loans provided to the independent contractors. In most cases, these loans are partially secured by receivables and equipment owned by the independent contractor. The interest rates on the loans range from zero to 8% per annum, and the remaining terms of the loans range from 2.5 months to 5.4 years at December 31, 2008. During 2008, we recorded revenues of \$22.0 million (2007 — \$22.1 million; 2006 — \$19.2 million) and pretax profits of \$9.5 million (2007 — \$9.0 million; 2006 — \$6.9 million) from our independent contractors.

## 18. Litigation

VITAS is party to a class action lawsuit filed in the Superior Court of California, Los Angeles County, in September 2006 by Bernadette Santos, Keith Knoche and Joyce White ("Santos"). This case alleges failure to pay overtime and failure to provide meal and rest periods to a purported class of California admissions nurses, chaplains and sales representatives. The case seeks payment of penalties, interest and Plaintiffs' attorney fees. VITAS contests these allegations. The lawsuit is in its early stages and we are unable to estimate our potential liability, if any, with respect to these allegations.

In April 2007, our Roto-Rooter subsidiary was named in a class action lawsuit filed in San Mateo Superior Court by Stanley Ita ("Ita") alleging class-wide wage and hour violations at one California branch. This suit alleged failure to provide meal and break periods, credit for work time beginning from the first call to dispatch rather than arrival at first assignment and improper calculations of work time and overtime. The case sought payment of penalties, interest and Plaintiffs' attorney fees. After the suit was filed, we offered a settlement to certain members of the class and paid approximately \$200,000. In January 2008, we agreed to a tentative settlement with the remaining members of the class for approximately \$1.8 million. The tentative settlement was preliminarily approved by the court in May 2008. Final approval and payment of the settlement was made in August 2008. The final settlement was accrued in 2007.

Regardless of outcome, defense of litigation adversely affects us through defense costs, diversion of our time and related publicity. In the normal course of business, we are a party to various claims and legal proceedings. We record a reserve for these matters when an adverse outcome is probable and the amount of the potential liability is reasonably estimable.

## 19. OIG Investigation

In April 2005, the Office of Inspector General ("OIG") for the Department of Health and Human Services served VITAS with civil subpoenas relating to VITAS' alleged failure to appropriately bill Medicare and Medicaid for hospice services. As part of this investigation, the OIG selected medical records for 320 past and current patients from VITAS' three largest programs for review. It also sought policies and procedures dating back to 1998 covering admissions, certifications, recertifications and discharges. During the third quarter of 2005 and again in May 2006, the OIG requested additional information from us. The Court dismissed a related qui tam complaint filed in U.S. District Court for the Southern District of Florida with prejudice in July 2007. The plaintiffs appealed this dismissal, which the Court of Appeals affirmed.

The government continues to investigate the complaint's allegations. We are unable to predict the outcome of this matter or the impact, if any, that the investigation may have on our business, results of operations, liquidity or capital resources. Regardless of outcome, responding to the subpoenas can adversely affect us through defense costs, diversion of our time and related publicity.

## 20. Related Party Transactions

In October 2004, VITAS entered into a pharmacy services agreement ("Agreement") with Omnicare, Inc. ("OCR") whereby OCR provides specified pharmacy services for VITAS and its hospice patients in geographical areas served by both VITAS and OCR. The Agreement has an initial term of three years that renews automatically for one-year terms. Either party may cancel the Agreement at the end of any term by giving written notice at least 90 days prior to the end of said term. In June 2004, VITAS entered into a pharmacy services agreement with excelleRx. The agreement has a one-year term and automatically renews unless either party provides a 90-day written termination notice. Subsequent to June 2004, OCR acquired excelleRx. Under both agreements, VITAS made purchases of \$32.9 million, \$33.6 million

Chemed Corporation and Subsidiary Companies

and \$30.4 million for the years ended December 31, 2008, 2007 and 2006, respectively. Accounts payable to OCR and its subsidiaries are not material at December 31, 2008 and 2007.

Mr. E. L. Hutton is non-executive Chairman of the Board and a director of the Company. He was a director of OCR until his retirement in the first quarter of 2008 at which time he assumed the honorary post of Chairman Emeritus of OCR's Board. Mr. Joel F. Gemunder, President and Chief Executive Officer of OCR., Dr. Andrea Lindell and Ms. Sandra Laney are directors of both OCR and the Company. Mr. Kevin J. McNamara, President, Chief Executive Officer and a director of the Company, is a director emeritus of OCR. We believe that the terms of these agreements are no less favorable to VITAS than we could negotiate with an unrelated party.

**21. Guarantor Subsidiaries**

Our 1.875% Senior Convertible Notes issued on May 14, 2007, are fully and unconditionally guaranteed on an unsecured, joint and severally liable basis by certain of our 100% owned subsidiaries. The equity method has been used with respect to the parent company's (Chemed) investment in subsidiaries. No consolidating adjustment column is presented for the condensed consolidating statement of cash flow since there were no significant consolidating entries for the periods presented. The following condensed, consolidating financial data present the composition of the parent company, the guarantor subsidiaries and the non-guarantor subsidiaries as of December 31, 2008 and 2007, and for the years ended December 31, 2008, 2007 and 2006 (in thousands):

Condensed Consolidating Balance Sheet

December 31, 2008

	Parent	Guarantor Subsidiaries	Non-Guarantor Subsidiaries	Consolidating Adjustments	Consolidated
<b>ASSETS</b>					
Cash and cash equivalents	\$ 65	\$ 202	\$ 3,361	\$ —	\$ 3,628
Accounts receivable, less allowances	1,261	96,112	703	—	98,076
Intercompany receivables	—	37,105	—	(37,105)	—
Inventories	—	7,021	548	—	7,569
Current deferred income taxes	(229)	15,511	110	—	15,392
Prepaid expenses and other current assets	2,624	7,982	990	—	11,596
Total current assets	<u>3,721</u>	<u>163,933</u>	<u>5,712</u>	<u>(37,105)</u>	<u>136,261</u>
Investments of deferred compensation plans held in trust	—	—	22,628	—	22,628
Properties and equipment, at cost, less accumulated depreciation	11,665	63,179	2,118	—	76,962
Identifiable intangible assets less accumulated amortization	—	61,303	—	—	61,303
Goodwill	—	444,433	4,288	—	448,721
Other assets	12,286	2,455	308	—	15,049
Investments in subsidiaries	568,038	11,196	—	(579,234)	—
Total assets	<u>\$ 595,710</u>	<u>\$ 746,499</u>	<u>\$ 35,054</u>	<u>\$ (616,339)</u>	<u>\$ 760,924</u>
<b>LIABILITIES AND STOCKHOLDERS' EQUITY</b>					
Accounts payable	\$ (1,688)	\$ 54,175	\$ 323	\$ —	\$ 52,810
Intercompany payables	29,513	—	7,592	(37,105)	—
Current portion of long-term debt	10,000	169	—	—	10,169
Income taxes	(1,965)	3,909	212	—	2,156
Accrued insurance	1,425	34,569	—	—	35,994
Accrued compensation	3,817	36,523	401	—	40,741
Other current liabilities	2,022	8,979	1,179	—	12,180
Total current liabilities	<u>43,124</u>	<u>138,324</u>	<u>9,707</u>	<u>(37,105)</u>	<u>154,050</u>
Deferred income taxes	(22,681)	38,310	(8,032)	—	7,597
Long-term debt	199,656	—	—	—	199,656
Deferred compensation liabilities	—	—	22,417	—	22,417
Other liabilities	4,019	1,593	—	—	5,612
Stockholders' equity	371,592	568,272	10,962	(579,234)	371,592
Total liabilities and stockholders' equity	<u>\$ 595,710</u>	<u>\$ 746,499</u>	<u>\$ 35,054</u>	<u>\$ (616,339)</u>	<u>\$ 760,924</u>

December 31, 2007

	Parent	Guarantor Subsidiaries	Non-Guarantor Subsidiaries	Consolidating Adjustments	Consolidated
<b>ASSETS</b>					
Cash and cash equivalents	\$ 3,877	\$ (1,584)	\$ 2,695	\$ —	\$ 4,988
Accounts receivable, less allowances	706	99,900	564	—	101,170
Intercompany receivables	42,241	—	(3,925)	(38,316)	—
Inventories	—	6,116	480	—	6,596
Current deferred income taxes	130	13,964	118	—	14,212
Prepaid expenses and other current assets	884	9,521	91	—	10,496
Total current assets	<u>47,838</u>	<u>127,917</u>	<u>23</u>	<u>(38,316)</u>	<u>137,462</u>
Investments of deferred compensation plans held in trust	—	—	29,417	—	29,417
Note receivable	9,701	—	—	—	9,701
Properties and equipment, at cost, less accumulated depreciation	4,306	68,303	1,904	—	74,513
Identifiable intangible assets less accumulated amortization	—	65,176	1	—	65,177
Goodwill	—	433,946	4,743	—	438,689
Other assets	12,658	2,450	303	—	15,411
Investments in subsidiaries	500,952	11,005	—	(511,957)	—
Total assets	<u>\$ 575,455</u>	<u>\$ 708,797</u>	<u>\$ 36,391</u>	<u>\$ (550,273)</u>	<u>\$ 770,370</u>
<b>LIABILITIES AND STOCKHOLDERS' EQUITY</b>					
Accounts payable	\$ (1,236)	\$ 47,035	\$ 369	\$ —	\$ 46,168
Intercompany payables	—	34,992	3,324	(38,316)	—
Current portion of long-term debt	10,000	162	—	—	10,162
Income taxes	1,137	3,034	50	—	4,221
Accrued insurance	255	36,082	—	—	36,337
Accrued compensation	3,882	35,505	685	—	40,072
Other current liabilities	2,047	10,486	1,396	—	13,929
Total current liabilities	<u>16,085</u>	<u>167,296</u>	<u>5,824</u>	<u>(38,316)</u>	<u>150,889</u>
Deferred income taxes	(23,174)	39,247	(10,271)	—	5,802
Long-term debt	214,500	169	—	—	214,669
Deferred compensation liabilities	—	—	29,149	—	29,149
Other liabilities	3,695	1,797	20	—	5,512
Stockholders' equity	364,349	500,288	11,669	(511,957)	364,349
Total liabilities and stockholders' equity	<u>\$ 575,455</u>	<u>\$ 708,797</u>	<u>\$ 36,391</u>	<u>\$ (550,273)</u>	<u>\$ 770,370</u>

Condensed Consolidating Income StatementFor the year ended December 31, 2008

	Parent	Guarantor Subsidiaries	Non-Guarantor Subsidiaries	Consolidating Adjustments	Consolidated
<b>Continuing Operations</b>					
Net sales and service revenues	\$ —	\$ 1,124,063	\$ 24,878	\$ —	\$ 1,148,941
Cost of services provided and goods sold	—	798,173	12,374	—	810,547
Selling, general and administrative expenses	19,644	158,214	(2,525)	—	175,333
Depreciation	504	20,382	695	—	21,581
Amortization	1,890	4,034	—	—	5,924
Other operating expenses — net	2,699	—	—	—	2,699
Total costs and expenses	<u>24,737</u>	<u>980,803</u>	<u>10,544</u>	<u>—</u>	<u>1,016,084</u>
Income/ (loss) from operations	<u>(24,737)</u>	<u>143,260</u>	<u>14,334</u>	<u>—</u>	<u>132,857</u>
Interest expense	(5,584)	(398)	(3)	—	(5,985)
Gain on extinguishment of debt	4,208	—	—	—	4,208
Other income/(expense) — net	4,382	(4,070)	(9,047)	—	(8,735)
Income/ (loss) before income taxes	<u>(21,731)</u>	<u>138,792</u>	<u>5,284</u>	<u>—</u>	<u>122,345</u>
Income tax (provision)/ benefit	7,181	(52,199)	(5,222)	—	(50,240)
Equity in net income of subsidiaries	86,655	1,403	—	(88,058)	—
Income from continuing operations	<u>72,105</u>	<u>87,996</u>	<u>62</u>	<u>(88,058)</u>	<u>72,105</u>
<b>Discontinued Operations</b>	<u>(1,088)</u>	<u>—</u>	<u>—</u>	<u>—</u>	<u>(1,088)</u>
<b>Net income</b>	<u>\$ 71,017</u>	<u>\$ 87,996</u>	<u>\$ 62</u>	<u>\$ (88,058)</u>	<u>\$ 71,017</u>

Chemed Corporation and Subsidiary Companies

<i>For the year ended December 31, 2007</i>	<b>Parent</b>	<b>Guarantor Subsidiaries</b>	<b>Non-Guarantor Subsidiaries</b>	<b>Consolidating Adjustments</b>	<b>Consolidated</b>
<b>Continuing Operations</b>					
Net sales and service revenues	\$ —	\$ 1,075,042	\$ 25,016	\$ —	\$ 1,100,058
Cost of services provided and goods sold	—	754,739	12,327	—	767,066
Selling, general and administrative expenses	18,846	159,074	6,140	—	184,060
Depreciation	488	19,003	627	—	20,118
Amortization	1,232	4,036	2	—	5,270
Other operating expenses — net	(1,138)	1,927	—	—	789
Total costs and expenses	19,428	938,779	19,096	—	977,303
Income/ (loss) from operations	(19,428)	136,263	5,920	—	122,755
Interest expense	(10,610)	(445)	(189)	—	(11,244)
Loss on extinguishment of debt	(13,798)	—	—	—	(13,798)
Other income — net	15,030	(10,809)	(96)	—	4,125
Income/ (loss) before income taxes	(28,806)	125,009	5,635	—	101,838
Income tax (provision)/ benefit	10,086	(46,782)	(2,367)	—	(39,063)
Equity in net income of subsidiaries	82,696	3,453	—	(86,149)	—
Income from continuing operations	63,976	81,680	3,268	(86,149)	62,775
<b>Discontinued Operations</b>	—	1,201	—	—	1,201
<b>Net income</b>	<b>\$ 63,976</b>	<b>\$ 82,881</b>	<b>\$ 3,268</b>	<b>\$ (86,149)</b>	<b>\$ 63,976</b>
<i>For the year ended December 31, 2006</i>	<b>Parent</b>	<b>Guarantor Subsidiaries</b>	<b>Non-Guarantor Subsidiaries</b>	<b>Consolidating Adjustments</b>	<b>Consolidated</b>
<b>Continuing Operations</b>					
Net sales and service revenues	—	\$ 996,714	\$ 21,873	—	\$ 1,018,587
Cost of services provided and goods sold	—	719,074	11,049	—	730,123
Selling, general and administrative expenses	11,239	144,276	5,668	—	161,183
Depreciation	479	15,710	586	—	16,775
Amortization	1,267	3,985	3	—	5,255
Other operating expenses — net	—	272	—	—	272
Total costs and expenses	12,985	883,317	17,306	—	913,608
Income/ (loss) from operations	(12,985)	113,397	4,567	—	104,979
Interest expense	(16,909)	(541)	(18)	—	(17,468)
Loss on extinguishment of debt	(430)	—	—	—	(430)
Investment impairment charge	(1,445)	—	—	—	(1,445)
Other income — net	21,742	(17,107)	13	—	4,648
Income/ (loss) before income taxes	(10,027)	95,749	4,562	—	90,284
Income tax (provision)/ benefit	3,818	(34,491)	(1,889)	—	(32,562)
Equity in net income of subsidiaries	59,059	2,673	—	(61,732)	—
Income from continuing operations	52,850	63,931	2,673	(61,732)	57,722
<b>Discontinued Operations</b>	(2,199)	(4,872)	—	—	(7,071)
<b>Net income</b>	<b>\$ 50,651</b>	<b>\$ 59,059</b>	<b>\$ 2,673</b>	<b>\$ (61,732)</b>	<b>\$ 50,651</b>

Condensed Consolidating Statement of Cash Flow

<i>For the year ended December 31, 2008</i>	<u>Parent</u>	<u>Guarantor Subsidiaries</u>	<u>Non-Guarantor Subsidiaries</u>	<u>Consolidated</u>
<b>Cash Flow from Operating Activities:</b>				
Net cash provided/(used) by operating activities	\$ (8,912)	\$ 118,904	\$ 2,091	\$ 112,083
<b>Cash Flow from Investing Activities:</b>				
Capital expenditures	(9,492)	(15,576)	(1,026)	(26,094)
Business combinations, net of cash acquired	—	(11,200)	—	(11,200)
Net proceeds from discontinued operations	8,824	—	—	8,824
Proceeds from sale of property and equipment	10	342	35	387
Other sources/(uses) — net	(660)	123	(7)	(544)
Net cash used by investing activities	(1,318)	(26,311)	(998)	(28,627)
<b>Cash Flow from Financing Activities:</b>				
Change in cash overdrafts payable	(1,106)	250	—	(856)
Change in intercompany accounts	90,906	(91,249)	343	—
Dividends paid to shareholders	(5,543)	—	—	(5,543)
Purchases of treasury stock	(69,788)	—	—	(69,788)
Proceeds from exercise of stock options	291	—	—	291
Realized excess tax benefit on share based compensation	2,422	—	—	2,422
Net increase in revolving line of credit	8,200	—	—	8,200
Repayment of long-term debt	(18,551)	(162)	—	(18,713)
Other sources/(uses) — net	(413)	354	(770)	(829)
Net cash provided/ (used) by financing activities	6,418	(90,807)	(427)	(84,816)
Net increase/(decrease) in cash and cash equivalents	(3,812)	1,786	666	(1,360)
Cash and cash equivalents at beginning of year	3,877	(1,584)	2,695	4,988
Cash and cash equivalents at end of year	\$ 65	\$ 202	\$ 3,361	\$ 3,628

<i>For the year ended December 31, 2007</i>	<u>Parent</u>	<u>Guarantor Subsidiaries</u>	<u>Non-Guarantor Subsidiaries</u>	<u>Consolidated</u>
<b>Cash Flow from Operating Activities:</b>				
Net cash provided by operating activities	\$ 93	\$ 97,008	\$ 2,483	\$ 99,584
<b>Cash Flow from Investing Activities:</b>				
Capital expenditures	(193)	(25,674)	(773)	(26,640)
Business combinations, net of cash acquired	—	(1,079)	—	(1,079)
Net proceeds/(payments) of discontinued operations	2,502	(7,904)	—	(5,402)
Proceeds from sale of property and equipment	2,963	116	25	3,104
Other uses — net	(919)	(751)	(31)	(1,701)
Net cash provided/ (used) by investing activities	4,353	(35,292)	(779)	(31,718)
<b>Cash Flow from Financing Activities:</b>				
Change in cash overdrafts payable	7	(926)	—	(919)
Change in intercompany accounts	66,095	(62,296)	(3,799)	—
Dividends (paid)/received to/from shareholders	(5,888)	1,446	(1,446)	(5,888)
Purchases of treasury stock	(131,704)	—	—	(131,704)
Proceeds from exercise of stock options	2,467	—	—	2,467
Realized excess tax benefit on share based compensation	3,091	—	—	3,091
Purchase of note hedges	(55,100)	—	—	(55,100)
Proceeds from issuance of warrants	27,614	—	—	27,614
Proceeds from issuance of long-term debt	300,000	—	—	300,000
Debt issuance costs	(6,949)	—	—	(6,949)
Repayment of long-term debt	(225,500)	(209)	—	(225,709)
Other sources/(uses) — net	40	(1)	906	945
Net cash used by financing activities	(25,827)	(61,986)	(4,339)	(92,152)
Net decrease in cash and cash equivalents	(21,381)	(270)	(2,635)	(24,286)
Cash and cash equivalents at beginning of year	25,258	(1,314)	5,330	29,274
Cash and cash equivalents at end of year	\$ 3,877	\$ (1,584)	\$ 2,695	\$ 4,988

<i>For the year ended December 31, 2006</i>	<u>Parent</u>	<u>Guarantor Subsidiaries</u>	<u>Non-Guarantor Subsidiaries</u>	<u>Consolidated</u>
<b>Cash Flow from Operating Activities:</b>				
Net cash provided by operating activities	\$ 6,326	\$ 88,434	\$ 3,829	\$ 98,589
<b>Cash Flow from Investing Activities:</b>				
Capital expenditures	(138)	(21,073)	(776)	(21,987)
Business combinations, net of cash acquired	—	(4,145)	—	(4,145)
Net payments of discontinued operations	(922)	—	—	(922)
Proceeds from sale of property and equipment	43	271	33	347
Investing activities of discontinued operations	—	(260)	—	(260)
Other sources/(uses) — net	(781)	16	—	(765)
Net cash used by investing activities	(1,798)	(25,191)	(743)	(27,732)
<b>Cash Flow from Financing Activities:</b>				
Change in cash overdrafts payable	(489)	3,060	—	2,571
Change in intercompany accounts	67,502	(66,065)	(1,437)	—
Dividends paid to shareholders	(6,322)	—	—	(6,322)
Purchases of treasury stock	(19,885)	—	—	(19,885)
Proceeds from exercise of stock options	3,861	—	—	3,861
Excess tax benefit on share-based compensation	5,600	—	—	5,600
Debt issuance costs	(154)	—	—	(154)
Repayment of long-term debt	(84,363)	(200)	—	(84,563)
Financing activities of discontinued operations	109	67	—	176
Net cash used by financing activities	(34,141)	(63,138)	(1,437)	(98,716)
Net increase/(decrease) in cash and cash equivalents	(29,613)	105	1,649	(27,859)
Cash and cash equivalents at beginning of year	54,871	(1,419)	3,681	57,133
Cash and cash equivalents at end of year	\$ 25,258	\$ (1,314)	\$ 5,330	\$ 29,274

## 22. Capital Stock Transactions

On April 26, 2007, our Board of Directors authorized a \$150 million stock repurchase program. On May 19, 2008 our Board of Directors authorized an additional \$56 million to the April 2007 stock repurchase program. For the year ended December 31, 2008, we repurchased 1.7 million shares at a weighted average cost per share of \$39.73 under the April 2007 program. For the year ended December 31, 2007, we repurchased 2.1 million shares at a weighted average cost per share of \$59.77 under the April 2007 and July 2006 programs.

## UNAUDITED SUMMARY OF QUARTERLY RESULTS

Chemed Corporation and Subsidiary Companies  
(in thousands, except per share and footnote data)

For the Year Ended December 31, 2008	First Quarter	Second Quarter	Third Quarter	Fourth Quarter	Total Year
<b>Continuing Operations</b>					
Total service revenues and sales	\$ 285,268	\$ 283,156	\$ 288,312	\$ 292,205	\$ 1,148,941
Gross profit	\$ 79,456	\$ 82,017	\$ 85,866	\$ 91,055	\$ 338,394
Income from operations	\$ 29,841	\$ 28,837	\$ 34,909	\$ 39,270	\$ 132,857
Interest expense	(1,597)	(1,422)	(1,570)	(1,396)	(5,985)
Gain/(loss) on extinguishment of debt	—	—	—	4,208	4,208
Other income/(expense)—net	(1,189)	886	(1,908)	(6,524)	(8,735)
Income before income taxes	27,055	28,301	31,431	35,558	122,345
Income taxes	(10,235)	(11,051)	(13,483)	(15,471)	(50,240)
Income from continuing operations (a)	16,820	17,250	17,948	20,087	72,105
<b>Discontinued Operations</b>					
Net Income (a)	\$ 16,820	\$ 17,250	\$ 17,948	\$ 18,999	\$ 71,017
<b>Earnings Per Share (a)</b>					
Income from continuing operations	\$ 0.70	\$ 0.73	\$ 0.80	\$ 0.90	\$ 3.13
Net income	\$ 0.70	\$ 0.73	\$ 0.80	\$ 0.85	\$ 3.08
<b>Diluted Earnings Per Share (a)</b>					
Income from continuing operations	\$ 0.69	\$ 0.73	\$ 0.79	\$ 0.89	\$ 3.08
Net income	\$ 0.69	\$ 0.73	\$ 0.79	\$ 0.84	\$ 3.04
<b>Average number of shares outstanding</b>					
Earnings per share	23,873	23,486	22,503	22,382	23,058
Diluted earnings per share	24,285	23,759	22,818	22,644	23,374

(a) The following amounts are included in income from continuing operations during the respective quarter (in thousands):

	First Quarter	Second Quarter	Third Quarter	Fourth Quarter	Total Year
<b>Pretax (cost)/benefit:</b>					
Stock option expense	\$ (1,391)	\$ (1,591)	\$ (2,102)	\$ (2,219)	\$ (7,303)
Unreserved prior year's insurance claim	(597)	—	—	—	(597)
Expenses incurred in connection with the Office of Inspector General investigation	15	(57)	(2)	(2)	(46)
Gain on extinguishment of debt	—	—	—	4,208	4,208
Impairment loss on transportation equipment	—	—	—	(2,699)	(2,699)
Total	\$ (1,973)	\$ (1,648)	\$ (2,104)	\$ (712)	\$ (6,437)
<b>Aftertax (cost)/benefit:</b>					
Stock option expense	\$ (884)	\$ (1,010)	\$ (1,334)	\$ (1,391)	\$ (4,619)
Unreserved prior year's insurance claim	(358)	—	—	—	(358)
Expenses incurred in connection with the Office of Inspector General investigation	9	(35)	(1)	(1)	(28)
Income tax credit related to prior years	322	—	—	—	322
Income tax impact of nondeductible losses on investments held in deferred compensation trusts	—	—	(1,237)	(1,825)	(3,062)
Gain on extinguishment of debt	—	—	—	2,664	2,664
Impairment loss on transportation equipment	—	—	—	(1,714)	(1,714)
Total	\$ (911)	\$ (1,045)	\$ (2,572)	\$ (2,267)	\$ (6,795)

## UNAUDITED SUMMARY OF QUARTERLY RESULTS

Chemed Corporation and Subsidiary Companies  
(in thousands, except per share and footnote data)

For the Year Ended December 31, 2007	First Quarter	Second Quarter	Third Quarter	Fourth Quarter	Total Year
<b>Continuing Operations</b>					
Total service revenues and sales	\$ 270,439	\$ 271,387	\$ 272,503	\$ 285,729	\$ 1,100,058
Gross profit	\$ 82,192	\$ 82,671	\$ 79,621	\$ 88,508	\$ 332,992
Income from operations	\$ 29,230	\$ 30,325	\$ 30,583	\$ 32,617	\$ 122,755
Interest expense	(3,742)	(3,400)	(2,515)	(1,587)	(11,244)
Gain/(loss) on extinguishment of debt	—	(13,715)	(83)	—	(13,798)
Other income/(expense)—net	869	2,188	11	1,057	4,125
Income before income taxes	26,357	15,398	27,996	32,087	101,838
Income taxes	(10,136)	(5,965)	(11,080)	(11,882)	(39,063)
Income from continuing operations (a)	16,221	9,433	16,916	20,205	62,775
Discontinued Operations	—	—	1,201	—	1,201
Net Income (a)	\$ 16,221	\$ 9,433	\$ 18,117	\$ 20,205	\$ 63,976
<b>Earnings Per Share (a)</b>					
Income from continuing operations	\$ 0.63	\$ 0.38	\$ 0.71	\$ 0.84	\$ 2.56
Net income	\$ 0.63	\$ 0.38	\$ 0.76	\$ 0.84	\$ 2.61
<b>Diluted Earnings Per Share (a)</b>					
Income from continuing operations	\$ 0.62	\$ 0.38	\$ 0.69	\$ 0.83	\$ 2.50
Net income	\$ 0.62	\$ 0.38	\$ 0.74	\$ 0.83	\$ 2.55
<b>Average number of shares outstanding</b>					
Earnings per share	25,716	24,506	23,933	23,959	24,520
Diluted earnings per share	26,162	25,080	24,466	24,460	25,077

(a) The following amounts are included in income from continuing operations during the respective quarter (in thousands):

	First Quarter	Second Quarter	Third Quarter	Fourth Quarter	Total Year
<b>Pretax (cost)/benefit:</b>					
Long-term incentive compensation	\$ (5,447)	\$ (1,620)	\$ —	\$ —	\$ (7,067)
Gain on sale of property	1,138	—	—	—	1,138
Stock option expense	(585)	(897)	(1,592)	(1,591)	(4,665)
Expenses incurred in connection with the Office of Inspector General investigation	(66)	(74)	(48)	(39)	(227)
Loss on extinguishment of debt	—	(13,715)	(83)	—	(13,798)
Costs related to litigation settlement	—	—	—	(1,927)	(1,927)
Other	467	—	—	—	467
Total	\$ (4,493)	\$ (16,306)	\$ (1,723)	\$ (3,557)	\$ (26,079)
<b>After-tax (cost)/benefit:</b>					
Long-term incentive compensation	\$ (3,414)	\$ (1,013)	\$ —	\$ —	\$ (4,427)
Gain on sale of property	724	—	—	—	724
Stock option expense	(371)	(570)	(1,011)	(1,010)	(2,962)
Expenses incurred in connection with the Office of Inspector General investigation:	(41)	(46)	(30)	(24)	(141)
Loss on extinguishment of debt	—	(8,726)	(52)	—	(8,778)
Costs related to litigation settlement	—	—	—	(1,168)	(1,168)
Income tax impact of nondeductible losses on investments held in deferred compensation trusts	—	—	(123)	77	(46)
Other	296	—	—	—	296
Total	\$ (2,806)	\$ (10,355)	\$ (1,216)	\$ (2,125)	\$ (16,502)

## SELECTED FINANCIAL DATA

Chemed Corporation and Subsidiary Companies  
(in thousands, except per share and footnote data, ratios, percentages and personnel)

	2008	2007	2006	2005	2004(b)
<b>Summary of Operations</b>					
Continuing operations (a)					
Service revenues and sales	\$1,148,941	\$1,100,058	\$1,018,587	\$915,970	\$734,877
Gross profit (excluding depreciation)	338,394	332,992	288,464	271,494	228,107
Depreciation	21,581	20,118	16,775	16,150	14,542
Amortization	5,924	5,270	5,255	4,922	3,779
Income from operations (b)	132,857	122,755	104,979	76,769	57,954
Income from continuing operations (c)	72,105	62,775	57,722	36,228	19,095
Net income (c)	71,017	63,976	50,651	35,817	27,512
Earnings per share					
Income from continuing operations	\$ 3.13	\$ 2.56	\$ 2.21	\$ 1.42	\$ 0.79
Net income	3.08	2.61	1.94	1.40	1.14
Average number of shares outstanding	23,058	24,520	26,118	25,552	24,120
Diluted earnings per share					
Income from continuing operations	\$ 3.08	\$ 2.50	\$ 2.16	\$ 1.38	\$ 0.78
Net income	3.04	2.55	1.90	1.36	1.12
Average number of shares outstanding	23,374	25,077	26,669	26,299	24,636
Cash dividends per share	\$ 0.24	\$ 0.24	\$ 0.24	\$ 0.24	\$ 0.24
<b>Financial Position—Year-End</b>					
Cash and cash equivalents	\$ 3,628	\$ 4,988	\$ 29,274	\$ 57,133	\$ 71,448
Working capital/(deficit)	(17,789)	(13,427)	(3,951)	35,355	28,439
Current ratio	0.88	0.91	0.98	1.21	1.17
Properties and equipment, at cost less accumulated depreciation	\$ 76,962	\$ 74,513	\$ 70,140	\$ 65,155	\$ 55,796
Total assets	760,924	770,370	791,461	837,343	823,981
Long-term debt	199,656	214,669	150,331	234,058	279,510
Stockholders' equity	371,592	364,349	421,361	384,175	332,092
<b>Other Statistics—Continuing Operations</b>					
Capital expenditures	\$ 26,094	\$ 26,640	\$ 21,987	\$ 25,734	\$ 18,290
Number of employees	11,884	11,783	11,621	10,881	9,822

- (a) Continuing operations exclude VITAS of Arizona, discontinued in 2006 and Service America, discontinued in 2004
- (b) The financial results of VITAS are included in the consolidated results of the Company beginning on February 24, 2004, the date the Company acquired the 63% of VITAS it did not own, bringing its ownership in VITAS to 100%.
- (c) The following amounts are included in income from continuing operations during the respective year (in thousands):

	2008	2007	2006	2005	2004
<b>After-tax benefit/(cost):</b>					
Stock option expense	\$ (4,619)	\$ (2,962)	\$ (769)	\$ (137)	\$ —
Income tax impact of nondeductible losses on investments held in deferred compensation trusts	(3,062)	(46)	424	112	—
Gain/(loss) on extinguishment of debt	2,664	(8,778)	(273)	(2,523)	(2,030)
Loss on impairment of transportation equipment	(1,714)	—	—	—	—
Unreserved prior-year's insurance claim	(358)	—	—	—	—
Income tax credits or adjustments related to prior years	322	—	2,115	1,961	1,620
Expenses incurred in connection with the Office of Inspector General investigation	(28)	(141)	(662)	(397)	—
Long-term incentive compensation	—	(4,427)	—	(3,434)	(5,437)
Costs related to litigation settlements	—	(1,168)	(169)	(10,757)	(1,897)
Gain on sale of property	—	724	—	—	—
Loss on impairment of investment	—	—	(918)	—	—
Adjustment to casualty insurance related to prior periods experience	—	—	—	1,014	—
Adjustment of transaction-related expenses of the VITAS acquisition	—	—	—	959	(222)
Equity in loss of VITAS	—	—	—	—	(4,105)
Expenses related to debt registration	—	—	—	—	(727)
Other	—	296	296	—	—
<b>Total</b>	<b>\$ (6,795)</b>	<b>\$ (16,502)</b>	<b>\$ 44</b>	<b>\$ (13,202)</b>	<b>\$ (12,798)</b>

**MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS****EXECUTIVE SUMMARY**

We operate through our two wholly owned subsidiaries: VITAS Healthcare Corporation ("VITAS") and Roto-Rooter Group, Inc. ("Roto-Rooter"). VITAS focuses on hospice care that helps make terminally ill patients' final days as comfortable as possible. Through its team of doctors, nurses, home health aides, social workers, clergy and volunteers, VITAS provides direct medical services to patients, as well as spiritual and emotional counseling to both patients and their families. Roto-Rooter is focused on providing plumbing and drain cleaning services to both residential and commercial customers. Through its network of company-owned branches, independent contractors and franchisees, Roto-Rooter offers plumbing and drain cleaning service to over 90% of the U.S. population.

The following is a summary of the key operating results for the years ended December 31, 2008, 2007 and 2006 (in thousands except per share amounts):

	2008	2007	2006
Consolidated service revenues and sales	<b>\$1,148,941</b>	\$1,100,058	\$1,018,587
Consolidated income from continuing operations	<b>\$ 72,105</b>	\$ 62,775	\$ 57,722
Diluted EPS from continuing operations	<b>\$ 3.08</b>	\$ 2.50	\$ 2.16

**2008 versus 2007**

The increase in consolidated service revenues and sales from 2007 to 2008 was driven by a 7% increase at VITAS offset by a 1% decrease at Roto-Rooter. The increase at VITAS was the result of an increase in average daily census ("ADC") of 3%, the annual Medicare price increase and an increase due to changes in the mix of care. The decrease at Roto-Rooter was driven by a 10% decrease in the job count offset by a 9% increase due to price increases and job mix changes. Consolidated income from continuing operations and diluted EPS from continuing operations increased as a result of higher service revenues and sales, which allowed us to further leverage our current cost structure. The 2007 results were negatively impacted by pretax losses of \$13.8 million (\$8.8 million aftertax) related to our refinancing transactions.

**2007 versus 2006**

The increase in consolidated service revenues and sales from 2006 to 2007 was driven by an 8% increase at both VITAS and Roto-Rooter. The increase at VITAS was the result of an increase in average daily census ("ADC") of 6% and the annual Medicare price increase of 3% offset by changes in the mix of care. The increase at Roto-Rooter was mainly driven by price increases and job mix changes. Job count was essentially flat between years. Consolidated income from continuing operations and diluted EPS from continuing operations increased as a result of higher service revenues and sales, which allowed us to further leverage our current cost structure. The 2007 results were negatively impacted by pretax losses of \$13.8 million (\$8.8 million aftertax) related to our refinancing transactions.

**Impact of Current Market Conditions**

Due mainly to the condition of the U.S. economy, customer call volume in 2008 was down approximately 15% from the prior year at Roto-Rooter. This led to a lower job count and lower total revenue at Roto-Rooter, as discussed above. We project very modest growth in Roto-Rooter revenue in 2009 as we anticipate the economy to begin recovering towards the end of the year. As Roto-Rooter's technicians are primarily commission-based, gross margin as a percent of revenue at Roto-Rooter remains fairly stable even during times of decreasing revenue.

We do not anticipate current market conditions will have a significant impact on VITAS' revenue or profitability in 2009. However, we anticipate a potential slow-down in our cash collections at VITAS as Federal and state agencies experience budgetary pressures during the course of 2009. We do not believe any such cash flow delay will impact our ability to meet obligations or operate our businesses.

**LIQUIDITY AND CAPITAL RESOURCES**

Significant factors affecting our cash flows during 2008 and financial position at December 31, 2008, include the following:

- Our continuing operations generated cash of \$112.1 million;
- On a net basis, we repaid approximately \$10.5 million of long-term debt;
- We repurchased our stock using cash of \$69.8 million;
- We spent \$26.1 million on capital expenditures.

## Chemed Corporation and Subsidiary Companies

The ratio of total debt to total capital was 36.1% at December 31, 2008, compared with 38.2% at December 31, 2007. Our current ratio was 0.88 and 0.91 at December 31, 2008 and 2007, respectively.

Collectively, the 2007 Facility and the Notes require us to meet certain restrictive financial covenants, in addition to non-financial covenants, including maximum leverage ratios, minimum fixed charge coverage and consolidated net worth ratios, limits on operating leases and minimum asset value limits. We are in compliance with all financial and non-financial debt covenants as of December 31, 2008 and we forecast to be in compliance through fiscal 2009. We have issued \$26.9 million in standby letters of credit as of December 31, 2008, mainly for insurance purposes. Issued letters of credit reduce our available credit under the revolving credit agreement. As of December 31, 2008, we have approximately \$139.9 million of unused lines of credit available and eligible to be drawn down under our revolving credit facility, excluding the expansion feature. We believe our cash flow from operating activities and our unused eligible lines of credit are sufficient to fund our obligations and operate our business in the near term.

### CASH FLOW

Our cash flows for 2008, 2007 and 2006 are summarized as follows (in millions):

	For the Years Ended December 31,		
	2008	2007	2006
Net cash provided by operating activities	\$ 112.1	\$ 99.6	\$ 98.6
Capital expenditures	(26.1)	(26.6)	(22.0)
Operating cash excess after capital expenditures	86.0	73.0	76.6
Purchase of treasury stock	(69.8)	(131.7)	(19.9)
Repayment of long-term debt	(18.7)	(225.7)	(84.6)
Business combinations	(11.2)	(1.1)	(4.1)
Net proceeds/(uses) from sale of discontinued operations	8.8	(5.4)	(0.9)
Proceeds from issuance of long-term debt, net of costs	8.2	293.1	(0.2)
Dividends paid	(5.5)	(5.9)	(6.3)
Issuance of capital stock, net of costs	0.3	2.5	3.9
Purchase of note hedge	—	(55.1)	—
Proceeds from issuance of warrants	—	27.6	—
Other—net	0.5	4.4	7.6
Decrease in cash and cash equivalents	\$ (1.4)	\$ (24.3)	\$ (27.9)

### COMMITMENTS AND CONTINGENCIES

In connection with the sale of DuBois Chemicals, Inc. (“DuBois”) in 1991, we provided allowances and accruals relating to several long-term costs, including income tax matters, lease commitments and environmental costs. Also, in conjunction with the sales of The Omnia Group (“Omnia”) and National Sanitary Supply Company in 1997 and the sale of Service America Network Inc. (“Service America”) in 2005, we provided long-term allowances and accruals relating to costs of severance arrangements, lease commitments and income tax matters. Additionally, we retained liability for Service America’s casualty insurance claims that were incurred prior to the disposal date. In connection with the sale of VITAS’ Phoenix operation in November 2006, we have accrued an estimate of our total exposure for the Medicare Cap through the date of sale. In the aggregate, we believe these allowances and accruals are adequate as of December 31, 2008. Based on reviews of our environmental-related liabilities under the DuBois sale agreement, we have estimated our remaining liability to be \$1.7 million. As of December 31, 2008, we are contingently liable for additional cleanup and related costs up to a maximum of \$14.9 million, for which no provision has been recorded in accordance with the applicable accounting guidance.

On September 28, 2006, we announced a preliminary settlement in regard to litigation related to the 2002 divestiture of our Patient Care business segment. Prior to the settlement, we had a long-term receivable from Patient Care of \$12.5 million. We also had current accounts receivable from Patient Care for the post-closing balance sheet valuation and for expenses paid by us after closing on Patient Care’s behalf of \$3.4 million. We were in litigation with Patient Care over the collection of these current amounts and their allegations that our acquisition of VITAS violated a non-compete covenant in the sales agreement. We agreed to forgive \$1.2 million of the current receivable related to the post-closing balance sheet valuation and convert the remaining amount into debt secured by a promissory note with the same terms as the \$12.5 million long-term receivable. We incurred additional costs related to the settlement of \$1.1 million for additional insurance and legal costs related to workers’ compensation claims incurred prior to the sale. The aftertax charge related to these amounts of \$1.5 million was recorded as discontinued operations in 2006.

## Chemed Corporation and Subsidiary Companies

In December 2007, the parties amended the terms of the long-term notes receivable from Patient Care. We agreed to waive the prepayment penalty provisions in the notes provided that Patient Care paid \$5 million of principal on or before December 31, 2007, and the remaining outstanding principal on or before March 31, 2008. The notes receivable were paid in full in the first quarter of 2008.

We also have a warrant to purchase 2% of Patient Care's common stock that we recorded as a \$1.4 million investment. As a result of financial information received in 2006, we determined that the value of the warrants was permanently impaired and recorded a pretax impairment charge of \$1.4 million. This charge is included in income from continuing operations on the consolidated statement of income for the year ended December 31, 2006.

VITAS is party to a class action lawsuit filed in the Superior Court of California, Los Angeles County, in September 2006 by Bernadette Santos, Keith Knoche and Joyce White ("Santos"). This case alleges failure to pay overtime and failure to provide meal and rest periods to a purported class of California admissions nurses, chaplains and sales representatives. The case seeks payment of penalties, interest and Plaintiffs' attorney fees. VITAS contests these allegations. The lawsuit is in its early stages and we are unable to estimate our potential liability, if any, with respect to these allegations.

In April 2007, our Roto-Rooter subsidiary was named in a class action lawsuit filed in San Mateo Superior Court by Stanley Ita ("Ita") alleging class-wide wage and hour violations at one California branch. This suit alleged failure to provide meal and break periods, credit for work time beginning from the first call to dispatch rather than arrival at first assignment and improper calculations of work time and overtime. The case sought payment of penalties, interest and Plaintiffs' attorney fees. After the suit was filed, we offered a settlement to certain members of the class and paid approximately \$200,000. In January 2008, we agreed to a tentative settlement with the remaining members of the class for approximately \$1.8 million. The tentative settlement was preliminarily approved by the court in May 2008. Final approval and payment of the settlement was made in August 2008. The final settlement was accrued in 2007.

In April 2005, the Office of Inspector General ("OIG") for the Department of Health and Human Services served VITAS with civil subpoenas relating to VITAS' alleged failure to appropriately bill Medicare and Medicaid for hospice services. As part of this investigation, the OIG selected medical records for 320 past and current patients from VITAS' three largest programs for review. It also sought policies and procedures dating back to 1998 covering admissions, certifications, recertifications and discharges. During the third quarter of 2005 and again in May 2006, the OIG requested additional information from us. The Court dismissed a related qui tam complaint filed in U.S. District Court for the Southern District of Florida with prejudice in July 2007. The plaintiffs appealed this dismissal, which the Court of Appeals affirmed.

Regardless of outcome, litigation and government investigations adversely affects us through defense costs, diversion of our time and related publicity. We record a reserve for these matters when an adverse outcome is probable and the amount of the potential liability is reasonably estimable.

### CONTRACTUAL OBLIGATIONS

The table below summarizes our debt and contractual obligations as of December 31, 2008 (in thousands):

	Total	Less than 1 year	1-3 Years	4 -5 Years	After 5 Years
Long-term debt obligations	\$ 209,825	\$ 10,169	\$ 12,700	\$ —	\$ 186,956
Interest obligation on long-term debt (a)	18,841	3,505	7,011	7,011	1,314
Operating lease obligations	52,108	16,247	21,431	10,393	4,037
Severance obligations	256	256	—	—	—
Liabilities related to uncertain tax positions	1,202	479	394	289	40
Obligations of discontinued operations	2,499	1,337	1,162	—	—
Purchase obligations (b)	52,810	52,810	—	—	—
Other current obligations (c)	40,741	40,741	—	—	—
Other long-term obligations (d)	26,144	—	1,863	1,864	22,417
Total contractual cash obligations	<u>\$ 404,426</u>	<u>\$ 125,544</u>	<u>\$ 44,561</u>	<u>\$ 19,557</u>	<u>\$ 214,764</u>

(a) Our interest obligation on our long-term debt includes only interest on fixed rate debt.

(b) Purchase obligations primarily consist of accounts payable at December 31, 2008.

(c) Other current obligations consist of accrued salaries and wages at December 31, 2008.

(d) Other long-term obligations comprise largely pension and excess benefit obligations.

## RESULTS OF OPERATIONS

## 2008 Versus 2007 – Consolidated Results

Set forth below are the year-to-year changes in the components of the statement of operations relating to continuing operations for 2008 versus 2007 (in thousands, except percentages):

	Increase/(Decrease)	
	Amount	Percent
Service revenues and sales		
VITAS	\$ 53,019	7
Roto-Rooter	(4,136)	(1)
Total	48,883	4
Cost of services provided and goods sold	43,481	6
Selling, general and administrative expenses	(8,727)	(5)
Depreciation	1,463	7
Amortization	654	12
Other expenses	1,910	242
Income from operations	10,102	8
Interest expense	5,259	(47)
Gain on extinguishment of debt	18,006	(130)
Other income —net	(12,860)	(312)
Income before income taxes	20,507	20
Income taxes	(11,177)	29
Income from continuing operations	\$ 9,330	15

Our service revenues and sales for the year ended December 31, 2008 increased \$48.9 million or 4.4% over the comparable prior year. The VITAS segment accounted for \$53.0 million of the increase offset by a \$4.1 million revenue decrease for the Roto-Rooter segment.

The VITAS segment revenue increase is the result of the following (dollars in thousands):

	Amount	Percent
Routine homecare	\$ 39,019	7
Continuous care	9,093	8
General inpatient	4,900	5
Medicare cap	7	(3)
Total revenues	\$ 53,019	7

The revenue increase for VITAS includes the annual increase in the Medicare reimbursement rate of approximately 3% to 4% in 2007 and 2% to 3% in 2008. In addition, the ADC for routine homecare and continuous care increased 3.4% and 2.1%, respectively, from 2007. ADC for general inpatient was flat between years. ADC is a key measure we use to monitor volume growth in our hospice programs. Changes in total program admissions and average length of stay for our patients are the main drivers of changes in ADC. The Medicare cap amount recorded in 2008 relates to one program's projected liability through year end for the 2009 measurement period. We are currently pursuing corrective actions to attempt to mitigate the liability before the end of the measurement period. The 2007 revenue reduction for Medicare cap is related to retroactive billings from prior periods for patients who transferred between hospice providers.

The Roto-Rooter segment revenue decrease is the result of the following (dollars in thousands):

	Amount	Percent
Plumbing	\$ 2,810	2
Sewer and drain cleaning	(4,961)	(3)
Other	(1,985)	(4)
Total revenues	\$ (4,136)	(1)

Plumbing revenues for 2008 increased from 2007 due to a 11% increase in the average price per job offset by a 9% decrease in the number of jobs performed. The increase in the plumbing price per job was driven mainly by job mix. Our excavation job count increased by 22% compared to 2007. The average revenue per excavation job is approximately 4.5

times greater than other average plumbing jobs. Sewer and drain cleaning revenues for 2008 decreased from 2007 due to a 11% decrease in jobs performed partially offset by a 8% increase in the average price per job. The decrease in other revenues is attributable primarily to decreased franchise fees and sales of drain cleaning products and equipment.

The consolidated gross margin was 29.4% in 2008 versus 30.3% in 2007. On a segment basis, VITAS' gross margin was 22.7% in 2008 and 22.4% in 2007. Roto-Rooter's gross margin was 45.6% in 2008 and 47.6% in 2007. The decrease in Roto-Rooter's gross margin in 2008 is primarily attributable to an increase in large medical claims affecting our health insurance costs.

Selling, general and administrative expenses ("SG&A") for 2008 decreased \$8.7 million (5%). The decrease is mainly attributable to a 2007 LTIP award of \$7.1 million. No LTIP awards were made in 2008. Additionally, our liability related to the deferred compensation plans decreased by approximately \$8.4 million due to market performance. The offset to the decreased liability is recorded in other (non-operating) income and expense. The remaining change in SG&A is the result of typical cost of living increases for salaries and benefits plus increases in certain selling expenses which vary based on changes in revenue.

The increase in other operating expenses relates to an impairment charge on certain transportation equipment. In December 2008, the Executive Committee of the Board of Directors authorized us to place the old equipment for sale. We determined that these assets meet the definition of held for sale under Statement of Financial Accounting Standard No. 144. As a result, we discontinued depreciation on these assets and wrote-down the assets to their fair value less selling costs resulting in a pre-tax charge to other operating expenses — net of approximately \$2.7 million.

Interest expense decreased \$5.3 million (47%) from 2007 to 2008 mainly due to the refinancing in May 2007 and the subsequent repayment of long-term debt. In the fourth quarter of 2008, we purchased approximately \$13.0 million face value of our Convertible Notes due 2014 for approximately \$8.5 million. This resulted in a pre-tax net gain of \$4.2 million comprised of \$4.5 million related to the purchase of the Convertible Notes partially offset by \$300,000 in the write-off of unamortized debt issuance costs. The net gain was recorded as a gain on extinguishment of debt in the accompanying statement of income in 2008. In conjunction with our May 2007 refinancing transactions, we recorded a loss on extinguishment of debt of \$13.8 million.

Other income/(expense) — net was an \$8.7 million expense in 2008 compared to \$4.1 million in income in 2007. The change is the result of a \$9.1 million loss from investments held in deferred compensation plans due to market conditions, as well as a decrease of approximately \$2.6 million in interest income due to lower cash balances and reduced market interest rates.

Our effective tax rate was 41.1% in 2008 compared to 38.4% in 2007. The increase in the effective income tax rate is due primarily to the impact of non-deductible market losses on investments in our deferred compensation benefit trusts.

In December 2008, we recorded a \$1.7 million pre-tax charge for retrospective casualty insurance claims related to our discontinued operations. We have recorded the reversal of a \$1.9 million over accrual and its related tax effects in discontinued operations during the year ended December 31, 2007 related to Medicare cap at our discontinued Phoenix program.

Chemed Corporation and Subsidiary Companies

Income from continuing operations for both periods include the following aftertax adjustments that increased/(reduced) aftertax earnings (in thousands):

	2008	2007
<b>VITAS</b>		
Costs associated with the OIG investigation	\$ (28)	\$ (141)
Income tax R&D credit for prior year activity	322	—
<b>Roto-Rooter</b>		
Costs related to class action litigation	—	(1,168)
Gain on sale of property	—	724
Unreserved prior year's insurance claims	(358)	—
<b>Corporate</b>		
Gain/(loss) on extinguishment of debt	2,664	(8,778)
Long-term incentive compensation	—	(4,427)
Stock option expense	(4,619)	(2,962)
Income tax impact of deferred compensation plans	(3,062)	(46)
Impairment of transportation equipment	(1,714)	—
Other	—	296
<b>Total</b>	<b>\$ (6,795)</b>	<b>\$ (16,502)</b>

**2008 Versus 2007 — Segment Results**

The change in net income for 2008 versus 2007 is due to (in thousands, except percentages):

	Increase/(Decrease)	
	Amount	Percent
<b>VITAS</b>	\$ 4,886	8
<b>Roto-Rooter</b>	(5,379)	(14)
<b>Corporate</b>	9,823	(27)
<b>Discontinued operations</b>	(2,289)	(191)
<b>Total</b>	<b>\$ 7,041</b>	<b>11</b>

**2007 Versus 2006 — Consolidated Results**

Set forth below are the year-to-year changes in the components of the statement of operations relating to continuing operations for 2007 versus 2006 (in thousands, except percentages):

	Increase/(Decrease)	
	Amount	Percent
<b>Service revenues and sales</b>		
VITAS	\$ 56,334	8
Roto-Rooter	25,137	8
Total	81,471	8
Cost of services provided and goods sold	36,943	5
Selling, general and administrative expenses	22,877	14
Depreciation	3,343	20
Amortization	15	—
Other expenses	517	190
Income from operations	17,776	17
Interest expense	6,224	(36)
Loss on extinguishment of debt	(13,368)	3,109
Loss from impairment of investment	1,445	(100)
Other income—net	(523)	(11)
Income before income taxes	11,554	13
Income taxes	(6,501)	20
Income from continuing operations	\$ 5,053	9

Our service revenues and sales for the year ended December 31, 2007, increased \$81.5 million, or 8%, versus revenues for the year ended December 31, 2006. The VITAS segment accounted for \$56.4 million of this increase and Roto-Rooter accounted for the remaining \$25.1 million of the increase.

The increase in VITAS' revenues for 2007 versus 2006 is attributable to the following (dollars in thousands):

	Amount	Percent
Routine homecare	\$ 54,860	11
Continuous care	(5,295)	(4)
General inpatient	3,113	3
Medicare Cap	3,656	(94)
Total revenues	\$ 56,334	8

The revenue increase for VITAS includes the annual increase in the Medicare reimbursement rate of approximately 3% to 4%. In addition, the ADC for routine homecare and general inpatient increased 7.3% and 1.5%, respectively, from 2006. ADC for continuous care decreased 7.6% from 2006. ADC is a key measure we use to monitor volume growth in our hospice programs. Changes in total program admissions and average length of stay for our patients are the main drivers of changes in ADC. Additionally, we had a \$3.7 million favorable comparison from 2006 related to reductions in revenue for the Medicare Cap. We recorded a reduction in revenue for Medicare Cap in 2007 of \$242,000 compared to \$3.9 million in 2006. The improvement is a result of improved admissions and consolidation of certain provider numbers within key programs. The 2007 revenue reduction is related to retroactive billings from prior periods for patients who transferred between hospice providers. No Medicare Cap liability for the 2007 or 2008 measurement periods have been recorded as of December 31, 2007.

The increase in Roto-Rooter's service revenues and sales for 2007 versus 2006 is attributable to the following (in thousands):

	<u>Amount</u>	<u>Percent</u>
Plumbing	\$ 13,973	11
Sewer and drain cleaning	6,353	4
Other	4,811	11
Total revenues	<u>\$ 25,137</u>	8

Plumbing revenues for 2007 increased from 2006 due to a 4% increase in the average price per job and a 7% increase in the number of jobs performed. Sewer and drain cleaning revenues for 2007 increased from 2006 due to a 7% increase in the average price per job offset by a 3% decrease in the number of jobs performed. The increase in other revenues is attributable primarily to increases in independent contractor operations.

The consolidated gross margin was 30.3% in 2007 versus 28.3% in 2006. On a segment basis, VITAS' gross margin was 22.4% in 2007 and 20.3% in 2006. The Medicare Cap accounts for approximately 0.5% of the increase in VITAS' gross margin. Approximately 0.5% of the improvement in gross margin relates to certain expenses that were historically cost of services but were centralized in 2007 and are now included in selling, general and administrative ("SG&A") expenses. The remaining improvement relates to better utilization of our labor in 2007. In 2006, we experienced lower gross margins due to excess patient care capacity. Roto-Rooter's gross margin was 47.6% in 2007 and 45.9% in 2006. The improvement in Roto-Rooter's gross margin is the result of price increases noted above coupled with continued improvement in retention of service technicians, which enhances overall productivity of the workforce and reduces our workers' compensation costs.

Selling, general and administrative expenses ("SG&A") for 2007 increased \$22.9 million (14%). The increase is attributable to an increase in LTIP costs of \$7.1 million, stock option expense of \$3.5 million and advertising costs of \$2.7 million. Additionally, \$3.8 million of the increase relates to the centralization of certain activities at our VITAS subsidiary which were previously at the program level and classified as cost of services prior to 2007. The remaining increase in SG&A is the result of typical cost of living increases for salaries and benefits plus increases in certain selling expenses which vary based on changes in revenue.

Depreciation expense increased \$3.3 million (20%) in 2007 compared to 2006 due to increased depreciation on computer hardware and leasehold improvements mainly at our VITAS subsidiary. Other expenses increased \$517,000 due to the impact of the settlement of a class action lawsuit at Roto-Rooter offset by the gain on sale of Roto-Rooter's Florida call center facility.

Interest expense decreased \$6.2 million (36%) from 2006 to 2007 mainly due to the refinancing in May 2007 and the subsequent repayment of long-term debt throughout the remainder of 2007. In conjunction with our May 2007 refinancing transactions, we recorded a loss on extinguishment of debt of \$13.8 million. In the third quarter of 2006, we recorded a \$1.4 million impairment charge related to our investment in the warrants of Patient Care as discussed in the commitments and contingencies section above.

Our effective income tax rate was 38.4% in 2007 versus 36.1% in 2006. The increase in our effective tax rate relates to the \$2.1 million tax adjustment required upon expiration of certain statutes in 2006. As a result of the adoption of FIN 48 on January 1, 2007, no such tax adjustments were necessary in 2007.

Chemed Corporation and Subsidiary Companies

Income from continuing operations increased \$5.1 million (9%) from 2006 to 2007. Income from continuing operations for both periods include the following aftertax adjustments that increased/(reduced) aftertax earnings (in thousands):

	2007	2006
<b>VITAS</b>		
Costs associated with the OIG investigation	\$ (141)	\$ (662)
Costs of class action litigation	—	(169)
<b>Roto-Rooter</b>		
Costs related to class action litigation	(1,168)	—
Gain on sale of property	724	—
Tax adjustments required upon expiration of statutes	—	1,251
<b>Corporate</b>		
Loss on extinguishment of debt	(8,778)	(273)
Long-term incentive compensation	(4,427)	—
Stock option expense	(2,962)	(769)
Tax adjustments required upon expiration of statutes	—	864
Income tax impact of deferred compensation plans	(46)	424
Impairment of Patient Care warrants	—	(918)
Other	296	296
<b>Total</b>	<b>\$ (16,502)</b>	<b>\$ 44</b>

Income/(loss) from discontinued operations for 2007 and 2006 follows (in thousands):

	For the Years Ended December 31,	
	2007	2006
<b>VITAS Phoenix</b>	<b>\$ 1,201</b>	<b>\$ (4,872)</b>
Service America	—	(32)
Adjustment to accruals of operations discontinued in prior years	—	(2,167)
<b>Income/(loss) from discontinued operations</b>	<b>\$ 1,201</b>	<b>\$ (7,071)</b>

In September 2006, our Board of Directors approved and we announced our intention to exit the hospice market in Phoenix, Arizona. As a result of our announcement, we performed interim impairment tests of our long-lived assets of the Phoenix operation as of September 30, 2006, in accordance with Statement of Financial Accounting Standards No. 144. An impairment charge of \$2.4 million was recorded for the referral network intangible asset and fixed assets during the third quarter of 2006. The sale was completed in November 2006. The acquiring corporation purchased the substantial majority of assets of the Phoenix program for \$2.5 million. In October 2007, we received notification from the Federal government's fiscal intermediary regarding our Medicare Cap liabilities related to the 2006 measurement period. The notification revealed that we were over accrued at our discontinued Phoenix operation by \$1.9 million. We recorded the reversal of this over accrual and its related tax effects in discontinued operations during the year ended December 31, 2007.

**2007 Versus 2006 — Segment Results**

The change in net income for 2007 versus 2006 is due to (in thousands, except percentages):

	Increase/(Decrease)	
	Amount	Percent
<b>VITAS</b>	<b>\$ 11,415</b>	<b>24</b>
Roto-Rooter	6,373	20
Corporate	(12,735)	55
Discontinued operations	8,272	(117)
<b>Total</b>	<b>\$ 13,325</b>	<b>26</b>

*CRITICAL ACCOUNTING POLICIES*

**Revenue Recognition**

For both the Roto-Rooter and VITAS segments, service revenues and sales are recognized when the earnings process has been completed. Generally, this occurs when services are provided or products are delivered. Sales of Roto-Rooter products, including drain cleaning machines and drain cleaning solution, comprise less than 3% of our total service revenues and sales for each of the three years in the period ended December 31, 2008.

VITAS recognizes revenue at the estimated net realizable amount due from third-party payers, which are primarily Medicare and Medicaid. Payers may deny payment for services in whole or in part on the basis that such services are not eligible for coverage and do not qualify for reimbursement. We estimate denials each period and make adequate provision in the financial statements. The estimate of denials is based on historical trends and known circumstances and generally does not vary materially from period to period on an aggregate basis.

VITAS is subject to certain limitations on Medicare payments for services. Specifically, if the number of inpatient care days any hospice program provides to Medicare beneficiaries exceeds 20% of the total days of hospice care such program provides to all patients for an annual period beginning September 28, the days in excess of the 20% figure may be reimbursed only at the routine homecare rate. We have never had a program reach the inpatient cap. None of our hospice programs are expected to be within 30% of the inpatient cap for the 2008 measurement period while the majority of our programs have expected cushion in excess of 75% of the inpatient cap. Due to the significant cushion at each program, we do not anticipate it to be reasonably likely that any program will be subject to the inpatient cap in the foreseeable future.

VITAS is also subject to a Medicare annual per-beneficiary cap. Compliance with the Medicare cap is measured by comparing the total Medicare payments received under a Medicare provider number with respect to services provided to all Medicare hospice care beneficiaries in the program or programs covered by that Medicare provider number between November 1 of each year and October 31 of the following year with the product of the per-beneficiary cap amount and the number of Medicare beneficiaries electing hospice care for the first time from that hospice program or programs during the relevant period.

We actively monitor each of our hospice programs, by provider number, as to their specific admissions, discharge rate and median length of stay data in an attempt to determine whether they are likely to exceed the Medicare cap. Should we determine that a provider number is likely to exceed the Medicare cap based on projected trends, we attempt to institute corrective action to influence the patient mix or to increase patient admissions. However, should we project our corrective action will not prevent that program from exceeding its Medicare cap, we estimate the amount of revenue recognized during the period that will require repayment to the Federal government under the Medicare cap and record that amount as a reduction in service revenue.

Our estimate of the Medicare cap liability is particularly sensitive to allocations made by our fiscal intermediary relative to patient transfers between hospices. We are allocated a percentage of the Medicare cap based on the total days a patient spent in hospice care. The allocation for patient transfers cannot be determined until a patient dies. As the number of days a patient spends in hospice is based on a future event, this allocation process may take several years. Therefore, we use only first time Medicare admissions in our estimate of the Medicare cap billing limitation. This method assumes that credit received for patients who transfer into our program will be offset by credit lost from patients who transfer out of our program. If the actual relationship of transfers in and transfers out for a given measurement period proves to be different for any program at or near a billing limitation, our estimate of the liability would increase or decrease on a dollar-for-dollar basis. While our method has historically been materially accurate, each program can vary during a given measurement period.

Based on the methodology discussed above, we recorded a Medicare cap liability of \$235,000 for the 2009 measurement period during the year ended December 31, 2008. Due to the variability caused by patient transfers, we have calculated the potential range of loss for all continuing programs to be between zero and \$5.0 million for the year ended December 31, 2008.

**Insurance Accruals**

For the Roto-Rooter segment and Chemed's Corporate Office, we self-insure for all casualty insurance claims (workers' compensation, auto liability and general liability). As a result, we closely monitor and frequently evaluate our historical claims experience to estimate the appropriate level of accrual for self-insured claims. Our third-party administrator ("TPA") processes and reviews claims on a monthly basis. Currently, our exposure on any single claim is capped at \$500,000. In developing our estimates, we accumulate historical claims data for the previous 10 years to calculate loss development factors ("LDF") by insurance coverage type. LDFs are applied to known claims to estimate the ultimate potential liability for known and unknown claims for each open policy year. LDFs are updated annually. Because this

methodology relies heavily on historical claims data, the key risk is whether the historical claims are an accurate predictor of future claims exposure. The risk also exists that certain claims have been incurred and not reported on a timely basis. To mitigate these risks, in conjunction with our TPA, we closely monitor claims to ensure timely accumulation of data and compare claims trends with the industry experience of our TPA.

For the VITAS segment, we self-insure for workers' compensation claims. Currently, VITAS' exposure on any single claim is capped at \$500,000. For VITAS' self-insurance accruals for workers' compensation, the valuation methods used are similar to those used internally for our other business units.

Our casualty insurance liabilities are recorded gross before any estimated recovery for amounts exceeding our stop loss limits. Estimated recoveries from insurance carriers are recorded as accounts receivable. Claims experience adjustments to our casualty and workers' compensation accrual for the years ended December 31, 2008, 2007 and 2006 were net, pretax debits/(credits) of \$52,000, (\$2.9 million) and (\$2.1 million), respectively.

As an indication of the sensitivity of the accrued liability to reported claims, our analysis indicates that a 1% across-the-board increase or decrease in the amount of projected losses for all of our continuing operations would increase or decrease the accrued insurance liability at December 31, 2008, by \$1.6 million or 4.5%. While the amount recorded represents our best estimate of the casualty and workers' compensation insurance liability, we have calculated, based on historical claims experience, the actual loss could reasonably be expected to increase or decrease by approximately \$2.4 million as of December 31, 2008.

### **Income Taxes**

Deferred taxes are provided on an asset and liability method whereby deferred tax assets are recognized for deductible temporary differences and operating loss carry-forwards and deferred tax liabilities are recognized for taxable temporary differences. Temporary differences are the differences between the reported amount of assets and liabilities and their tax basis. Deferred tax assets are reduced by a valuation allowance when, in our opinion, it is more likely than not that some portion or all of the deferred tax assets will not be realized. Deferred tax assets and liabilities are adjusted for the effects of changes in laws and rates on the date of enactment.

We are subject to income taxes in the Federal and most state jurisdictions. We are periodically audited by various taxing authorities. Significant judgment is required to determine our provision for income taxes. On January 1, 2007, we adopted FASB Interpretation No. 48 (FIN 48), "Accounting for Uncertainty in Income Taxes — an Interpretation of FASB Statement 109," which prescribes a comprehensive model for how to recognize, measure, present and disclose in financial statements uncertain tax positions taken or expected to be taken on a tax return. Upon adoption of FIN 48, the financial statements reflect expected future tax consequences of such uncertain positions assuming the taxing authorities' full knowledge of the position and all relevant facts.

### **Goodwill and Intangible Assets**

Identifiable, definite-lived intangible assets arise from purchase business combinations and are amortized using either an accelerated method or the straight-line method over the estimated useful lives of the assets. The selection of an amortization method is based on which method best reflects the economic pattern of usage of the asset. The VITAS trade name is considered to have an indefinite life. Goodwill and the VITAS trade name are tested at least annually for impairment. The valuation of goodwill and the VITAS trade name is dependent upon many factors, some of which are market-driven and beyond our control. The valuation of goodwill and the VITAS trade name indicate that the fair value exceeds the carrying value at October 1, 2008.

### **Stock-based Compensation Plans**

Effective January 1, 2006, we adopted the provisions of Statement of Financial Accounting Standards No. 123, revised ("SFAS 123(R)") which establishes accounting for stock-based compensation for employees. Under SFAS 123(R), stock-based compensation cost is measured at the grant date, based on the fair value of the award and recognized as expense over the employee's requisite service period on a straight-line basis.

We estimate the fair value of stock options using the Black-Scholes valuation model, consistent with the provisions of SFAS 123(R) and the Securities and Exchange Commission (SEC) Staff Accounting Bulletin No. 110. We determine expected term, volatility, dividend yield and forfeiture rate based on our historical experience. We believe that historical experience is the best indicator of these factors.

*RECENT ACCOUNTING STATEMENTS*

In June 2008, the FASB issued Staff Position No. EITF 03-6-1, “Determining Whether Instruments Granted in Share-Based Payment Transactions are Participating Securities.” The new guidance requires that unvested share-based payment awards containing non-forfeitable rights to dividends or dividend equivalents are participating securities and shall be included in the computation of earnings per share pursuant to the two-class method. The new standard is effective for all fiscal years beginning after December 15, 2008 and must be applied retrospectively for all periods presented. Adoption of the new guidance in fiscal 2009 will not have a material impact on our earnings per share.

In June 2008, the EITF reached a consensus on EITF Issue No. 07-5, “Determining Whether an Instrument (or an Embedded Feature) Is Indexed to an Entity’s Own Stock”. The consensus provides additional guidance when determining whether an option or warrant on an entity’s own shares are eligible for the equity classification provided for in EITF 00-19. The consensus is effective for fiscal years beginning after December 15, 2008. As such, we adopted the new standard on January 1, 2009. The adoption of EITF Issue No. 07-5 did not impact the accounting for our 2007 convertible debt transaction.

In May 2008, the FASB issued Staff Position No. APB 14-1, “Accounting for Convertible Debt Instruments that may be Settled in Cash Upon Conversion (Including Partial Cash Settlement).” This new guidance requires all convertible debentures classified as Instruments B or C under EITF 90-19 to separately account for the debt and equity pieces of the instrument. At inception of the convertible instrument, cash flows related to the convertible instrument are to be discounted using a market rate of interest. This will create a discount at inception to be recorded in equity. The debt portion is to be accreted to its face value, through interest expense, over the life of the instrument using the effective interest method. This will result in higher interest expense over the life of the instrument and an increase in equity at the inception of the instrument. Debt issuance costs are also to be allocated between the debt and equity components using a rationale method. Finally, the FSP requires that the Company value any embedded features of the instrument, other than the conversion option, as a part of the liability. The new standard is effective for all fiscal years (and interim periods) beginning after December 15, 2008. As such, we adopted the new standard on January 1, 2009. The FSP is to be applied retrospectively. Upon adoption, our \$200 million, 1.875% Convertible Debentures issued in May 2007 had a discount of approximately \$55 million. Additionally, the gain on extinguishment of debt decreased by approximately \$830,000 upon retrospective adoption due to a portion of the extinguishment being attributed to the equity component of our convertible debenture.

In May 2008, the FASB issued Statement of Financial Accounting Standard No. 162 “The Hierarchy of Generally Accepted Accounting Principles” (“SFAS 162”). The purpose of this standard is to provide a consistent framework for determining what accounting principles should be used when preparing U.S. GAAP financial statements. SFAS 162 categorizes accounting pronouncements in a descending order of authority. In the instance of potentially conflicting accounting principles, the standard in the highest category must be used. This statement will be effective 60 days after the SEC approves the Public Company Accounting and Oversight Board’s related amendments. We believe that SFAS 162 will have no impact on our existing accounting methods.

In December 2007, the FASB issued Statement of Financial Accounting Standard No. 141(R) “Business Combinations (revised 2007)” (“SFAS 141(R)”), which changes certain aspects of the accounting for business combinations. This Statement retains the fundamental requirements in Statement No. 141 that the purchase method of accounting be used for all business combinations and for an acquirer to be identified for each business combination. SFAS 141(R) modifies existing accounting guidance in the areas of deal and restructuring costs, acquired contingencies, contingent consideration, in-process research and development, accounting for subsequent tax adjustments and assessing the valuation date. This Statement applies prospectively to business combinations for which the acquisition date is on or after the beginning of the first annual reporting period beginning on or after December 15, 2008. An entity may not apply it before that date. There was no impact on our financial statements as a result of the adoption of SFAS 141(R); however our accounting for all business combinations after adoption will comply with the new standard.

In December 2007, the FASB issued Statement of Financial Accounting Standard No. 160 “Non-controlling Interests in Consolidated Financial Statements — an amendment of ARB No. 51” (“SFAS 160”), which requires ownership interests in subsidiaries held by others to be clearly identified, labeled and presented in the consolidated balance sheet within equity but separate from the parent company’s equity. SFAS 160 also affects the accounting requirements when the parent company either purchases a higher ownership interest or deconsolidates the equity investment. This Statement applies prospectively to business combinations for which the acquisition date is on or after the beginning of the first annual reporting period beginning on or after December 15, 2008. An entity may not apply it before that date. There was no impact on our financial statements as a result of the adoption of SFAS No. 160. We currently do not have non-controlling interests in our consolidated financial statements.

**CHEMED CORPORATION AND SUBSIDIARY COMPANIES**  
**OPERATING STATISTICS FOR VITAS SEGMENT**  
**FOR THE YEARS ENDED DECEMBER, 2008 AND 2007**  
(unaudited)

OPERATING STATISTICS	Three Months Ended December 31,		Years Ended December 31,	
	2008	2007	2008	2007
<b>OPERATING STATISTICS</b>				
Net revenue (\$000)				
Homecare	\$ 149,816	\$ 143,125	\$ 585,891	\$ 546,872
Inpatient	23,398	23,927	97,895	92,995
Continuous care	32,877	30,150	124,894	115,801
Total before Medicare cap allowance	\$ 206,091	\$ 197,202	\$ 808,680	\$ 755,668
Medicare cap allowance	(235)	—	(235)	(242)
Total	<u>\$ 205,856</u>	<u>\$ 197,202</u>	<u>\$ 808,445</u>	<u>\$ 755,426</u>
Net revenue as a percent of total before Medicare cap allowance				
Homecare	72.6%	72.6%	72.5%	72.4%
Inpatient	11.4	12.1	12.1	12.3
Continuous care	16.0	15.3	15.4	15.3
Total before Medicare cap allowance	100.0	100.0	100.0	100.0
Medicare cap allowance	(0.1)	—	—	—
Total	<u>99.9%</u>	<u>100.0%</u>	<u>100.0%</u>	<u>100.0%</u>
Average daily census ("ADC") (days)				
Homecare	7,458	7,121	7,374	6,966
Nursing home	3,452	3,610	3,535	3,581
Routine homecare	10,910	10,731	10,909	10,547
Inpatient	386	417	417	417
Continuous care	533	512	524	513
Total	<u>11,829</u>	<u>11,660</u>	<u>11,850</u>	<u>11,477</u>
Total Admissions	13,314	13,594	55,799	54,798
Total Discharges	13,693	13,700	55,691	54,530
Average length of stay (days)	83.1	75.7	75.4	76.5
Median length of stay (days)	14.0	14.0	14.0	13.0
ADC by major diagnosis				
Neurological	33.1%	32.8%	32.7%	33.1%
Cancer	19.3	20.4	19.8	20.1
Cardio	12.5	13.5	12.8	14.1
Respiratory	6.5	6.8	6.6	6.8
Other	28.6	26.5	28.1	25.9
Total	<u>100.0%</u>	<u>100.0%</u>	<u>100.0%</u>	<u>100.0%</u>
Admissions by major diagnosis				
Neurological	18.6%	18.5%	18.4%	18.5%
Cancer	35.9	36.6	35.7	36.1
Cardio	11.1	11.9	11.6	12.6
Respiratory	7.6	7.3	7.8	7.5
Other	26.8	25.7	26.5	25.3
Total	<u>100.0%</u>	<u>100.0%</u>	<u>100.0%</u>	<u>100.0%</u>
Direct patient care margins				
Routine homecare	53.3%	51.6%	51.7%	51.1%
Inpatient	14.9	18.8	17.2	18.4
Continuous care	20.1	17.6	18.1	18.0
Homecare margin drivers (dollars per patient day)				
Labor costs	\$ 48.99	\$ 49.59	\$ 49.87	\$ 49.14
Drug costs	7.87	7.73	7.74	7.90
Home medical equipment	6.32	5.91	6.24	5.78
Medical supplies	2.22	2.49	2.32	2.25
Inpatient margin drivers (dollars per patient day)				
Labor costs	\$ 266.86	\$ 272.46	\$ 264.45	\$ 265.47
Continuous care margin drivers (dollars per patient day)				
Labor costs	\$ 514.93	\$ 506.72	\$ 512.61	\$ 486.90
Bad debt expense as a percent of revenues	1.1%	1.0%	1.0%	0.9%
Accounts receivable — days of revenue outstanding	49.1	43.4	N.A.	N.A.

*CORPORATE GOVERNANCE*

We submitted our Annual Certification of the Chief Executive Officer to the New York Stock Exchange (“NYSE”) regarding the NYSE corporate governance listing standards on May 22, 2008. We also filed our Certifications of the President and Chief Executive Officer, the Executive Vice President and Chief Financial Officer and the Vice President and Controller pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 as Exhibits 31.1, 31.2 and 31.3, respectively, to our Annual Report on Form 10-K for the year ended December 31, 2008.

*SAFE HARBOR STATEMENT UNDER THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995 REGARDING FORWARD-LOOKING INFORMATION*

In addition to historical information, this report contains forward-looking statements and performance trends that are based upon assumptions subject to certain known and unknown risks, uncertainties, contingencies and other factors. Such forward-looking statements and trends include, but are not limited to, the impact of laws and regulations on our operations, our estimate of future effective income tax rates and the recoverability of deferred tax assets. Variances in any or all of the risks, uncertainties, contingencies, and other factors from our assumptions could cause actual results to differ materially from these forward-looking statements and trends. Our ability to deal with the unknown outcomes of these events, many of which are beyond our control, may affect the reliability of our projections and other financial matters.

**EXHIBIT 21**  
**SUBSIDIARIES OF CHEMED CORPORATION**

The following is a list of subsidiaries of the Company as of December 31, 2008: Other subsidiaries which have been omitted from the list would not, when considered in the aggregate, constitute a significant subsidiary. Each of the companies is incorporated under the laws of the state following its name. The percentage given for each company represents the percentage of voting securities of such company owned by the Company or, where indicated, subsidiaries of the Company as of December 31, 2008.

All of the majority owned companies listed below are included in the consolidated financial statements as of December 31, 2008.

Chemed RT, Inc. (Delaware, 100%)

Comfort Care Holdings Co. (Nevada, 100%)

Complete Plumbing Services, Inc. (New York, 49% by Roto-Rooter Services Company; included within the consolidated financial statements as a consolidated subsidiary)

Consolidated HVAC, Inc. (Ohio, 100% by Roto-Rooter Services Company)

Jet Resource, Inc. (Delaware, 100%)

Nurotoco of Massachusetts, Inc. (Massachusetts, 100% by Roto-Rooter Services Company)

Nurotoco of New Jersey, Inc. (Delaware, 80% by Roto-Rooter Services Company)

Roto RT, Inc. (Delaware, 100% by Roto-Rooter Group, Inc.)

Roto-Rooter Canada, Ltd. (British Columbia, 100% by Roto-Rooter Services Company)

Roto-Rooter Corporation (Iowa, 100% by Roto-Rooter Group, Inc.)

Roto-Rooter Development Company (Delaware, 100% by Roto-Rooter Corporation)

Roto-Rooter Group, Inc. (Delaware, 100%)

Roto-Rooter Services Company (Iowa, 100% by Roto-Rooter Group, Inc.)

RR Plumbing Services Corporation (New York, 49% by Roto-Rooter Group, Inc.; included within the consolidated financial statements as a consolidated subsidiary)

R.R. UK, Inc. (Delaware, 100% by Roto-Rooter Group, Inc.)

VITAS Care Solutions, Inc. (Delaware, 100% by VITAS Healthcare Corporation)

VITAS Healthcare Corporation (Delaware, 100% by Comfort Care Holdings Co.)

VITAS Hospice Services, L.L.C. (Delaware, 100% by VITAS Healthcare Corporation)

VITAS Healthcare Corporation of Arizona (Delaware, 100% by VITAS Hospice Services, L.L.C.)

VITAS Healthcare Corporation of California (Delaware, 100% by VITAS Hospice Services, L.L.C.)

VITAS Healthcare Corporation of Illinois (Delaware, 100% by VITAS Hospice Services, L.L.C.)

VITAS Healthcare Corporation of Florida (Florida, 100% by VITAS Hospice Services, L.L.C.)

VITAS Healthcare Corporation of Ohio (Delaware, 100% by VITAS Hospice Services, L.L.C.)

VITAS Healthcare Corporation of Atlantic (Delaware, 100% by VITAS Hospice Services, L.L.C.)

VITAS Healthcare of Texas, L.P. (Texas, 99% by VITAS Holding Corporation, the limited partner, 1% by VITAS Hospice Services, L.L.C., the general partner)

VITAS Healthcare Corporation Midwest (Delaware, 100% by VITAS Hospice Services, L.L.C.)

VITAS Healthcare Corporation of Georgia (Delaware, 100% by VITAS Hospice Services, L.L.C.)

VITAS HME Solutions, Inc. (Delaware, 100% by VITAS Hospice Services, L.L.C.)

VITAS of North Florida, Inc. (Florida, 100% by VITAS Hospice Services, L.L.C.)

VITAS Holdings Corporation (Delaware, 100% by VITAS Hospice Services, L.L.C.)

VITAS Solutions, Inc. (Delaware, 100% by VITAS Hospice Services, L.L.C.)

Hospice Care Incorporated (Delaware, 100% by VITAS Hospice Services, L.L.C.)

**EXHIBIT 23**

**CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM**

We hereby consent to the incorporation by reference in the Registration Statement on Form S-3 (No. 333-145555) and Form S-8 (Nos. 2- 87202, 2-80712, 33-65244, 33-61063, 333-109104, 333-118714, 333-34525, 333-87071, 333-134107 and 333-87073) of Chemed Corporation of our report dated February 27, 2009 relating to the financial statements and the effectiveness of internal control over financial reporting, which appears in the Annual Report to Stockholders, which is incorporated in this Annual Report on Form 10-K. We also consent to the incorporation by reference of our report dated February 27, 2009 relating to the financial statement schedule, which appears in this Form 10-K.

/s/ PricewaterhouseCoopers LLP

PricewaterhouseCoopers LLP

Cincinnati, Ohio

February 27, 2009

**EXHIBIT 24**

**POWER OF ATTORNEY**

The undersigned director of CHEMED CORPORATION ("Company") hereby appoints EDWARD L. HUTTON, KEVIN J. MCNAMARA and NAOMI C. DALLOB as his true and lawful attorneys-in-fact for the purpose of signing the Company's Annual Report on Form 10-K for the year ended December 31, 2008, and all amendments thereto, to be filed with the Securities and Exchange Commission. Each of such attorneys-in-fact is appointed with full power to act without the other.

Dated: February 19, 2009

/s/ Joel F. Gemunder

\_\_\_\_\_  
Joel F. Gemunder

---

**POWER OF ATTORNEY**

The undersigned director of CHEMED CORPORATION ("Company") hereby appoints EDWARD L. HUTTON, KEVIN J. MCNAMARA and NAOMI C. DALLOB as his true and lawful attorneys-in-fact for the purpose of signing the Company's Annual Report on Form 10-K for the year ended December 31, 2008, and all amendments thereto, to be filed with the Securities and Exchange Commission. Each of such attorneys-in-fact is appointed with full power to act without the other.

Dated: February 19, 2009

/s/ Patrick P. Grace

Patrick P. Grace

---

**POWER OF ATTORNEY**

The undersigned director of CHEMED CORPORATION ("Company") hereby appoints EDWARD L. HUTTON, KEVIN J. MCNAMARA and NAOMI C. DALLOB as his true and lawful attorneys-in-fact for the purpose of signing the Company's Annual Report on Form 10-K for the year ended December 31, 2008, and all amendments thereto, to be filed with the Securities and Exchange Commission. Each of such attorneys-in-fact is appointed with full power to act without the other.

Dated: February 19, 2009

/s/ Edward L. Hutton

Edward L. Hutton

---

**POWER OF ATTORNEY**

The undersigned director of CHEMED CORPORATION ("Company") hereby appoints EDWARD L. HUTTON, KEVIN J. MCNAMARA and NAOMI C. DALLOB as his true and lawful attorneys-in-fact for the purpose of signing the Company's Annual Report on Form 10-K for the year ended December 31, 2008, and all amendments thereto, to be filed with the Securities and Exchange Commission. Each of such attorneys-in-fact is appointed with full power to act without the other.

Dated: February 18, 2009

/s/ Thomas C. Hutton

Thomas C. Hutton

---

**POWER OF ATTORNEY**

The undersigned director of CHEMED CORPORATION ("Company") hereby appoints EDWARD L. HUTTON, KEVIN J. MCNAMARA and NAOMI C. DALLOB as her true and lawful attorneys-in-fact for the purpose of signing the Company's Annual Report on Form 10-K for the year ended December 31, 2008, and all amendments thereto, to be filed with the Securities and Exchange Commission. Each of such attorneys-in-fact is appointed with full power to act without the other.

Dated: February 16, 2009

/s/ Sandra E. Laney

Sandra E. Laney

---

**POWER OF ATTORNEY**

The undersigned director of CHEMED CORPORATION ("Company") hereby appoints EDWARD L. HUTTON, KEVIN J. MCNAMARA and NAOMI C. DALLOB as his true and lawful attorneys-in-fact for the purpose of signing the Company's Annual Report on Form 10-K for the year ended December 31, 2008, and all amendments thereto, to be filed with the Securities and Exchange Commission. Each of such attorneys-in-fact is appointed with full power to act without the other.

Dated: February 19, 2009

/s/ Timothy S. O'Toole

Timothy S. O'Toole

---

**POWER OF ATTORNEY**

The undersigned director of CHEMED CORPORATION ("Company") hereby appoints EDWARD L. HUTTON, KEVIN J. MCNAMARA and NAOMI C. DALLOB as his true and lawful attorneys-in-fact for the purpose of signing the Company's Annual Report on Form 10-K for the year ended December 31, 2008, and all amendments thereto, to be filed with the Securities and Exchange Commission. Each of such attorneys-in-fact is appointed with full power to act without the other.

Dated: February 17, 2009

/s/ Donald E. Saunders

Donald E. Saunders

---

**POWER OF ATTORNEY**

The undersigned director of CHEMED CORPORATION ("Company") hereby appoints EDWARD L. HUTTON, KEVIN J. MCNAMARA and NAOMI C. DALLOB as his true and lawful attorneys-in-fact for the purpose of signing the Company's Annual Report on Form 10-K for the year ended December 31, 2008, and all amendments thereto, to be filed with the Securities and Exchange Commission. Each of such attorneys-in-fact is appointed with full power to act without the other.

Dated: February 17, 2009

/s/ George J. Walsh III

George J. Walsh III

---

**POWER OF ATTORNEY**

The undersigned director of CHEMED CORPORATION ("Company") hereby appoints EDWARD L. HUTTON, KEVIN J. MCNAMARA and NAOMI C. DALLOB as his true and lawful attorneys-in-fact for the purpose of signing the Company's Annual Report on Form 10-K for the year ended December 31, 2008, and all amendments thereto, to be filed with the Securities and Exchange Commission. Each of such attorneys-in-fact is appointed with full power to act without the other.

Dated: February 16, 2009

/s/ Frank E. Wood

Frank E. Wood

---

**POWER OF ATTORNEY**

The undersigned director of CHEMED CORPORATION ("Company") hereby appoints EDWARD L. HUTTON, KEVIN J. MCNAMARA and NAOMI C. DALLOB as his true and lawful attorneys-in-fact for the purpose of signing the Company's Annual Report on Form 10-K for the year ended December 31, 2008, and all amendments thereto, to be filed with the Securities and Exchange Commission. Each of such attorneys-in-fact is appointed with full power to act without the other.

Dated: February 18, 2009

/s/ Walter L. Krebs

Walter L. Krebs

---

**POWER OF ATTORNEY**

The undersigned director of CHEMED CORPORATION ("Company") hereby appoints EDWARD L. HUTTON, KEVIN J. MCNAMARA and NAOMI C. DALLOB as his true and lawful attorneys-in-fact for the purpose of signing the Company's Annual Report on Form 10-K for the year ended December 31, 2008, and all amendments thereto, to be filed with the Securities and Exchange Commission. Each of such attorneys-in-fact is appointed with full power to act without the other.

Dated: February 19, 2009

/s/ Andrea R. Lindell

Andrea R. Lindell

CERTIFICATION PURSUANT TO RULES 13a-14(a)/15d-14(a) OF THE EXCHANGE ACT OF 1934

I, Kevin J. McNamara, certify that:

1. I have reviewed this annual report on Form 10-K of Chemed Corporation (“registrant”);
2. Based on my knowledge, this report does not contain any untrue statement of material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3. Based on my knowledge, the financial statements, and other financial information included in this annual report, fairly present in all material respects the financial condition, results of operations, and cash flow of the registrant as of, and for, the periods presented in this report;
4. The registrant’s other certifying officers and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rule 13a-15(f) and 15d-15(f)) for the registrant and have:
  - a) Designed such disclosure controls and procedures, or caused such disclosure controls or procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by other within those entities, particularly during the period in which this report is being prepared;
  - b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
  - c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
  - d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s fourth quarter in 2008 that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting.
5. The registrant’s other certifying officers and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of registrant’s board of directors:
  - a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information;
  - b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Dated: February 27, 2009

/s/ Kevin J. McNamara

Kevin J. McNamara

(President and Chief Executive Officer)

**EXHIBIT 31.2**

**CERTIFICATION PURSUANT TO RULES 13a-14(a)/15d-14(a) OF THE EXCHANGE ACT OF 1934**

I, David P. Williams, certify that:

1. I have reviewed this annual report on Form 10-K of Chemed Corporation (“registrant”);
2. Based on my knowledge, this report does not contain any untrue statement of material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3. Based on my knowledge, the financial statements, and other financial information included in this annual report, fairly present in all material respects the financial condition, results of operations, and cash flow of the registrant as of, and for, the periods presented in this report;
4. The registrant’s other certifying officers and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rule 13a-15(f) and 15d-15(f)) for the registrant and have:
  - a) Designed such disclosure controls and procedures, or caused such disclosure controls or procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by other within those entities, particularly during the period in which this report is being prepared;
  - b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
  - c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
  - d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s fourth quarter in 2008 that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting.
5. The registrant’s other certifying officers and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of registrant’s board of directors:
  - a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information;
  - b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Dated: February 27, 2009

/s/ David P. Williams

\_\_\_\_\_  
David P. Williams

(Executive Vice President and Chief Financial Officer)

## CERTIFICATION PURSUANT TO RULES 13a-14(a)/15d-14(a) OF THE EXCHANGE ACT OF 1934

I, Arthur V. Tucker, Jr., certify that:

1. I have reviewed this annual report on Form 10-K of Chemed Corporation (“registrant”);
2. Based on my knowledge, this report does not contain any untrue statement of material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3. Based on my knowledge, the financial statements, and other financial information included in this annual report, fairly present in all material respects the financial condition, results of operations, and cash flow of the registrant as of, and for, the periods presented in this report;
4. The registrant’s other certifying officers and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rule 13a-15(f) and 15d-15(f)) for the registrant and have:
  - a) Designed such disclosure controls and procedures, or caused such disclosure controls or procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by other within those entities, particularly during the period in which this report is being prepared;
  - b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
  - c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
  - d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s fourth quarter in 2008 that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting.
5. The registrant’s other certifying officers and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of registrant’s board of directors:
  - a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information;
  - b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Dated: February 27, 2009

/s/ Arthur V. Tucker, Jr.

Arthur V. Tucker, Jr.

(Vice President and Controller)

**EXHIBIT 32.1**

**CERTIFICATION BY KEVIN J. MCNAMARA  
PURUSANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002**

Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, the undersigned, as President and Chief Executive Officer of Chemed Corporation (“Company”), does hereby certify that:

- 1) The Company’s Annual Report on Form 10-K for the year ending December 31, 2008 (“Report”), fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
- 2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Dated: February 27, 2009

/s/ Kevin J. McNamara

Kevin J. McNamara  
(President and Chief Executive Officer)

**EXHIBIT 32.2**

**CERTIFICATION DAVID P. WILLIAMS  
PURUSANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002**

Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, the undersigned, as Executive Vice President and Chief Financial Officer of Chemed Corporation (“Company”), does hereby certify that:

- 1) The Company’s Annual Report on Form 10-K for the year ending December 31, 2008 (“Report”), fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
- 2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Dated: February 27, 2009

/s/ David P. Williams

David P. Williams

(Executive Vice President and Chief Financial Officer)

**EXHIBIT 32.3**

**CERTIFICATION BY ARTHUR V. TUCKER, JR.  
PURUSANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002**

Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, the undersigned, as Vice President and Controller of Chemed Corporation (“Company”), does hereby certify that:

- 1) The Company’s Annual Report on Form 10-K for the year ending December 31, 2008 (“Report”), fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
- 2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Dated: February 27, 2009

/s/ Arthur V. Tucker, Jr.

Arthur V. Tucker, Jr.

(Vice President and Controller)